documents incorporated referencefontb center table width aligncenter cellspacing cellpadding border tr td widthfont sizenbspfonttd td widthfont sizenbspfonttd td widthfont sizenbspfonttd tr tr td alignleft valigntop div stylemarginleft px textindent px font sizepartsnbspi ii iii fontdiv td tdfont sizenbspfonttd td alignleft valigntop font sizeportions registrants annual report shareholders fiscal year annual report fonttd tr tr td alignleft valigntopdiv stylemarginleft px textindent px font sizeparts iii fontdiv td tdfont sizenbspfonttd td alignleft valigntop font sizeportions registrants proxy statement annual meeting proxy statement fonttd tr table center p alignleft hr size width alignleft colorblack noshade div alignleft hr size width alignleft colorblack noshade div pagebreak phr noshadep h alignleft stylebreakbeforealwaysnbsphp p aligncenter bfont sizepart ifontb center table width aligncenter cellspacing cellpadding border tr td widthfont sizenbspfonttd td widthfont sizenbspfonttd td widthfont sizenbspfonttd td widthfont sizenbspfonttd td widthfont sizenbspfonttd td widthfont sizenbspfonttd td widthfont sizenbspfonttd td widthfont sizenbspfonttd td widthfont sizenbspfonttd tr tr td colspan aligncenter nowrapbfont sizeitemfontbtd tdtd tdtd tdtd td colspan aligncenter nowrapbfont sizefontbtd tr tr td colspan aligncenter nowraphr size noshadetd tdtd tdtd tdtd td colspan aligncenter nowraphr size noshadetd tr tr valignbottom bgcoloreeeeee td alignright valigntopfont sizenbspfonttd td alignright valigntop nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignleft valigntop font sizebusiness fonttd tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tr tr td alignright valigntopfont sizenbspfonttd td alignright valigntop nowrapfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignleft valigntop nbspnbspfont sizegeneral fonttdtdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tr tr valignbottom bgcoloreeeeee td alignright valigntopfont sizenbspfonttd td alignright valigntop nowrapfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignleft valigntop nbspnbspfont sizesegments business fonttd tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tr tr td alignright valigntopfont sizenbspfonttd td alignright valigntop nowrapfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignleft valigntop nbspnbspfont sizeconsumer fonttd tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tr tr valignbottom bgcoloreeeeee td alignright valigntopfont sizenbspfonttd td alignright valigntop nowrapfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignleft valigntop nbspnbspfont sizepharmaceutical fonttd tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tr tr td alignright valigntopfont sizenbspfonttd td alignright valigntop nowrapfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignleft valigntop nbspnbspfont sizemedical devices diagnostics fonttd tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tr tr valignbottom bgcoloreeeeee td alignright valigntopfont sizenbspfonttd td alignright valigntop nowrapfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignleft valigntop nbspnbspfont sizegeographic areas fonttd tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tr tr td alignright valigntopfont sizenbspfonttd td alignright valigntop nowrapfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttdtd alignleft valigntop nbspnbspfont sizeraw materials fonttd tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tr tr valignbottom bgcoloreeeeee td alignright valigntopfont sizenbspfonttd td alignright valigntop nowrapfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignleft valigntop nbspnbspfont sizepatents trademarks fonttd tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tr tr td alignright valigntopfont sizenbspfonttd td alignright valigntop nowrapfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignleft valigntop nbspnbspfont sizeseasonality fonttd tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tr tr valignbottom bgcoloreeeeee td alignright valigntopfont sizenbspfonttd td alignright valigntop nowrapfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignleft valigntop nbspnbspfont sizecompetition fonttd tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tr tr td alignright valigntopfont sizenbspfonttd td alignright valigntop nowrapfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignleft valigntop nbspnbspfont sizeresearch fonttd tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tr tr valignbottom bgcoloreeeeee td alignright valigntopfont sizenbspfonttd td alignright valigntop nowrapfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignleft valigntop nbspnbspfont sizeenvironment fonttd tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tr tr td alignright valigntopfont sizenbspfonttdtd alignright valigntop nowrapfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignleft valigntop nbspnbspfont sizeregulation fonttd tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tr tr valignbottom bgcoloreeeeee td alignright valigntopfont sizenbspfonttd td alignright valigntop nowrapfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignleft valigntop nbspnbspfont sizeavailable information fonttd tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tr tr td alignright valigntopfont sizenbspfonttd td alignright valigntop nowrapfont sizeafonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignleft valigntop font sizerisk factors fonttd tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tr tr valignbottom bgcoloreeeeee td alignright valigntopfont sizenbspfonttd td alignright valigntop nowrapfont sizebfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignleft valigntop font sizeunresolved staff comments fonttd tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tr tr td alignright valigntopfont sizenbspfonttd td alignright valigntop nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignleft valigntop font sizeproperties fonttd tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tr tr valignbottom bgcoloreeeeee td alignright valigntopfont sizenbspfonttd td alignright valigntop nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignleft valigntop font sizelegal proceedings fonttd tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd trtr td alignright valigntopfont sizenbspfonttd td alignright valigntop nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignleft valigntop font sizesubmission matters vote security holders fonttd tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tr tr valignbottom bgcoloreeeeee td alignright valigntopfont sizenbspfonttd td alignright valigntop nowrapfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignleft valigntop nbspnbspfont sizeexecutive officers registrant fonttd tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tr tr td colspan aligncenter valigntop br bfont sizepartnbspiifontbtd tr tr valignbottom bgcoloreeeeee td alignright valigntopfont sizenbspfonttd td alignright valigntop nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignleft valigntop font sizemarket registrants common equity related stockholder matters issuer purchases equity securities fonttd tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tr tr td alignright valigntopfont sizenbspfonttd td alignright valigntop nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignleft valigntop font sizeselected financial data fonttd tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tr tr valignbottom bgcoloreeeeee td alignright valigntopfont sizenbspfonttd td alignright valigntop nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignleft valigntop font sizemanagements discussion analysis financial condition results operations fonttd tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd trtr td alignright valigntopfont sizenbspfonttd td alignright valigntop nowrapfont sizeafonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignleft valigntop font sizequantitative qualitative disclosures market risk fonttd tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tr tr valignbottom bgcoloreeeeee td alignright valigntopfont sizenbspfonttd td alignright valigntop nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignleft valigntop font sizefinancial statements supplementary data fonttd tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tr tr td alignright valigntopfont sizenbspfonttd td alignright valigntop nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignleft valigntop font sizechanges disagreements accountants accounting financial disclosure fonttd tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tr tr valignbottom bgcoloreeeeee td alignright valigntopfont sizenbspfonttd td alignright valigntop nowrapfont sizeafonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignleft valigntop font sizecontrols procedures fonttd tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tr tr td alignright valigntopfont sizenbspfonttd td alignright valigntop nowrapfont sizebfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignleft valigntop font sizeother information fonttd tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tr tr valignbottom bgcoloreeeeee td colspan aligncenter valigntop br bfont sizepartnbspiiifontbtd tr tr td alignright valigntopfont sizenbspfonttd td alignright valigntop nowrapfont sizefonttdtdfont sizenbspfonttd tdfont sizenbspfonttd td alignleft valigntop font sizedirectors executive officers registrant fonttd tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tr tr valignbottom bgcoloreeeeee td alignright valigntopfont sizenbspfonttd td alignright valigntop nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignleft valigntop font sizeexecutive compensation fonttd tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tr tr td alignright valigntopfont sizenbspfonttd td alignright valigntop nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignleft valigntop font sizesecurity ownership certain beneficial owners management related stockholder matters fonttd tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tr tr valignbottom bgcoloreeeeee td alignright valigntopfont sizenbspfonttd td alignright valigntop nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignleft valigntop font sizecertain relationships related transactions fonttd tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tr tr td alignright valigntopfont sizenbspfonttd td alignright valigntop nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignleft valigntop font sizeprincipal accounting fees services fonttd tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tr tr valignbottom bgcoloreeeeee td colspan aligncenter valigntop br bfont sizepartnbspivfontbtd tr tr td alignright valigntopfont sizenbspfonttd td alignright valigntop nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignleft valigntop font sizeexhibits financial statement schedulesfonttd tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tr tr valignbottom bgcoloreeeeee td alignright valigntopfont sizenbspfonttd td alignright valigntop nowrapfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignleft valigntop font sizesignatures fonttd tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tr tr td alignright valigntopfont sizenbspfonttd td alignright valigntop nowrapfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignleft valigntop font sizereport independent registered public accounting firm financial statement schedule fonttd tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tr tr valignbottom bgcoloreeeeee td alignright valigntopfont sizenbspfonttd td alignright valigntop nowrapfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignleft valigntop font sizeexhibit index fonttd tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tr table center pagebreak phr noshadep h alignleft stylebreakbeforealwaysnbsphp p aligncenter bfont sizepart ifontb p alignleft bfont sizeitem nbspnbspbusinessfontb p alignleft bfont sizegeneralfontb p alignleftnbspnbspnbspnbspnbsp font sizejohnsonnbsp johnson subsidiaries approximately employees worldwide engaged manufacture sale broad range products health care field johnson johnson operating companies conducting business virtually countries world johnsonnbsp johnsons primary focus products related human health wellbeing johnsonnbsp johnson incorporated state new jersey font p alignleftnbspnbspnbspnbspnbsp font sizethe companys structure based principle decentralized management executive committeeof johnsonnbsp johnson principal management group responsible operations allocation resources company committee oversees coordinates activities consumer pharmaceutical medical devices diagnostics business segments subsidiary within business segments exceptions managed citizens country located font p alignleft bfont sizesegments businessfontb p alignleftnbspnbspnbspnbspnbsp font sizejohnsonnbsp johnsons worldwide business divided three segments consumer pharmaceutical medical devices diagnostics additional information required item incorporated herein reference narrative tabular graphic descriptions segments operating results managements discussion analysis results operations financial condition pagesnbsp notenbsp segments business geographic areas notes consolidated financial statements nbsp annual report filed exhibitnbsp report formnbspk font p alignleft bfont sizeconsumerfontb p alignleftnbspnbspnbspnbspnbsp font sizethe consumer segment manufactures markets broad range products used baby childnbspcare skin care oral wound care womens health care fields well nutritional overthecounter pharmaceutical products major brands include aveenosup stylefontsize verticalalign texttopsup skin care products bandaidsup stylefontsize verticalalign texttopsup brand adhesive bandages carefreesup stylefontsize verticalalign texttopsup pantiliners cleannbsp clearsup stylefontsize verticalalign texttopsup teen skin care products johnsonssup stylefontsize verticalalign texttopsup baby adult lines products motrinsup stylefontsize verticalalign texttopsup ib ibuprofen products pepcidsup stylefontsize verticalalign texttopsup ac acid controller johnsonnbsp johnsonnbsp merck consumer pharmaceuticals co neutrogenasup stylefontsize verticalalign texttopsup skin hair care products rocsup stylefontsize verticalalign texttopsup skin care products splendasup stylefontsize verticalalign texttopsup calorie sweetener stayfreesup stylefontsize verticalalign texttopsup sanitary protection products broad family tylenolsup stylefontsize verticalalign texttopsup acetaminophen products products available without prescription marketed principally general public sold wholesalers directly independent chain retail outlets throughout world font p alignleft bfont sizepharmaceuticalfontb p alignleftnbspnbspnbspnbspnbsp font sizethe pharmaceutical segment includes products following therapeutic areas antifungal antiinfective cardiovascular contraceptive dermatology gastrointestinal hematology immunology neurology oncology pain management psychotropic central nervous system urology products distributed directly retailers wholesalers health care professionals prescription use general public key products pharmaceutical segment include risperdalsup stylefontsize verticalalign texttopsup risperidone risperdalsup stylefontsize verticalalign texttopsupconstasup stylefontsize verticalalign texttopsup risperidone longacting injection treatment symptoms schizophrenia procritsup stylefontsize verticalalign texttopsup epoetin alfa sold outside us eprexsup stylefontsize verticalalign texttopsup biotechnologyderived product stimulates red blood cell production remicadesup stylefontsize verticalalign texttopsup infliximab monoclonal antibody therapy indicated treat symptoms crohns disease rheumatoid arthritis ankylosing spondylitis psoriatic arthritis ulcerative colitis topamaxsup stylefontsize verticalalign texttopsup topiramate antiepileptic migraine prevention treatment duragesicsup stylefontsize verticalalign texttopsup fentanyl transdermal system sold outside us durogesicsup stylefontsize verticalalign texttopsup treatment chronic pain offers novel delivery system levaquinsup stylefontsize verticalalign texttopsup levofloxacin floxinsup stylefontsize verticalalign texttopsup ofloxacin antiinfective field ortho evrasup stylefontsize verticalalign texttopsup norelgestrominethinyl estradiol transdermal system first contraceptive patch approved us food drug administration fda orthonbsptricyclensup stylefontsize verticalalign texttopsupnbsplo norgestimateethinyl estradiol low dose oral contraceptive font p aligncenter pagebreak phr noshadep h alignleft stylebreakbeforealwaysnbsphp div alignleft font sizedoxilsup stylefontsize verticalalign texttopsup doxorubicin hci liposome injection cancer treatment ditropansup stylefontsize verticalalign texttopsup xl oxybutynin chloride treatment overactive bladder razadynesuptmsup galantamine hbr patients mild moderate alzheimers disease natrecorsup stylefontsize verticalalign texttopsup nesiritide novel agent approved congestive heart failure velcadesup stylefontsize verticalalign texttopsup bortezomib oncology treatment concertasup stylefontsize verticalalign texttopsup methylphenidate hcl product treatment attention deficit hyperactivity disorder font div p alignleft bfont sizemedical devices diagnosticsfontb p alignleftnbspnbspnbspnbspnbsp font sizethe medical devices diagnostics segment includes broad range products distributed wholesalers hospitals retailers used principally professional fields physicians nurses therapists hospitals diagnostic laboratories clinics products include cordis circulatory disease management products depuys orthopaedic joint reconstruction spinal care products ethicons wound care womens health products ethicon endosurgerys minimally invasive surgical products lifescans blood glucose monitoring products orthoclinical diagnostics professional diagnostic products vision cares disposable contact lenses distribution health care professional markets done directly surgical supply dealers font p alignleft bfont sizegeographic areasfontb p alignleftnbspnbspnbspnbspnbspfont sizethe international business johnson johnson conducted subsidiaries located countries outside united states selling products virtually countries throughout world products made sold international business include many described businessnbsp consumer nbsppharmaceutical nbspmedical devices diagnostics however principal markets products methods distribution international business vary country culture products sold international business include developed united states also developed subsidiaries abroad font p alignleftnbspnbspnbspnbspnbsp font sizeinvestments activities countries outside united states subject higher risks comparable us activities investment commercial climate influenced restrictive economic policies political uncertainties font p alignleft bfont sizeraw materialsfontb p alignleftnbspnbspnbspnbspnbsp font sizeraw materials essential johnson johnsons operating companies businesses generally readily available multiple sources font p alignleft bfont sizepatents trademarksfontb p alignleftnbspnbspnbspnbspnbsp font sizejohnson johnson made practice obtaining patent protection products processes possible johnson johnson owns licensed number patents relating products manufacturing processes aggregate believed material importance operation business sales companys two largest products risperdalsup stylefontsize verticalalign texttopsup procritsup stylefontsize verticalalign texttopsupeprexsup stylefontsize verticalalign texttopsup accounted approximately johnson johnsons total revenues respectively fiscal accordingly patents related products believed material relation johnson johnson whole font p alignleftnbspnbspnbspnbspnbsp font sizeduring duragesicsup stylefontsize verticalalign texttopsup fentanyl transdermal system united states certain international markets eprexsup stylefontsize verticalalign texttopsup epoetin alfa international markets lost lose basic patent protection subject generic competition duragesicsup stylefontsize verticalalign texttopsup sales declined nbspbillion compared due negative impact generic competition primarily united states regarding eprexsup stylefontsize verticalalign texttopsup generic competition limited near term due lack approved generic compounds combined sales duragesicsup stylefontsize verticalalign texttopsup eprexsup stylefontsize verticalalign texttopsup accounted approximately johnsonnbsp johnsons worldwide sales material patent scheduled expire next two years related risperdalsup stylefontsize verticalalign texttopsup scheduled expire united states december possibility pediatric extension fontp aligncenterfont size font pagebreak phr noshadep h alignleft stylebreakbeforealwaysnbsphp p alignleftnbspnbspnbspnbspnbsp font sizejohnson johnson made practice selling products trademarks obtaining protection trademarks available means johnson johnsons trademarks protected registration united states countries products marketed johnson johnson considers trademarks aggregate material importance operation business font p alignleft bfont sizeseasonalityfontb p alignleftnbspnbspnbspnbspnbsp font sizeworldwide sales reflect significant degree seasonality however spending heavier fourth quarter year quarters reflects increased spending decisions principally advertising research grants font p alignleft bfont sizecompetitionfontb p alignleftnbspnbspnbspnbspnbsp font sizein product lines johnson johnson companies compete companies large small located throughout world competition strong product lines without regard number size competing companies involved competition research involving development improvement new existing products processes particularly significant development new improved products important johnson johnsons success areas business competitive environment requires substantial investments continuing research multiple sales forces addition development maintenance customer acceptance products johnson johnsons consumer businesses involves significant expenditures advertising promotion font p alignleft bfont sizeresearchfontb p alignleftnbspnbspnbspnbspnbsp font sizeresearch activities important segments johnson johnsons business major research facilities located united states also australia belgium brazil canada china france germany japan netherlands united kingdom costs worldwide companysponsored research activities relating development new products improvement existing products technical support products compliance governmental regulations protection consumers patients excluding inprocess research development charges amounted nbspmillion nbspmillion nbspmillion fiscal years respectively costs charged directly income year incurred font p alignleft bfont sizeenvironmentfontb p alignleftnbspnbspnbspnbspnbsp font sizeduring past year johnson johnson companies subject variety federal state local environmental protection measures johnson johnson believes operations comply material respects applicable environmental laws regulations johnson johnsons compliance requirements expected material effect upon capital expenditures cash flows earnings competitive position fontp alignleft bfont sizeregulationfontb p alignleftnbspnbspnbspnbspnbsp font sizemost johnson johnsons business subject varying degrees governmental regulation countries operations conducted general trend toward regulation increasing stringency united states drug device diagnostics cosmetic industries long subject regulation various federal state agencies primarily product safety efficacy manufacturing advertising labeling exercise broad regulatory powers fda continues result increases amounts testing documentation required fda clearance new drugs devices corresponding increase expense product introduction similar trends also evident major markets outside united states font p alignleftnbspnbspnbspnbspnbsp font sizethe costs human health care continue subject study investigation regulation governmental agencies legislative bodies around world united states attention focused drug prices profits programs encourage doctors write prescriptions particular drugs recommend use purchase particular medical devices payers become potent font p aligncenterfont size font pagebreak phr noshadep h alignleft stylebreakbeforealwaysnbsphp div alignleft font sizeforce market place increased attention paid drug medical device pricing appropriate drug medical device utilization quality costs health care also uncertainty united states impact medicare prescription drug improvement modernization act enacted font div p alignleftnbspnbspnbspnbspnbsp font sizethe regulatory agencies whose purview johnson johnson companies operate administrative powers may subject companies actions product withdrawals recalls seizure products civil criminal sanctions cases johnson johnsons operating companies may deem advisable initiate product recalls font p alignleftnbspnbspnbspnbspnbsp font sizein addition business practices health care industry come increased scrutiny particularly united states government agencies state attorneys general resulting investigations prosecutions carry risk significant civil criminal penalties font divnbspdiv table width border cellpadding cellspacing tr td widthtd td widthtd tr tr valigntop tdtd td bfont sizeavailable informationfontbtd tr tablep alignleftnbspnbspnbspnbspnbsp font sizecopies johnson johnsons quarterly reports formnbspq annual report formnbspk current reports formnbspk amendments foregoing provided without charge shareholder submitting written request secretary principal executive offices company calling companys securities exchange commission sec filings also available companys web site iwwwinvestorjnjcomgovernancei soon reasonably practicable electronically filed furnished sec sec filings also available secs web site iwwwsecgovi addition charters audit committee compensation benefits committee nominating corporate governance committee board directors companys principles corporate governance policy business conduct employees code business conduct ethics members board directors executive officers available iwwwinvestorjnjcomgovernancei web site address provided without charge shareholder submitting written request provided font p alignleft bfont sizeitem anbspnbspnbspnbspnbsprisk factorsfontb p alignleftnbspnbspnbspnbspnbsp font sizenot applicable font p alignleft bfont sizeitem bnbspnbspnbspnbspnbspunresolved staff commentsfontb p alignleftnbspnbspnbspnbspnbsp font sizenot applicable font p alignleft bfont sizeitem nbspnbspnbspnbspnbsppropertiesfontb p alignleftnbspnbspnbspnbspnbsp font sizejohnson johnson worldwide subsidiaries operate manufacturing facilities occupying approximately nbspmillion square feet floor space font p alignleftnbspnbspnbspnbspnbsp font sizethe manufacturing facilities used industry segments johnson johnsons business approximately follows font center table width aligncenter cellspacing cellpadding border tr td widthfont sizenbspfonttd td widthfont sizenbspfonttd td widthfont sizenbspfonttd td widthfont sizenbspfonttd td widthfont sizenbspfonttd td widthfont sizenbspfonttd tr tr td colspantd tdtd td colspan aligncenter nowrapbfont sizesquare feetfontbtd tr tr td colspan aligncenter nowrapbfont sizesegmentfontbtd tdtd td colspan aligncenter nowrapbfont sizein thousandsfontbtdtr tr td colspan aligncenter nowraphr size noshadetd tdtd td colspan aligncenter nowraphr size noshadetd tr tr valignbottom bgcoloreeeeee td colspan alignleft valigntop div stylemarginleft px textindent px font sizeconsumer fontdiv td tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tr tr td colspan alignleft valigntop div stylemarginleft px textindent px font sizepharmaceutical fontdiv td tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tr tr valignbottom bgcoloreeeeee td colspan alignleft valigntop div stylemarginleft px textindent px font sizemedical devices diagnostics fontdiv td tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tr tr td colspanfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignlefthr size noshadetd tdfont sizenbspfonttd tr tr tdfont sizenbspfonttd td alignleft valigntop div stylemarginleft px textindent px font sizeworldwide total fontdiv td tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tr tr td colspanfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignlefthr size noshadetd tdfont sizenbspfonttd tr table center p alignleftnbspnbspnbspnbspnbsp font sizewithin united states nbspfacilities used consumer segment pharmaceutical segmentand medical devices diagnostics segment johnsonnbsp johnsons manufacturing operations outside united states often conducted facilities serve one segment business font p aligncenterfont size font pagebreak phr noshadep h alignleft stylebreakbeforealwaysnbsphp p alignleftnbspnbspnbspnbspnbsp font sizethe locations manufacturing facilities major geographic areas world follows font center table width aligncenter cellspacing cellpadding border tr td widthfont sizenbspfonttd td widthfont sizenbspfonttd td widthfont sizenbspfonttd td widthfont sizenbspfonttd td widthfont sizenbspfonttd td widthfont sizenbspfonttd td widthfont sizenbspfonttd td widthfont sizenbspfonttd td widthfont sizenbspfonttd td widthfont sizenbspfonttd tr tr td colspantd tdtd td colspan aligncenter nowrapbfont sizenumberfontbtd tdtd td colspantd tr tr td colspantd tdtd td colspan aligncenter nowrapbfont sizeoffontbtd tdtd td colspan aligncenter nowrapbfont sizesquare feetfontbtd tr tr td colspan aligncenter nowrapbfont sizegeographic areafontbtd tdtd td colspan aligncenter nowrapbfont sizefacilitiesfontbtd tdtd td colspan aligncenter nowrapbfont sizein thousandsfontbtd tr tr td colspan aligncenter nowraphr size noshadetd tdtd td colspan aligncenter nowraphr size noshadetd tdtd td colspan aligncenter nowraphr size noshadetd tr tr valignbottom bgcoloreeeeee td colspan alignleft valigntop div stylemarginleft px textindent px font sizeunited states fontdiv td tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd trtr td colspan alignleft valigntop div stylemarginleft px textindent px font sizeeurope fontdiv td tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tr tr valignbottom bgcoloreeeeee td colspan alignleft valigntop div stylemarginleft px textindent px font sizewestern hemisphere excluding usa fontdiv td tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tr tr td colspan alignleft valigntop div stylemarginleft px textindent px font sizeafrica asia pacific fontdiv td tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tr tr td colspanfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignlefthr size noshadetd tdfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignlefthr size noshadetd tdfont sizenbspfonttd tr tr valignbottom bgcoloreeeeee tdfont sizenbspfonttd td alignleft valigntop div stylemarginleft px textindent px font sizeworldwide total fontdiv td tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tr tr td colspanfont sizenbspfonttdtdfont sizenbspfonttd tdfont sizenbspfonttd td alignlefthr size noshadetd tdfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignlefthr size noshadetd tdfont sizenbspfonttd tr table center p alignleftnbspnbspnbspnbspnbsp font sizein addition manufacturing facilities discussed johnson johnson maintains numerous office warehouse facilities throughout world research facilities also discussed item business research font p alignleftnbspnbspnbspnbspnbsp font sizejohnson johnson generally seeks manufacturing facilities although principally locations abroad leased office warehouse facilities often leased font p alignleftnbspnbspnbspnbspnbsp font sizejohnson johnsons properties maintained good operating condition repair well utilized font p alignleftnbspnbspnbspnbspnbsp font sizefor information regarding lease obligations see notenbsp rental expense lease commitments notes consolidated financial statements nbsp annual report filed exhibitnbsp report formnbspk segment information additions property plant equipment contained notenbsp segments business geographic areas notes consolidated financial statements nbsp annual report filed exhibitnbsp report formnbspk font p alignleft bfont sizeitem nbspnbspnbspnbspnbsplegal proceedingsfontb p alignleftnbspnbspnbspnbspnbsp font sizethe information set forth note legal proceedings notes consolidated financial statements pagesnbsp annual report incorporated herein reference filed exhibitnbsp report formnbspk font p alignleftnbspnbspnbspnbspnbsp font sizethe company subsidiaries parties number proceedings brought comprehensive environmental response compensation liability act commonly known superfund comparable state laws primary relief sought cost past future remediation feasible predict determine outcome proceedings opinion company proceedings would material adverse effect results operations cash flows financial position company font p alignleft bfont sizeitem nbspnbspsubmission matters vote security holdersfontb p alignleftnbspnbspnbspnbspnbsp font sizenot applicable fontp alignleft bfont sizeexecutive officers registrantfontb p alignleftnbspnbspnbspnbspnbsp font sizelisted executive officers johnson johnson marchnbsp unless otherwise indicated employee company affiliates held position indicated past five years family relationships executive officers arrangement understanding executive officer person pursuant executive officer selected annual meeting board directors executive officers elected board hold office one year respective successors elected qualified earlier resignation removal font p aligncenterfont size font pagebreak phr noshadep h alignleft stylebreakbeforealwaysnbsphp p alignleftnbspnbspnbspnbspnbsp font sizeinformation regard directors company including following executive officers directors incorporated herein reference pagesnbsp johnson johnsons proxy statement dated marchnbsp font center table width aligncenter cellspacing cellpadding border tr td widthfont sizenbspfonttd td widthfont sizenbspfonttd td widthfont sizenbspfonttd td widthfont sizenbspfonttd td widthfont sizenbspfonttd td widthfont sizenbspfonttd td widthfont sizenbspfonttd tr tr td aligncenter nowrapbfont sizenamefontbtd tdtd td colspan aligncenter nowrapbfont sizeagefontbtd tdtd td aligncenter nowrapbfont sizepositionfontbtd tr tr td aligncenter nowraphr size noshadetd tdtd td colspan aligncenter nowraphr size noshadetd tdtd td aligncenter nowraphr size noshadetd tr tr valignbottom bgcoloreeeeee td alignleft valigntop div stylemarginleft px textindent px font sizerobert j darretta fontdiv td tdfont sizenbspfonttd td alignright valigntopfont sizenbspfonttd td alignright valigntop nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignleft valigntop div stylemarginleft px textindent px font sizevice chairman board directors member executive committee chief financial officer fontdiv td trtr td alignleft valigntop div stylemarginleft px textindent px font sizerussell c deyo fontdiv td tdfont sizenbspfonttd td alignright valigntopfont sizenbspfonttd td alignright valigntop nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignleft valigntop div stylemarginleft px textindent px font sizemember executive committee vice president general counsel chief compliance officera fontdiv td tr tr valignbottom bgcoloreeeeee td alignleft valigntop div stylemarginleft px textindent px font sizemichael j dormer fontdiv td tdfont sizenbspfonttd td alignright valigntopfont sizenbspfonttd td alignright valigntop nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignleft valigntop div stylemarginleft px textindent px font sizemember executive committee worldwide chairman medical devicesb fontdiv td tr tr td alignleft valigntop div stylemarginleft px textindent px font sizekaye fostercheek fontdiv td tdfont sizenbspfonttd td alignright valigntopfont sizenbspfonttd td alignright valigntop nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignleft valigntop div stylemarginleft px textindent px font sizemember executive committee vice president human resourcesc fontdiv td tr tr valignbottom bgcoloreeeeee td alignleft valigntop div stylemarginleft px textindent px font sizecolleen goggins fontdiv td tdfont sizenbspfonttd td alignright valigntopfont sizenbspfonttd td alignright valigntop nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignleft valigntop div stylemarginleft px textindent px font sizemember executive committee worldwide chairman consumer personal care groupd fontdiv td tr tr td alignleft valigntop div stylemarginleft px textindent px font sizeper peterson md phdnbspfontdiv tdtdfont sizenbspfonttd td alignright valigntopfont sizenbspfonttd td alignright valigntop nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignleft valigntop div stylemarginleft px textindent px font sizemember executive committee chairman research development pharmaceuticals groupe fontdiv td tr tr valignbottom bgcoloreeeeee td alignleft valigntop div stylemarginleft px textindent px font sizechristine poon fontdiv td tdfont sizenbspfonttd td alignright valigntopfont sizenbspfonttd td alignright valigntop nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignleft valigntop div stylemarginleft px textindent px font sizevice chairman board directors member executive committee worldwide chairman medicines nutritionals fontdiv td tr tr td alignleft valigntop div stylemarginleft px textindent px font sizejoseph c scodari fontdiv td tdfont sizenbspfonttd td alignright valigntopfont sizenbspfonttd td alignright valigntop nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignleft valigntop div stylemarginleft px textindent px font sizemember executive committee worldwide chairman pharmaceuticals groupf fontdiv td tr tr valignbottom bgcoloreeeeee td alignleft valigntop div stylemarginleft px textindent px font sizenicholas j valeriani fontdiv td tdfont sizenbspfonttd td alignright valigntopfont sizenbspfonttd td alignright valigntop nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignleft valigntop div stylemarginleft px textindent px font sizemember executive committee worldwide chairman cardiovascular devices diagnosticsg fontdiv td tr tr td alignleft valigntop div stylemarginleft px textindent px font sizewilliam c weldon fontdiv td tdfont sizenbspfonttd td alignright valigntopfont sizenbspfonttd td alignright valigntop nowrapfont sizefonttd tdfont sizenbspfonttdtdfont sizenbspfonttd td alignleft valigntop div stylemarginleft px textindent px font sizechairman board directors chairman executive committee chief executive officer fontdiv td tr table center div alignleft hr size width alignleft colorblack noshade div table width border cellpadding cellspacing tr td widthtd td widthtd tr tr valigntop tdfont sizeafonttd td alignleft font sizemr r c deyo joined company became associate general counsel became member executive committee vice president administration vice president general counsel chief compliance officer april fonttd tr tr tdnbsptd tr tr valigntop tdfont sizebfonttd td alignleft font sizemrnbspmnbspj dormer joined company company group chairman worldwide franchise chairman depuy codman company acquired depuy inc time acquisition chief operating officer depuy inc since mrnbspdormer became member executive committee franchise group chairman medical devices aprilnbsp mrnbspdormer named worldwide chairman medical devices fonttd tr tr tdnbsptd tr tr valigntop tdfont sizecfonttd td alignleft font sizemsnbspknbspi fostercheek joined company vice president human resources johnson johnson consumer products companies march named vice president human resources consumer personal care group named member human resources leadership team consumer personal care group operating committee ms fostercheek became member executive committee vice president human resources company january prior joining company msnbspfostercheek served various human resources management positions pfizer inc nbspyears recently supporting pharmaceutical business japan asia africa middle east latin america fonttd tr table p table width border cellpadding cellspacing trtd widthtd td widthtd tr tr valigntop tdfont sizednbspfonttd td alignleft font sizemsnbspc goggins joined company held various positions becoming president personal products company named president johnson johnson consumer products company company group chairman north america johnson johnson consumer products msnbspgoggins became member executive committee worldwide chairman consumer personal care group fonttd tr table p table width border cellpadding cellspacing tr td widthtd td widthtd tr tr valigntop tdfont sizeefonttd td alignleft font sizedrnbsppnbspa peterson joined company vice president drug discovery rwnbspjohnson pharmaceutical research institute named group vice president pharmaceutical research institute april president november drnbsppeterson named chairman research development pharmaceuticals group drnbsppeterson became member executive committee fonttd tr table p aligncenterfont size font pagebreak phr noshadep h alignleft stylebreakbeforealwaysnbsphp p table width border cellpadding cellspacing tr td widthtd td widthtd tr tr valigntop tdfont sizeffonttd td alignleft font sizemrnbspjnbspc scodari joined company president centocor company acquired centocor time acquisition president chief operating officer centocor member centocors board directors since december march named company group chairman north american pharmaceutical business became member pharmaceuticals group operating committee march mrnbspscodari named company group chairman biopharmaceutical businesses mrnbspscodari named worldwide chairman pharmaceuticals group became member executive committee marchnbsp fonttd tr table p table width border cellpadding cellspacingtr td widthtd td widthtd tr tr valigntop tdfont sizegfonttd td alignleft font sizemr nnbspj valeriani joined company held various positions becoming president ethicon endosurgery inc january named company group chairman ethicon endosurgery additional responsibility johnsonnbsp johnson medical products medical devices diagnostics business canada became worldwide franchise chairman depuy franchise mrnbspvaleriani became member executive committee vice president human resources september february assumed additional responsibilities worldwide chairman diagnostics january mrnbspvaleriani appointed worldwide chairman cardiovascular devices diagnostics relinquished human resources responsibilities fonttd tr table p alignleft p aligncenter bfont sizepart iifontb divnbspdiv table width border cellpadding cellspacing tr td widthtd td widthtd tr tr valigntop tdbfont sizeitem fontbtd td bfont sizemarket registrants common equity related stockholder matters issuer purchases equity securitiesfontbtd tr table p alignleftnbspnbspnbspnbspnbsp font sizeas februarynbsp record holders common stock company information called item incorporated herein reference material captioned managements discussion analysis results operations financial conditionnbsp dividends nbsp common stock market prices nbsp notenbsp notes consolidated financial statements nbsp annual report filed exhibitnbsp report formnbspk font p alignleft bfont sizeissuer purchases equity securitiesfontb p alignleftnbspnbspnbspnbspnbsp font sizethe following table provides information respect common stock share purchases company fiscal fourth quarter stock purchases made part systematic plan meet companys compensation programs font center table width aligncenter cellspacing cellpadding border trtd widthfont sizenbspfonttd td widthfont sizenbspfonttd td widthfont sizenbspfonttd td widthfont sizenbspfonttd td widthfont sizenbspfonttd td widthfont sizenbspfonttd td widthfont sizenbspfonttd td widthfont sizenbspfonttd td widthfont sizenbspfonttd tr tr tdtd tdtd td colspan aligncenter nowrapbfont sizetotal number sharesfontbtd tdtd td colspan aligncenter nowrapbfont sizeaverage price paidfontbtd tr tr td alignleft nowrapbfont sizefiscal monthfontbtd tdtd td colspan aligncenter nowrapbfont sizepurchasedfontbtd tdtd td colspan aligncenter nowrapbfont sizeper sharefontbtd tr tr td aligncenter nowraphr size noshadetd tdtd td colspan aligncenter nowraphr size noshadetd tdtd td colspan aligncenter nowraphr size noshadetd tr tr valignbottom bgcoloreeeeee td alignleft valigntop div stylemarginleft px textindent px font sizeoctobernbsp octobernbsp fontdiv td tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignright valignbottomfont sizefonttd td alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tr tr td alignleft valigntop div stylemarginleft px textindent px font sizeoctobernbsp novembernbsp fontdiv td tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignright valignbottomfont sizefonttd td alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tr tr valignbottom bgcoloreeeeee td alignleft valigntop div stylemarginleft px textindent px font sizenovembernbsp januarynbsp fontdiv td tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignright valignbottomfont sizefonttdtd alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tr table center p alignleft bfont sizeitem nbspnbspnbspnbspnbspselected financial datafontb p alignleftnbspnbspnbspnbspnbsp font sizethe information called item incorporated herein reference material captioned summary operations statistical data nbsp annual report filed exhibitnbsp report formnbspk font divnbspdiv table width border cellpadding cellspacing tr td widthtd td widthtd tr tr valigntop tdbfont sizeitem fontbtd td bfont sizemanagements discussion analysis financial condition results operationsfontbtd tr table p alignleftnbspnbspnbspnbspnbsp font sizethe information called item incorporated herein reference narrative tabular graphic material included managements discussion analysis results operations financial condition pagesnbsp annual report filed exhibitnbsp report formnbspk font p aligncenterfont size font pagebreak phr noshadep h alignleft stylebreakbeforealwaysnbsphp p alignleft bfont sizeitemnbspanbspnbspnbspnbspnbspquantitative qualitative disclosures market riskfontb p alignleftnbspnbspnbspnbspnbsp font sizethe information called item incorporated herein reference narrative graphic material captioned managements discussion analysis results operations financial conditionnbsp liquidity capital resources pagesnbsp annual report filed exhibitnbsp report formnbspk font p alignleft bfont sizeitem nbspnbspnbspnbspnbspfinancial statements supplementary datafontb p alignleftnbspnbspnbspnbspnbsp font sizethe information called item incorporated herein reference audited consolidated financial statements notes thereto material captioned report independent registered public accounting firm pagesnbsp annual report filed exhibitnbsp report formnbspk fontdivnbspdiv table width border cellpadding cellspacing tr td widthtd td widthtd tr tr valigntop tdbfont sizeitem fontbtd td bfont sizechanges disagreements accountants accounting financial disclosurefontbtd tr table p alignleftnbspnbspnbspnbspnbsp font sizenot applicable font divnbspdiv table width border cellpadding cellspacing tr td widthtd td widthtd tr tr valigntop tdbfont sizeitemnbspafontbtd td bfont sizenbspnbspnbspnbspnbspcontrols proceduresfontbtd tr table p alignleftnbspnbspnbspnbspnbsp ifont sizedisclosure controls proceduresfontifont size end fiscal fourth quarter company evaluated effectiveness design operation disclosure controls procedures companys disclosure controls procedures designed ensure information required disclosed company reports files submits securities exchange act recorded processed summarized reported within time periods specified secs rules forms disclosure controls procedures include without limitation controls procedures designed ensure information required disclosed company reports files submits securities exchange act accumulated communicated companys management including principal executive principal financial officers persons performing similar functions appropriate allow timely decisions regarding required disclosure williamnbspc weldon chairman chief executive officer robertnbspj darretta vice chairman chief financial officer reviewed participated evaluation based evaluation messrsnbspweldon darretta concluded date evaluation companys disclosure controls procedures effective font p alignleftnbspnbspnbspnbspnbsp ifont sizeinternal controlfontifont size managements report internal control financial reporting included report formnbspk item fiscal quarter ended januarynbsp changes companys internal control financial reporting materially affected reasonably likely materially affect companys internal control financial reporting font p alignleftnbspnbspnbspnbspnbsp ifont sizemanagements report internal control financial reporting fontifont sizeundersection sarbanesoxley act management required assess effectiveness companys internal control financial reporting end fiscal year report based assessment whether companys internal control financial reporting effective font p alignleftnbspnbspnbspnbspnbsp font sizemanagement company responsible establishing maintaining adequate internal control financial reporting companys internal control financial reporting designed provide reasonable assurance reliability companys financial reporting preparation financial statements accordance generally accepted accounting principles font p alignleftnbspnbspnbspnbspnbsp font sizeinternal controls financial reporting matter well designed inherent limitations therefore internal control financial reporting determined effective provide reasonable assurance respect financial statement preparation may prevent detect misstatements moreover projections evaluation effectiveness future periods subject risk controls may become inadequate changes conditions degree compliance policies procedures may deteriorate font p aligncenterfont size font pagebreak phr noshadep h alignleft stylebreakbeforealwaysnbsphp p alignleftnbspnbspnbspnbspnbsp font sizethe companys management assessed effectiveness companys internal control financial reporting januarynbsp making assessment company used criteria established committee sponsoring organizations treadway commission coso internal controlintegrated framework criteria areas control environment risk assessment control activities information communication monitoring companys assessment included extensive documenting evaluating testing design operating effectiveness internal control financial reporting font p alignleftnbspnbspnbspnbspnbsp font sizebased companys processes assessment described management concluded januarynbsp companys internal control financial reporting effective font p alignleftnbspnbspnbspnbspnbsp font sizemanagements assessment effectiveness companys internal control financial reporting januarynbsp audited pricewaterhousecoopers llp independent registered public accounting firm stated report appears report independent registered public accounting firm nbsp annual report incorporated herein reference filed exhibitnbsp report formnbspk font p alignleft bfont sizeitem bnbspnbspnbspnbspnbspother informationfontb p alignleftnbspnbspnbspnbspnbsp font sizeon marchnbsp company announced board directors approved stock repurchase program authorizing company buy back nbspbillion companys common stock repurchases take place open market timetotime based market conditions therepurchase program time limit may suspended periods discontinued font p aligncenter bfont sizepart iiifontb p alignleft bfont sizeitem nbspnbspdirectors executive officers registrantfontb p alignleftnbspnbspnbspnbspnbsp font sizethe information called item incorporated herein reference anbspthe material caption election directorsnbsp nominees nbspother information pages proxy statement bnbspthe material part hereof caption executive officers registrant cnbspthe discussion audit committee heading directors fees committees meetings pagesnbsp proxy statement dnbspthe material caption sectionnbspa beneficial ownership reporting compliance nbsp proxy statement font p alignleftnbspnbspnbspnbspnbsp font sizethe companys policy business conduct covers employees including chief executive officer chief financial officer controller meets requirements sec rules promulgated sectionnbsp sarbanesoxley act policy business conduct available companys web site iwwwinvestorjnjcomgovernancei copies available shareholders without charge upon written request secretary companys principal address substantive amendment policy business conduct waiver policy granted chief executive officer chief financial officer controller posted companys web site iwwwinvestorjnjcomgovernancei within five business days retained web site least one year font p alignleftnbspnbspnbspnbspnbsp font sizein addition company adopted code business conduct ethics members board directors executive officers code business conduct ethics members board directors executive officers available companys web site iwwwinvestorjnjcomgovernancei copies available shareholders without charge upon written request secretary companys principal address substantive amendment code waiver code granted member board directors executive officer posted companys web site iwwwinvestorjnjcomgovernancei within five business days retained web site least one year font p alignleft bfont sizeitem nbspnbspexecutive compensationfontb p alignleftnbspnbspnbspnbspnbsp font sizethenbspinformation called item incorporated herein reference following sections proxy statement election directorsnbsp directors fees committees meetings pagesnbsp compensationnbsp benefits committee report executive compensation pagesnbsp font p aligncenterfont size font pagebreak phr noshadep h alignleft stylebreakbeforealwaysnbsphpdiv alignleft font size shareholder return performance graphs pagesnbsp executive compensation pagesnbsp font div divnbspdiv table width border cellpadding cellspacing tr td widthtd td widthtd tr tr valigntop tdbfont sizeitem fontbtd td bfont sizesecurity ownership certain beneficial owners management related stockholder mattersfontbtd tr table p alignleftnbspnbspnbspnbspnbsp font sizethe information called item incorporated herein reference material captioned election directorsnbsp stock ownershipcontrol nbsp proxy statement notenbsp notes consolidated financial statements nbsp annual report filed exhibitnbsp report formnbspk font p alignleft bfont sizeequity compensation plan informationfontb p alignleftnbspnbspnbspnbspnbsp font sizethe following table provides certain information january concerning shares companys common stock may issued existing equity compensation plans font center table width aligncenter cellspacing cellpadding border tr td widthfont sizenbspfonttd td widthfont sizenbspfonttd td widthfont sizenbspfonttd td widthfont sizenbspfonttd td widthfont sizenbspfonttd td widthfont sizenbspfonttd td widthfont sizenbspfonttd td widthfont sizenbspfonttd td widthfont sizenbspfonttd td widthfont sizenbspfonttd td widthfont sizenbspfonttd td widthfont sizenbspfonttd td widthfont sizenbspfonttd tr tr tdtd tdtd td colspan aligncenter nowrapbfont sizenumber shares befontbtd tdtd td colspan aligncenter nowrapbfont sizeweighted averagefontbtd tdtd td colspan aligncenter nowrapbfont sizenumber sharesfontbtd tr tr tdtd tdtd td colspan aligncenter nowrapbfont sizeissued upon exercise offontbtd tdtd td colspan aligncenter nowrapbfont sizeexercise pricefontbtd tdtdtd colspan aligncenter nowrapbfont sizeremaining available forfontbtd tr tr tdtd tdtd td colspan aligncenter nowrapbfont sizeoutstanding optionsfontbtd tdtd td colspan aligncenter nowrapbfont sizeof outstandingfontbtd tdtd td colspan aligncenter nowrapbfont sizefuture issuance underfontbtd tr tr tdtd tdtd td colspan aligncenter nowrapbfont sizeand rightsfontbtd tdtd td colspan aligncenter nowrapbfont sizeoptions rightsfontbtd tdtd td colspan aligncenter nowrapbfont sizeequity compensation plansfontbtd tr tr tdtd tdtd td colspan aligncenter nowrapbfont sizeasnbspofnbspjannbspnbspfontb td tdtd td colspan aligncenter nowrapbfont sizeasnbspofnbspjannbspnbspfontb td tdtd td colspan aligncenter nowrapbfont sizeasnbspofnbspjannbspnbspfontb supfont sizefontsuptd tr tr tdtd tdtd td colspan aligncenter nowraphr size noshadetd tdtd td colspan aligncenter nowraphr size noshadetd tdtd td colspan aligncenter nowraphr size noshadetd tr tr valignbottom bgcoloreeeeee td alignleft valigntop div stylemarginleft px textindent px font sizeequity compensation plans approved shareholderssupsup fontdiv td tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignright valignbottomfont sizefonttd td alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tr tr td alignleft valigntop div stylemarginleft px textindent px font sizeequity compensation plans approved shareholderssupsup fontdiv td tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignright valignbottomfont sizefonttd td alignright valignbottom nowrapfont sizefonttdtdfont sizenbspfonttd tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tr tr valignbottom bgcoloreeeeee td alignleft valigntop div stylemarginleft px textindent px font sizetotal fontdiv td tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignright valignbottomfont sizefonttd td alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tr table center p alignleft hr size width alignleft colorblack noshade p table width border cellpadding cellspacing tr td widthtd td widthtd tr tr valigntop tdsupfont sizefontsupfont sizenbspfonttd td alignleft font sizeincluded category following equity compensation plans approved companys shareholders stock option plan stock option plan stock compensation plan long term incentive plan fonttd tr table p table width border cellpadding cellspacing tr td widthtd td widthtd tr tr valigntop tdsupfont sizenbspfontsuptd td alignleft font sizeincluded category nbspshares common stock issuable various equity compensation plans assumed company upon acquisition following companies alza corporation sciosnbspinc biosensenbspinc innovasive devicesnbspinc inverness medical technologynbspinc centocornbspinc shares listed issuable category issued plans approved shareholders companies prior acquisition assumption plans company time acquisitions options acquire equity acquired company replaced options acquire common stock company stock options equity awards type made plans since assumption plans company stock options equity awards type made underany plans future fonttd tr table p table width border cellpadding cellspacing tr td widthtd td widthtd tr tr valigntop tdnbsptd td alignleft font sizethe shares included column issued plans approved shareholders applicable acquired company nbspshares issuable biosense stock option plan nbspshares issuable scios nonofficer stock option plan nbspshares issuable alza nonstatutory plan nbspshares issuable warrants inverness medical plan fonttd tr table p table width border cellpadding cellspacing tr td widthtd td widthtd tr tr valigntop tdsupfont sizenbspfontsuptd td alignleft font sizealso included category nbspshares common stock issuable upon exercise outstanding stock options companys stock option plan nonemployee directors fonttd tr tr tdnbsptd tr tr valigntop tdsupfont sizenbspfontsuptd td alignleft font sizethis column excludes shares reflected column number shares issued upon exercise outstanding options rights jannbspnbsp fonttd tr table p alignleft bfont sizeitem nbspnbspcertain relationships related transactionsfontb p alignleftnbspnbspnbspnbspnbsp font sizethe information called item incorporated herein reference material captioned election directorsnbsp certain business relationships nbsp proxy statement font p aligncenterfont size font pagebreak phr noshadep h alignleft stylebreakbeforealwaysnbsphpp alignleft bfont sizeitem nbspnbspprincipal accounting fees servicesfontb p alignleftnbspnbspnbspnbspnbsp font sizethe information called item incorporated herein reference material headings ratification appointment independent registered public accounting firm preapproval audit nonaudit services pagesnbsp proxy statement font p aligncenter bfont sizepart ivfontb p alignleft bfont sizeitem nbspnbspexhibits financial statement schedulesfontb p alignleftnbspnbspnbspnbspnbsp font sizeanbspthe following documents filed part report font p alignleftnbspnbspnbspnbspnbspnbspnbspnbspnbspnbsp font sizeinbspfinancial statementsi font p alignleftnbspnbspnbspnbspnbsp font sizethe following audited consolidated financial statements notes thereto report independent registered public accounting firm pages annual report incorporated herein reference filed exhibitnbsp report formnbspk font p alignleftnbspnbspnbspnbspnbspnbspnbspnbspnbspnbsp font sizeconsolidated balance sheets end fiscal years font p alignleftnbspnbspnbspnbspnbspnbspnbspnbspnbspnbsp font sizeconsolidated statements earnings fiscal years font p alignleftnbspnbspnbspnbspnbspnbspnbspnbspnbspnbsp font sizeconsolidated statements equity fiscal years font p alignleftnbspnbspnbspnbspnbspnbspnbspnbspnbspnbsp font sizeconsolidated statements cash flows fiscal years nbspnbspnbspnbspnbspnbspnbspnbspnbspnbspnbspnbspnbspnbspnbspnbspnbsp font p alignleftnbspnbspnbspnbspnbspnbspnbspnbspnbspnbsp font sizenotes consolidated financial statements font p alignleftnbspnbspnbspnbspnbspnbspnbspnbspnbspnbsp font sizereport independent registered public accounting firm font p alignleftnbspnbspnbspnbspnbspnbspnbspnbspnbspnbsp font sizenbspifinancial statement schedulesi font p alignleftnbspnbspnbspnbspnbspnbspnbspnbspnbspnbsp font sizeschedule iinbsp valuation qualifying accounts font p alignleftnbspnbspnbspnbspnbsp font sizeschedules listed omitted required applicable fontp alignleftnbspnbspnbspnbspnbspnbspnbspnbspnbspnbsp font sizenbspiexhibits required filed item l regulation ski font p alignleftnbspnbspnbspnbspnbsp font sizethe information called item incorporated herein reference exhibit index report font p aligncenterfont size font pagebreak phr noshadep h alignleft stylebreakbeforealwaysnbsphp p aligncenter bfont sizejohnson johnson subsidiariesfontb p aligncenter bfont sizeschedule iinbsp valuation qualifying accountsfontb p aligncenter bfont sizefiscal years ended januarynbsp januarynbsp decembernbsp fontb div aligncenter bfont sizedollars millionsfontb div center table width aligncenter cellspacing cellpadding border tr td widthfont sizenbspfonttd td widthfont sizenbspfonttd td widthfont sizenbspfonttd td widthfont sizenbspfonttd td widthfont sizenbspfonttd td widthfont sizenbspfonttd td widthfont sizenbspfonttd td widthfont sizenbspfonttd td widthfont sizenbspfonttd td widthfont sizenbspfonttd td widthfont sizenbspfonttd td widthfont sizenbspfonttd td widthfont sizenbspfonttd td widthfont sizenbspfonttd td widthfont sizenbspfonttd td widthfont sizenbspfonttd td widthfont sizenbspfonttd tr tr tdtd tdtd td colspan aligncenter nowrapbfont sizebalance atfontbtd tdtd td colspantd tdtd td colspantd tdtd td colspan aligncenter nowrapbfont sizebalance atfontbtd tr tr tdtd tdtd td colspan aligncenter nowrapbfont sizebeginningfontbtd tdtd td colspantd tdtd td colspan aligncenter nowrapbfont sizepaymentsfontbtd tdtd td colspan aligncenter nowrapbfont sizeend offontbtd trtr tdtd tdtd td colspan aligncenter nowrapbfont sizeof periodfontbtd tdtd td colspan aligncenter nowrapbfont sizeaccrualsfontbtd tdtd td colspan aligncenter nowrapbfont sizeotherfontbtd tdtd td colspan aligncenter nowrapbfont sizeperiodfontbtd tr tr tdtd tdtd td colspan aligncenter nowraphr size noshadetd tdtd td colspan aligncenter nowraphr size noshadetd tdtd td colspan aligncenter nowraphr size noshadetd tdtd td colspan aligncenter nowraphr size noshadetd tr tr valignbottom bgcoloreeeeee td alignleft valigntop div stylemarginleft px textindent px font size fontdiv td tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizenbspfonttd tdfont sizenbspfonttd tr tr td alignleft valigntop div stylemarginleft px textindent px font sizeaccrued rebates returns promotionssupsup fontdiv td tdfont sizenbspfonttd td alignright valignbottomfont sizefonttd td alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizefonttd td alignleft valignbottom nowrapsupfont sizefontsuptd tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizefonttd td alignleft valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tr tr valignbottom bgcoloreeeeee td alignleft valigntop div stylemarginleft px textindent px font sizereserve doubtful accounts fontdiv td tdfont sizenbspfonttdtd alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizefonttd td alignleft valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tr tr td alignleft valigntop div stylemarginleft px textindent px font sizereserve cash discounts fontdiv td tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizefonttd td alignleft valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tr tr tdfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignlefthr size noshadetd tdfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignlefthr size noshadetd tdfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignlefthr size noshadetd tdfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignlefthr size noshadetd tdfont sizenbspfonttd tr tr valignbottom bgcoloreeeeee tdfont sizenbspfonttd tdfont sizenbspfonttd td alignright valignbottomfont sizefonttd td alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizefonttd td alignleft valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd trtr tdfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignlefthr size noshadetd tdfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignlefthr size noshadetd tdfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignlefthr size noshadetd tdfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignlefthr size noshadetd tdfont sizenbspfonttd tr tr td alignleft valigntop div stylemarginleft px textindent px font size fontdiv td tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizenbspfonttd tdfont sizenbspfonttd tr tr valignbottom bgcoloreeeeee td alignleft valigntop div stylemarginleft px textindent px font sizeaccrued rebates returns promotionssupsup fontdiv td tdfont sizenbspfonttd td alignright valignbottomfont sizefonttd td alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizefonttd td alignleft valignbottom nowrapsupfont sizefontsuptd tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizefonttd td alignleft valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tr tr td alignleft valigntop div stylemarginleft px textindent px font sizereserve doubtful accounts fontdiv td tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttdtdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizefonttd td alignleft valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tr tr valignbottom bgcoloreeeeee td alignleft valigntop div stylemarginleft px textindent px font sizereserve cash discounts fontdiv td tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizefonttd td alignleft valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tr tr tdfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignlefthr size noshadetd tdfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignlefthr size noshadetd tdfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignlefthr size noshadetd tdfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignlefthr size noshadetd tdfont sizenbspfonttd tr tr tdfont sizenbspfonttd tdfont sizenbspfonttd td alignright valignbottomfont sizefonttd td alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizefonttd td alignleft valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tr tr tdfont sizenbspfonttdtdfont sizenbspfonttd tdfont sizenbspfonttd td alignlefthr size noshadetd tdfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignlefthr size noshadetd tdfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignlefthr size noshadetd tdfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignlefthr size noshadetd tdfont sizenbspfonttd tr tr valignbottom bgcoloreeeeee td alignleft valigntop div stylemarginleft px textindent px font size fontdiv td tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizenbspfonttd tdfont sizenbspfonttd tr tr td alignleft valigntop div stylemarginleft px textindent px font sizeaccrued rebates returns promotionssupsup fontdiv td tdfont sizenbspfonttd td alignright valignbottomfont sizefonttd td alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizefonttd td alignleft valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tr tr valignbottom bgcoloreeeeee td alignleft valigntop div stylemarginleft px textindent px font sizereserve doubtful accounts fontdiv td tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizefonttdtdfont sizenbspfonttd tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizefonttd td alignleft valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tr tr td alignleft valigntop div stylemarginleft px textindent px font sizereserve cash discounts fontdiv td tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizefonttd td alignleft valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tr tr tdfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignlefthr size noshadetd tdfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignlefthr size noshadetd tdfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignlefthr size noshadetd tdfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignlefthr size noshadetd tdfont sizenbspfonttd tr tr valignbottom bgcoloreeeeee tdfont sizenbspfonttd tdfont sizenbspfonttd td alignright valignbottomfont sizefonttd td alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizefonttd td alignleft valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tr tr tdfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignlefthr size noshadetdtdfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignlefthr size noshadetd tdfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignlefthr size noshadetd tdfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignlefthr size noshadetd tdfont sizenbspfonttd tr table center div alignleft hr size width alignleft colorblack noshade div p table width border cellpadding cellspacing tr td widthtd td widthtd tr tr valigntop tdsupfont sizenbspfontsuptd td alignleft font sizeincludes reserve customer rebates million million million januarynbsp januarynbsp decembernbsp respectively fonttd tr tr tdnbsptd tr tr valigntop tdsupfont sizenbspfontsuptd td alignleft font sizeincludes nbspmillion related previously estimated performancebased rebate allowances managed care contracts fonttd tr tr tdnbsptd tr tr valigntop tdsupfont sizenbspfontsuptd td alignleft font sizeincludes million related previously estimated performancebased rebate allowances managed care contracts fonttd tr table p aligncenterfont size font pagebreak phr noshadep h alignleft stylebreakbeforealwaysnbsphp p aligncenter bfont sizesignaturesfontb p alignleftnbspnbspnbspnbspnbsp font sizepursuant requirements section securities exchange act registrant duly causedthis report signed behalf undersigned thereunto duly authorized font p alignleft font sizedate marchnbsp font table width border cellpadding cellspacing tr td widthtd td widthtd tr tr valigntop tdnbsptd td aligncenter font sizejohnson johnson fonttd tr tr valigntop tdnbsptd td alignleft hr size alignleft colorblack noshadetd tr tr valigntop tdnbsptd td aligncenter font sizeregistrant fonttd tr table p table width border cellpadding cellspacing tr td widthtd td widthtd td widthtd tr tr valigntop tdnbsptd tdfont sizebynbspfonttd td alignleft font sizesw c weldon fonttd tr table table width border cellpadding cellspacing tr td widthtd td widthtd tr tr valigntop tdnbsptd td alignleft hr size alignleft colorblack noshadetd tr tr valigntop tdnbsptd td aligncenter font sizew c weldon chairman board directors fonttd tr tr valigntop tdnbsptd td aligncenter font sizeand chief executive officer fonttdtr table p table width border cellpadding cellspacing tr td widthtd td widthtd tr tr valigntop tdnbsptd td alignleftnbspnbspnbspnbspnbsp font sizepursuant requirements securities exchange act report signed following persons behalf registrant capacities dates indicated fonttd tr table center table width aligncenter cellspacing cellpadding border tr td widthfont sizenbspfonttd td widthfont sizenbspfonttd td widthfont sizenbspfonttd td widthfont sizenbspfonttd td widthfont sizenbspfonttd tr tr td aligncenter nowrapbfont sizesignaturefontbtd tdtd td aligncenter nowrapbfont sizetitlefontbtd tdtd td aligncenter nowrapbfont sizedatefontbtd tr tr td aligncenter nowraphr size noshadetd tdtd td aligncenter nowraphr size noshadetd tdtd td aligncenter nowraphr size noshadetd tr tr td colspanfont sizenbspfonttd tr tr td alignleft valigntop font sizes w c weldonbr hr size noshadew c weldon fonttd tdfont sizenbspfonttd td alignleft valigntop font sizechairman board directorsbr chief executive officer director principal executive officer fonttd tdfont sizenbspfonttd td alignleft valigntop font sizemarchnbsp fonttd tr tr td colspanfont sizenbspfonttd tr tr td colspanfont sizenbspfonttd tr trtd alignleft valigntop font sizes r j darrettabr hr size noshader j darretta fonttd tdfont sizenbspfonttd td alignleft valigntop font sizevice chairman board directors chief financial officer director principal financial officer fonttd tdfont sizenbspfonttd td alignleft valigntop font sizemarchnbsp fonttd tr tr td colspanfont sizenbspfonttd tr tr td alignleft valigntop font sizes c poonbr hr size noshadec poon fonttd tdfont sizenbspfonttd td alignleft valigntop font sizevice chairman board directors director fonttd tdfont sizenbspfonttd td alignleft valigntop font sizemarchnbsp fonttd tr tr td colspanfont sizenbspfonttd tr tr td alignleft valigntop font sizes j cosgrovebr hr size noshades j cosgrove fonttd tdfont sizenbspfonttd td alignleft valigntop font sizecontroller fonttd tdfont sizenbspfonttd td alignleft valigntop font sizemarchnbsp fonttd tr tr td colspanfont sizenbspfonttd tr tr td alignleft valigntop font sizes colemanbr hr size noshadem coleman fonttd tdfont sizenbspfonttd td alignleft valigntop font sizedirector fonttd tdfont sizenbspfonttd td alignleft valigntop font sizemarchnbsp fonttd tr tr td colspanfont sizenbspfonttd tr tr td alignleft valigntop font sizes j g cullenbr hr size noshadej g cullen fonttdtdfont sizenbspfonttd td alignleft valigntop font sizedirector fonttd tdfont sizenbspfonttd td alignleft valigntop font sizemarchnbsp fonttd tr tr td colspanfont sizenbspfonttd tr tr td alignleft valigntop font sizes e johnsbr hr size noshadem e johns fonttd tdfont sizenbspfonttd td alignleft valigntop font sizedirector fonttd tdfont sizenbspfonttd td alignleft valigntop font sizemarchnbsp fonttd tr tr td colspanfont sizenbspfonttd tr tr td alignleft valigntop font sizes jordanbr hr size noshadea jordan fonttd tdfont sizenbspfonttd td alignleft valigntop font sizedirector fonttd tdfont sizenbspfonttd td alignleft valigntop font sizemarchnbsp fonttd tr tr td colspanfont sizenbspfonttd tr tr td alignleft valigntop font sizes g langbobr hr size noshadea g langbo fonttd tdfont sizenbspfonttd td alignleft valigntop font sizedirector fonttd tdfont sizenbspfonttd td alignleft valigntop font sizemarchnbsp fonttd tr tr td colspanfont sizenbspfonttd tr table center p aligncenterfont size font pagebreak phr noshadep h alignleft stylebreakbeforealwaysnbsphpcenter table width aligncenter cellspacing cellpadding border tr td widthfont sizenbspfonttd td widthfont sizenbspfonttd td widthfont sizenbspfonttd td widthfont sizenbspfonttd td widthfont sizenbspfonttd tr tr td aligncenter nowrapbfont sizesignaturefontbtd tdtd td aligncenter nowrapbfont sizetitlefontbtd tdtd td aligncenter nowrapbfont sizedatefontbtd tr tr td aligncenter nowraphr size noshadetd tdtd td aligncenter nowraphr size noshadetd tdtd td aligncenter nowraphr size noshadetd tr tr td alignleft valigntop font sizes l lindquistbr hr size noshades l lindquist fonttd tdfont sizenbspfonttd td alignleft valigntop font sizedirector fonttd tdfont sizenbspfonttd td alignleft valigntop font sizemarchnbsp fonttd tr tr td colspanfont sizenbspfonttd tr tr td alignleft valigntop font sizes lf mullinbr hr size noshadelf mullin fonttd tdfont sizenbspfonttd td alignleft valigntop font sizedirector fonttd tdfont sizenbspfonttd td alignleft valigntop font sizemarchnbsp fonttd tr tr td colspanfont sizenbspfonttd tr tr td alignleft valigntop font sizes c princebr hr size noshadec prince fonttd tdfont sizenbspfonttd td alignleft valigntop font sizedirector fonttd tdfont sizenbspfonttd td alignleft valigntop font sizemarchnbsp fonttd tr trtd colspanfont sizenbspfonttd tr tr td alignleft valigntop font sizes reinemundbr hr size noshades reinemund fonttd tdfont sizenbspfonttd td alignleft valigntop font sizedirector fonttd tdfont sizenbspfonttd td alignleft valigntop font sizemarchnbsp fonttd tr tr td colspanfont sizenbspfonttd tr tr td alignleft valigntop font sizes satcherbr hr size noshaded satcher fonttd tdfont sizenbspfonttd td alignleft valigntop font sizedirector fonttd tdfont sizenbspfonttd td alignleft valigntop font sizemarchnbsp fonttd tr tr td colspanfont sizenbspfonttd tr table center p aligncenterfont size font pagebreak phr noshadep h alignleft stylebreakbeforealwaysnbsphp p aligncenter bfont sizereport independent registered public accounting firm onfontb div aligncenter bfont sizefinancial statement schedulefontb div p alignleft font sizeto board directors font div alignleft font sizejohnson johnson font div p alignleftnbspnbspnbspnbspnbsp font sizeour audits consolidated financial statements managements assessment effectiveness internal control financial reporting effectiveness internal control financial reporting referred report dated februarynbsp appearing annual report shareholders johnson johnson report consolidated financial statements assessment incorporated reference annual report formnbspk also included audit financial statement schedule listed itemnbspa formnbspk opinion financial statement schedule presents fairly material respects theinformation set forth therein read conjunction related consolidated financial statements font p alignleft font sizes pricewaterhousecoopers llp font div alignleft hr size width alignleft colorblack noshade div div alignleft font sizepricewaterhousecoopers llp font div p alignleft font sizenew york new york font div alignleft font sizefebruarynbsp font div p aligncenterfont size font pagebreak phr noshadep h alignleft stylebreakbeforealwaysnbsphp p aligncenter bfont sizeexhibit indexfontb center table width aligncenter cellspacing cellpadding border tr td widthfont sizenbspfonttd td widthfont sizenbspfonttd td widthfont sizenbspfonttd td widthfont sizenbspfonttd td widthfont sizenbspfonttd tr tr td colspan aligncenter nowrapbfont sizereg skfontbtd tdtd tdtd tr tr td colspan aligncenter nowrapbfont sizeexhibit tablefontbtd tdtd td aligncenter nowrapbfont sizedescriptionfontbtd tr tr td colspan aligncenter nowrapbfont sizeitem nofontbtd tdtd td aligncenter nowrapbfont sizeof exhibitfontbtd tr tr td colspan aligncenter nowraphr size noshadetd tdtd td aligncenter nowraphr size noshadetd tr tr td alignright valigntopfont sizenbspfonttd td alignright valigntop nowrapfont sizefonttd td alignleft valigntop nowrapfont sizeaifonttd tdfont sizenbspfonttd td alignleft valigntop font sizerestated certificate incorporation dated aprilnbsp nbsp incorporated herein reference exhibitnbspa registrants formnbspk annual report year ended decembernbsp fonttdtr tr td alignright valigntopfont sizenbspfonttd td alignright valigntop nowrapfont sizefonttd td alignleft valigntop nowrapfont sizeaiifonttd tdfont sizenbspfonttd td alignleft valigntop font sizecertificate amendment restated certificate incorporation company dated maynbsp nbsp incorporated herein reference exhibitnbspa registrants formnbspk annual report year ended januarynbsp fonttd tr tr td alignright valigntopfont sizenbspfonttd td alignright valigntop nowrapfont sizefonttd td alignleft valigntop nowrapfont sizeaiiifonttd tdfont sizenbspfonttd td alignleft valigntop font sizecertificate amendment restated certificate incorporation company dated maynbsp nbsp incorporated herein reference exhibitnbspaiii registrants formnbspk annual report year ended decembernbsp fonttd tr tr td alignright valigntopfont sizenbspfonttd td alignright valigntop nowrapfont sizefonttd td alignleft valigntop nowrapfont sizeaivfonttd tdfont sizenbspfonttd td alignleft valigntop font sizecertificate amendment restated certificate incorporation company effective maynbsp nbsp incorporated herein reference exhibitnbsp registrants formnbspq quarterly report quarter ended julynbsp fonttd tr tr td alignright valigntopfont sizenbspfonttd td alignright valigntop nowrapfont sizefonttd td alignleft valigntop nowrapfont sizebfonttd tdfont sizenbspfonttd td alignleft valigntop font sizebylaws company amended effective junenbsp nbsp incorporated herein reference exhibitnbsp registrants formnbspq quarterly report quarter ended julynbsp fonttd tr tr td alignright valigntopfont sizenbspfonttd td alignright valigntop nowrapfont sizefonttd td alignleft valigntop nowrapfont sizeafonttd tdfont sizenbspfonttd td alignleft valigntop font sizeupon request securities exchange commission registrant furnish copy instruments defining rights holders long term debt registrant fonttd tr tr td alignright valigntopfont sizenbspfonttd td alignright valigntop nowrapfont sizefonttd td alignleft valigntop nowrapfont sizeafonttd tdfont sizenbspfonttd td alignleft valigntop font sizestock option plan nonemployee directorsnbsp incorporated herein reference exhibitnbspa registrants formnbspk annual report year ended decembernbsp fonttdtr tr td alignright valigntopfont sizenbspfonttd td alignright valigntop nowrapfont sizefonttd td alignleft valigntop nowrapfont sizebfonttd tdfont sizenbspfonttd td alignleft valigntop font size stock option plan amendednbsp incorporated herein reference exhibitnbspb registrants formnbspk annual report year ended decembernbsp fonttd tr tr td alignright valigntopfont sizenbspfonttd td alignright valigntop nowrapfont sizefonttd td alignleft valigntop nowrapfont sizecfonttd tdfont sizenbspfonttd td alignleft valigntop font size stock option plan amendednbsp incorporated herein reference exhibitnbspb registrants formnbspk annual report year ended januarynbsp fonttd tr tr td alignright valigntopfont sizenbspfonttd td alignright valigntop nowrapfont sizefonttd td alignleft valigntop nowrapfont sizedfonttd tdfont sizenbspfonttd td alignleft valigntop font size stock compensation plannbsp incorporated herein reference exhibitnbspe registrants formnbspk annual report year ended decembernbsp fonttd tr tr td alignright valigntopfont sizenbspfonttd td alignright valigntop nowrapfont sizefonttd td alignleft valigntop nowrapfont sizeefonttd tdfont sizenbspfonttd td alignleft valigntop font size longterm incentive plannbspnbspincorporated herein reference exhibitnbsp registrants registration statement filed commission maynbsp file nonbsp fonttd tr tr td alignright valigntopfont sizenbspfonttd td alignright valigntop nowrapfont sizefonttd td alignleft valigntop nowrapfont sizeffonttd tdfont sizenbspfonttd td alignleft valigntop font sizeform stock option certificate restricted shares nonemployee directors certificate longterm incentive plannbsp incorporated herein reference exhibitnbsp registrants formnbspq quarterly report quarter ended julynbsp fonttd tr tr td alignright valigntopfont sizenbspfonttd td alignright valigntop nowrapfont sizefonttd td alignleft valigntop nowrapfont sizegfonttd tdfont sizenbspfonttd td alignleft valigntop font sizeform restricted stock unit certificate longterm incentive plannbsp incorporated herein reference exhibitnbsp registrants formnbspq quarterly report quarter ended octobernbsp fonttd tr tr td alignright valigntopfont sizenbspfonttd td alignright valigntop nowrapfont sizefonttd td alignleft valigntop nowrapfont sizehfonttd tdfont sizenbspfonttd td alignleft valigntop font sizeexecutive bonus plannbsp incorporated herein reference exhibitnbsp registrants formnbsps registration statement filed commission novembernbsp file nonbsp fonttd tr tr td alignright valigntopfont sizenbspfonttd td alignright valigntop nowrapfont sizefonttd td alignleft valigntop nowrapfont sizeifonttd tdfont sizenbspfonttd td alignleft valigntop font sizeexecutive incentive plan amendednbsp incorporated herein reference exhibitnbspf registrants formnbspk annual report year ended decembernbsp fonttd tr tr td alignright valigntopfont sizenbspfonttd td alignright valigntop nowrapfont sizefonttd td alignleft valigntop nowrapfont sizejfonttd tdfont sizenbspfonttd td alignleft valigntop font sizedomestic deferred compensation certificate extra compensation plan amendednbsp incorporated herein reference exhibitnbspg registrants formnbspk annual report year ended decembernbsp fonttd tr table center p aligncenterfont size font pagebreak phr noshadep h alignleft stylebreakbeforealwaysnbsphp center table width aligncenter cellspacing cellpadding border tr td widthfont sizenbspfonttd td widthfont sizenbspfonttd td widthfont sizenbspfonttd td widthfont sizenbspfonttd td widthfont sizenbspfonttd tr tr td colspan aligncenter nowrapbfont sizereg skfontbtd tdtd tdtd tr tr td colspan aligncenter nowrapbfont sizeexhibit tablefontbtd tdtd td aligncenter nowrapbfont sizedescriptionfontbtd tr tr td colspan aligncenter nowrapbfont sizeitem nofontbtd tdtd td aligncenter nowrapbfont sizeof exhibitfontbtd trtr td colspan aligncenter nowraphr size noshadetd tdtd td aligncenter nowraphr size noshadetd tr tr td alignright valigntopfont sizenbspfonttd td alignright valigntop nowrapfont sizefonttd td alignleft valigntop nowrapfont sizekfonttd tdfont sizenbspfonttd td alignleft valigntop font sizedeferred fee plan nonemployee directors amended incorporated herein reference exhibitnbsph registrants formnbspk annual report year ended januarynbsp fonttd tr tr td alignright valigntopfont sizenbspfonttd td alignright valigntop nowrapfont sizefonttd td alignleft valigntop nowrapfont sizelfonttd tdfont sizenbspfonttd td alignleft valigntop font sizeexecutive income deferral plan amendednbsp incorporated herein reference exhibitnbspi registrants formnbspk annual report year ended decembernbsp fonttd tr tr td alignright valigntopfont sizenbspfonttd td alignright valigntop nowrapfont sizefonttd td alignleft valigntop nowrapfont sizemfonttd tdfont sizenbspfonttd td alignleft valigntop font sizeexcess savings plannbsp incorporated herein reference exhibitnbspj registrants formnbspk annual report year ended decembernbsp fonttd tr tr td alignright valigntopfont sizenbspfonttd td alignright valigntop nowrapfont sizefonttd td alignleft valigntop nowrapfont sizenfonttd tdfont sizenbspfonttd td alignleft valigntop font sizesupplemental retirement plan incorporated herein reference exhibit h registrants annual report year ended januarynbsp fonttd tr tr td alignright valigntopfont sizenbspfonttd td alignright valigntop nowrapfont sizefonttd td alignleft valigntop nowrapfont sizeofonttd tdfont sizenbspfonttd td alignleft valigntop font sizeexecutive life insurance plan incorporated herein reference exhibit inbspof registrants annual report year ended januarynbsp fonttd tr tr td alignright valigntopfont sizenbspfonttd td alignright valigntop nowrapfont sizefonttd td alignleft valigntop nowrapfont sizepfonttd tdfont sizenbspfonttd td alignleft valigntop font sizestock option gain deferral plannbsp incorporated herein reference exhibitnbspm registrants formnbspk annual report year ended januarynbsp fonttd tr tr td alignright valigntopfont sizenbspfonttd td alignright valigntop nowrapfont sizefonttd td alignleft valigntop nowrapfont sizeqfonttd tdfont sizenbspfonttd td alignleft valigntop font sizeestate preservation plannbsp incorporated herein reference exhibitnbspn registrants formnbspk annual report year ended januarynbsp fonttd tr tr td alignright valigntopfont sizenbspfonttd td alignright valigntop nowrapfont sizefonttd td alignleft valigntop nowrapfont sizerfonttd tdfont sizenbspfonttd td alignleft valigntop font sizesummary employment arrangements michaelnbspj dormernbsp filed document fonttd tr tr td alignright valigntopfont sizenbspfonttd td alignright valigntop nowrapfont sizefonttd td alignleft valigntop nowrapfont sizesfonttd tdfont sizenbspfonttd td alignleft valigntop font sizesummary compensation arrangements named executive officers directors filed document fonttd tr tr td alignright valigntopfont sizenbspfonttd td alignright valigntop nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignleft valigntop font sizestatement computation ratio earnings fixed charges filed document fonttd tr tr td alignright valigntopfont sizenbspfonttd td alignright valigntop nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignleft valigntop font sizenbsppages companys annual report shareholders fiscal year portions annual report incorporated reference report deemed filed filed document fonttd tr tr td alignright valigntopfont sizenbspfonttd td alignright valigntop nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignleft valigntop font sizesubsidiaries filed document fonttd tr tr td alignright valigntopfont sizenbspfonttd td alignright valigntop nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignleft valigntop font sizeconsent independent registered publicaccounting firmnbsp filed document fonttd tr tr td alignright valigntopfont sizenbspfonttd td alignright valigntop nowrapfont sizefonttd td alignleft valigntop nowrapfont sizeafonttd tdfont sizenbspfonttd td alignleft valigntop font sizecertification chief executive officer pursuant sectionnbsp sarbanesoxley act nbsp filed document fonttd tr tr td alignright valigntopfont sizenbspfonttd td alignright valigntop nowrapfont sizefonttd td alignleft valigntop nowrapfont sizebfonttd tdfont sizenbspfonttd td alignleft valigntop font sizecertification chief financial officer pursuant sectionnbsp sarbanesoxley act nbsp filed document fonttd tr tr td alignright valigntopfont sizenbspfonttd td alignright valigntop nowrapfont sizefonttd td alignleft valigntop nowrapfont sizeafonttd tdfont sizenbspfonttd td alignleft valigntop font sizecertification chief executive officer pursuant sectionnbsp sarbanesoxley act nbsp furnished document fonttd tr tr td alignright valigntopfont sizenbspfonttd td alignright valigntop nowrapfont sizefonttd td alignleft valigntop nowrapfont sizebfonttd tdfont sizenbspfonttd td alignleft valigntop font sizecertification chief financial officer pursuant sectionnbsp sarbanesoxley act nbsp furnished document fonttd tr tr td alignright valigntopfont sizenbspfonttd td alignright valigntop nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignleft valigntop font sizecautionary statement pursuant private securities litigation reform act nbsp safe harbor forwardlooking statements filed document fonttd tr table center div alignleft hr size width alignleft colorblack noshade div p table width border cellpadding cellspacing tr td widthtd td widthtd tr tr valigntoptdfont sizenbspfonttd td alignleft font sizemanagement contract compensatory plan fonttd tr table p alignleftnbspnbspnbspnbspnbsp font sizea copy exhibits listed provided without charge shareholder submitting written request specifying desired exhibits secretary principal executive offices company font p aligncenterfont size font body html text document document typeexr sequence filenameyexvwrhtm descriptionexr summary employment arrangements michael j dormer text html head titleexrtitle head body bgcolorffffff pagebreak h alignleft stylebreakbeforealwaysnbsphp div stylewidth marginleft begin logical div alignright stylemarginleft marginright fontsize pt fontfamily arial helvetica color background ffffff bfont stylefontfamily 'times new roman ' timesexhibitrfontb div div stylemargintop pt fontsize ptnbspdiv div aligncenter stylemarginleft marginright fontsize pt fontfamily arial helvetica color background ffffff bfont stylefontfamily 'times new roman ' timessummary employment arrangements michael j dormerfontb div div stylemargintop pt fontsize ptnbspdiv div alignleft stylemarginleft marginright textindent fontsize pt fontfamily 'times new roman ' times color background ffffff certain arrangements benefits place mrmichael j dormer worldwide chairman medical devices member executive committee arising prior employment chief operating officer depuy inc johnson johnson acquired depuy mrdormer offered employment agreement replace existing employment agreement depuy inc mrdormer company agreed rescind employment agreement appointed executive committee named franchise group chairman medical devices certain benefits arrangements mrdormers employment agreement retained following arrangements benefits place continue available mrdormer div div stylemargintop pt fontsize ptnbspdiv table width border cellpadding cellspacing tr td widthtd td widthtd td widthtdtr tr valigntop stylefontsize pt fontfamily 'times new roman ' times color background ffffff tdnbsptd td td td alignleft mrdormer terminated reasons cause receive severance pay equal greater one years compensation based average previous two years base salary bonus companys severance pay policy td tr tr stylelineheight pt fontsize pttdnbsptdtr tr valigntop stylefontsize pt fontfamily 'times new roman ' times color background ffffff tdnbsptd td td td alignleft mrdormers pension benefits cover preacquisition service depuy inc td tr tr stylelineheight pt fontsize pttdnbsptdtr tr valigntop stylefontsize pt fontfamily 'times new roman ' times color background ffffff tdnbsptd td td td alignleft upon retirement involuntary termination employment company pay relocation costs associated mrdormers relocation united kingdom pursuant companys relocation policy event mrdormer dies residing united states employment company provide full relocation assistance familys relocation united kingdom including managing sale home united states td tr tr stylelineheight pt fontsize pttdnbsptdtr tr valigntop stylefontsize pt fontfamily 'times new roman ' times color background ffffff tdnbsptd td td td alignleft company funded term life insurance policy benefit mrdormers family offset negative estate tax implications mrdormer spouse die residing united states employment company td tr table div body html text document document typeexs sequence filenameyexvwshtm descriptionexs summary compensation arrangements text html head titleexstitlehead body bgcolorffffff pagebreak h alignleft stylebreakbeforealwaysnbsphp div stylewidth marginleft begin logical div alignright stylemarginleft marginright fontsize pt fontfamily arial helvetica color background ffffff bfont stylefontfamily 'times new roman ' timesexhibitsfontb div div stylemargintop pt fontsize ptnbspdiv div aligncenter stylemarginleft marginright fontsize pt fontfamily arial helvetica color background ffffff bfont stylefontfamily 'times new roman ' timessummary compensation arrangements forbr named executive officers directorsfontb div div stylemargintop pt fontsize ptnbspdiv div alignleft stylemarginleft marginright fontsize pt fontfamily arial helvetica color background ffffff bfont stylefontfamily 'times new roman ' timescompensation arrangements named executive officersfontb div div stylemargintop pt fontsize ptnbspdiv div alignleft stylemarginleft marginright textindent fontsize pt fontfamily 'times new roman ' times color background ffffff following description compensation arrangements approved compensation benefits committee board directors johnson johnson compensation committee february companys chief executive officer four highly compensated executive officers named executive officers div div stylemargintop pt fontsize ptnbspdiv div alignleft stylemarginleft marginright fontsize pt fontfamily arial helvetica color background ffffff bifont stylefontfamily 'times new roman ' timesannual base salaryfontib div div stylemargintop pt fontsize ptnbspdiv div alignleft stylemarginleft marginright textindent fontsize pt fontfamily 'times new roman ' times color background ffffff compensation committee approved following base salaries effective february named executive officers div div stylemargintop pt fontsize ptnbspdiv table border width aligncenter cellpadding cellspacing stylefontsize pt font family 'times new roman ' times color background ffffff table width row tr stylefontsize pt valignbottom td widthnbsptd colindex typemaindata td widthnbsptd colindex typegutter td width alignrightnbsptd colindex typelead td width alignrightnbsptd colindex typebody td width alignleftnbsptd colindex typehang tr tr valignbottom stylebackground cceeff td alignleft valignbottom div styletextindent pt marginleft pt font stylefontsize ptwilliam c weldon font divtd td nbsp td td nowrap alignright valignbottom td td nowrap alignleft valignbottom td td nowrap alignleft valignbottom nbsp td tr tr valignbottom td nowrap alignleft valignbottom div styletextindent pt marginleft pt font stylefontsize ptchairmanceo font div td td nbsp td td nowrap alignleft valignbottom nbsp td td nowrap alignright valignbottom nbsp td td nowrap alignleft valignbottom nbsp td tr tr valignbottom td alignleft valignbottom div styletextindent pt marginleft pt font stylefontsize ptnbsp font div td td nbsp td td nowrap alignright valignbottom nbsp td td nowrap alignleft valignbottom nbsp td td nowrap alignleft valignbottom nbsp td tr tr valignbottom stylebackground cceeff td alignleft valignbottom div styletextindent pt marginleft pt font stylefontsize ptrobert j darretta font div td td nbsp td td nowrap alignright valignbottom td td nowrap alignleft valignbottom td td nowrap alignleft valignbottom nbsp td tr tr valignbottom td nowrap alignleft valignbottom div styletextindent pt marginleft pt font stylefontsize ptvice chairmancfofont div td td nbsp td td nowrap alignleft valignbottom nbsp td td nowrap alignright valignbottom nbsp td td nowrap alignleft valignbottom nbsp td tr tr valignbottom td alignleft valignbottom div styletextindent pt marginleft pt font stylefontsize ptnbsp font div td td nbsp td td nowrap alignright valignbottom nbsp td td nowrap alignleft valignbottom nbsp td td nowrap alignleft valignbottom nbsp td tr tr valignbottom stylebackground cceeff td alignleft valignbottom div styletextindent pt marginleft pt font stylefontsize ptchristine poon font div td td nbsp td td nowrap alignright valignbottom td td nowrap alignleft valignbottom td td nowrap alignleft valignbottom nbsp td tr tr valignbottom td alignleft valignbottom div styletextindent pt marginleft pt font stylefontsize ptvice chairmanworldwide chairman medicines nutritionals font div td td nbsp td td nowrap alignleft valignbottom nbsp td td nowrap alignright valignbottom nbsp td td nowrap alignleft valignbottom nbsp td tr tr valignbottom td alignleft valignbottom div styletextindent pt marginleft ptfont stylefontsize ptnbsp font div td td nbsp td td nowrap alignright valignbottom nbsp td td nowrap alignleft valignbottom nbsp td td nowrap alignleft valignbottom nbsp td tr tr valignbottom stylebackground cceeff td alignleft valignbottom div styletextindent pt marginleft pt font stylefontsize ptmichael j dormer font div td td nbsp td td nowrap alignright valignbottom td td nowrap alignleft valignbottom td td nowrap alignleft valignbottom nbsp td tr tr valignbottom td alignleft valignbottom div styletextindent pt marginleft pt font stylefontsize ptworldwide chairman medical devices font div td td nbsp td td nowrap alignleft valignbottom nbsp td td nowrap alignright valignbottom nbsp td td nowrap alignleft valignbottom nbsp td tr tr valignbottom td alignleft valignbottom div styletextindent pt marginleft pt font stylefontsize ptnbsp font div td td nbsp td td nowrap alignright valignbottom nbsp td td nowrap alignleft valignbottom nbsp td td nowrap alignleft valignbottom nbsp td tr tr valignbottom stylebackground cceeff td alignleft valignbottomdiv styletextindent pt marginleft pt font stylefontsize ptper peterson font div td td nbsp td td nowrap alignright valignbottom td td nowrap alignleft valignbottom td td nowrap alignleft valignbottom nbsp td tr tr valignbottom td alignleft valignbottom div styletextindent pt marginleft pt font stylefontsize ptchairman rd pharmaceuticals group font div td td nbsp td td nowrap alignleft valignbottom nbsp td td nowrap alignright valignbottom nbsp td td nowrap alignleft valignbottom nbsp td tr table div alignleft stylemarginleft marginright textindent fontsize pt fontfamily 'times new roman ' times color background ffffff div div stylemargintop pt fontsize ptnbspdiv div alignleft stylemarginleft marginright fontsize pt fontfamily arial helvetica color background ffffff bifont stylefontfamily 'times new roman ' timesbonusfontib div div stylemargintop pt fontsize ptnbspdiv div alignleft stylemarginleft marginright textindent fontsize pt fontfamily 'times new roman ' times color background ffffff compensation committee approved following bonus payments performance divided discretion compensation committee cash fair market value common stock awards february div div stylemargintop pt fontsize ptnbspdiv table border width aligncenter cellpadding cellspacing stylefontsize pt font family 'times new roman ' times color background ffffff table width row tr stylefontsize pt valignbottom td widthnbsptd colindex typemaindata td widthnbsptd colindex typegutter td widthnbsptd colindex typemaindata td widthnbsptd tr tr valignbottom stylebackground cceeff td nowrap alignleft valignbottom div styletextindent pt marginleft pt font stylefontsize ptmrweldon font divtd td nbsp td td nowrap alignleft valignbottom td tr tr valignbottom td nowrap alignleft valignbottom div styletextindent pt marginleft pt font stylefontsize ptmrdarretta font div td td nbsp td td nowrap alignleft valignbottom td tr tr valignbottom stylebackground cceeff td nowrap alignleft valignbottom div styletextindent pt marginleft pt font stylefontsize ptmspoon font div td td nbsp td td nowrap alignleft valignbottom td tr tr valignbottom td nowrap alignleft valignbottom div styletextindent pt marginleft pt font stylefontsize ptmrdormer font div td td nbsp td td nowrap alignleft valignbottom td tr tr valignbottom stylebackground cceeff td nowrap alignleft valignbottom div styletextindent pt marginleft pt font stylefontsize ptdrpeterson font div td td nbsp td td nowrap alignleft valignbottom td tr table div alignleft stylemarginleft marginright textindent fontsize pt fontfamily 'times new roman ' times color background ffffff div div stylemargintop pt fontsize ptnbspdiv div alignleft stylemarginleft marginright fontsize pt fontfamily arial helvetica color background ffffff bifont stylefontfamily 'times new roman ' timesstock option restricted share unit grantsfontib div div stylemargintop pt fontsize ptnbspdivdiv alignleft stylemarginleft marginright textindent fontsize pt fontfamily 'times new roman ' times color background ffffff compensation committee approved following stock option restricted share unit rsu grants companys longterm incentive plan stock options granted exercise price fair market value companys common stock date grant options become exercisable february div p aligncenterfont stylefontsize ptfont div pagebreak phr noshadep h alignleft stylebreakbeforealwaysnbsphp div stylewidth marginleft begin logical div alignleft stylemarginleft marginright textindent fontsize pt fontfamily 'times new roman ' times color background ffffff expire february rsus granted fair market value companys common stock date grant rsus vest february upon rsu holder still employed company date receive one share companys common stock div div stylemargintop pt fontsize ptnbspdiv table border width aligncenter cellpadding cellspacing stylefontsize pt font family 'times new roman ' times color background ffffff table width row tr stylefontsize pt valignbottom td widthnbsptd colindex typemaindata td widthnbsptd colindex typegutter td widthnbsptd colindex typemaindata td widthnbsptd colindex typegutter td widthnbsptd colindex typemaindata td widthnbsptd tr tr valignbottom stylebackground cceeff td nowrap alignleft valignbottom div styletextindent pt marginleft pt font stylefontsize ptmrweldon fontdivtd tdnbsptd td alignleft valignbottom font stylefontsize pt stock options fonttd tdnbsptd td nowrap alignleft valignbottom font stylefontsize pt rsus fonttd tr tr valignbottom td nowrap alignleft valignbottom div styletextindent pt marginleft pt font stylefontsize ptmrdarretta font div td td nbsp td td alignleft valignbottom font stylefontsize pt stock options font td td nbsp td td nowrap alignleft valignbottom font stylefontsize pt rsus font td tr tr valignbottom stylebackground cceefftd nowrap alignleft valignbottom div styletextindent pt marginleft pt font stylefontsize ptmspoon font div td td nbsp td td alignleft valignbottom font stylefontsize pt stock options font td td nbsp td td nowrap alignleft valignbottom font stylefontsize pt rsus font td tr tr valignbottom td nowrap alignleft valignbottom div styletextindent pt marginleft pt font stylefontsize ptmrdormer font div td td nbsp td td alignleft valignbottom font stylefontsize pt stock options font td td nbsp td td nowrap alignleft valignbottom font stylefontsize pt rsus font td tr tr valignbottom stylebackground cceeff td nowrap alignleft valignbottom div styletextindent pt marginleft pt font stylefontsize ptdrpeterson font div td td nbsp td td alignleft valignbottom font stylefontsize pt stock options font td td nbsp td td alignleft valignbottom font stylefontsize pt rsus font td tr table div alignleft stylemarginleft marginright textindent fontsize pt fontfamily 'times new roman ' times color background ffffff div div stylemargintop pt fontsize ptnbspdiv div alignleft stylemarginleft marginright fontsize pt fontfamily arial helvetica color background ffffff bifont stylefontfamily 'times new roman ' timeslong term incentive plan awardsfontib divdiv stylemargintop pt fontsize ptnbspdiv div alignleft stylemarginleft marginright textindent fontsize pt fontfamily 'times new roman ' times color background ffffff compensation committee approved following longterm incentive plan awards february recognition performance companys certificate extra compensation cec program awards paid retirement termination employment end fiscal year cec value per unit value cec units preliminary subject increase decrease based performance company div div stylemargintop pt fontsize ptnbspdiv table border width aligncenter cellpadding cellspacing stylefontsize pt font family 'times new roman ' times color background ffffff table width row tr stylefontsize pt valignbottom td widthnbsptd colindex typemaindata td widthnbsptd colindex typegutter td widthnbsptd colindex typemaindata td widthnbsptd tr tr valignbottom stylebackground cceeff td nowrap alignleft valignbottom div styletextindent pt marginleft pt font stylefontsize ptmrweldon font div td td nbsp td td alignleft valignbottom font stylefontsize pt cec units font td tr tr valignbottom td nowrap alignleft valignbottom div styletextindent pt marginleft pt font stylefontsize ptmrdarretta font div td td nbsp td td alignleft valignbottom font stylefontsize pt cec units font td tr tr valignbottom stylebackground cceeff td nowrap alignleft valignbottom div styletextindent pt marginleft pt font stylefontsize ptmspoon font div td td nbsp td td alignleft valignbottom font stylefontsize pt cec units font td tr tr valignbottom td nowrap alignleft valignbottom div styletextindent pt marginleft pt font stylefontsize ptmrdormer font div td td nbsp tdtd alignleft valignbottom font stylefontsize pt cec units font td tr tr valignbottom stylebackground cceeff td nowrap alignleft valignbottom div styletextindent pt marginleft pt font stylefontsize ptdrpeterson font div td td nbsp td td alignleft valignbottom font stylefontsize pt cec units font td tr table div alignleft stylemarginleft marginright textindent fontsize pt fontfamily 'times new roman ' times color background ffffff div div stylemargintop pt fontsize ptnbspdiv div alignleft stylemarginleft marginright fontsize pt fontfamily arial helvetica color background ffffff bfont stylefontfamily 'times new roman ' timescompensation arrangements nonemployee directorsfontb div div stylemargintop pt fontsize ptnbspdiv div alignleft stylemarginleft marginright textindent fontsize pt fontfamily 'times new roman ' times color background ffffff nonemployee director receives annual fee services director addition directors receive service committee board directors chairperson committee presiding director paid annual fee div div stylemargintop pt fontsize ptnbspdiv div alignleft stylemarginleft marginright textindent fontsize pt fontfamily 'times new roman ' times color background ffffff longterm incentive plan nonemployee director receives nonretainer equity compensation year form restricted deferred stock value nonemployee director received grant shares restricted stock based upon fair market value common stock company february service board except mrcharles prince elected board date director receives onetime grant shares company common stock upon first becoming member board directors div p aligncenter stylefontsize pt fontfamily 'times new roman ' times color background ffffff div end logical body html text document document typeex sequence filenameyexvhtm descriptionex statement computation ratio earnings fixed charges text html head titleextitlehead body bgcolorffffff pagebreak h alignleft stylebreakbeforealwaysnbsphp p alignright bfont sizeexhibitnbspfontb p aligncenter bfont sizejohnson johnson subsidiariesfontb p aligncenter bfont sizestatement computation ratio earnings fixed chargessupsupfontb div aligncenter bfont sizedollars millionsfontb div center table width aligncenter cellspacing cellpadding border tr td widthfont sizenbspfonttd td widthfont sizenbspfonttd td widthfont sizenbspfonttd td widthfont sizenbspfonttd td widthfont sizenbspfonttd td widthfont sizenbspfonttd td widthfont sizenbspfonttd td widthfont sizenbspfonttd td widthfont sizenbspfonttd td widthfont sizenbspfonttd td widthfont sizenbspfonttd td widthfont sizenbspfonttd td widthfont sizenbspfonttd td widthfont sizenbspfonttd td widthfont sizenbspfonttd td widthfont sizenbspfonttd td widthfont sizenbspfonttd td widthfont sizenbspfonttd td widthfont sizenbspfonttd td widthfont sizenbspfonttd td widthfont sizenbspfonttd td widthfont sizenbspfonttd td widthfont sizenbspfonttd tr tr td colspantd tdtd td colspantd tr tr td colspantd tdtd td colspan aligncenter nowrapbfont sizefiscal year endedfontbtd tr tr td colspantd tdtd td colspan aligncenter nowraphr size noshadetd tr tr td colspantd tdtd td colspan aligncenter nowrapbfont sizejanuarynbspfontbtd tdtd td colspan aligncenter nowrapbfont sizejanuary fontbtd tdtd td colspan aligncenter nowrapbfont sizedecembernbspfontbtd tdtd td colspan aligncenter nowrapbfont sizedecember fontbtd tdtd td colspan aligncenter nowrapbfont sizedecember fontbtd trtr td colspantd tdtd td colspan aligncenter nowrapbfont sizefontbtd tdtd td colspan aligncenter nowrapbfont sizefontbtd tdtd td colspan aligncenter nowrapbfont sizefontbtd tdtd td colspan aligncenter nowrapbfont sizefontbtd tdtd td colspan aligncenter nowrapbfont sizefontbtd tr tr td colspantd tdtd td colspan aligncenter nowraphr size noshadetd tdtd td colspan aligncenter nowraphr size noshadetd tdtd td colspan aligncenter nowraphr size noshadetd tdtd td colspan aligncenter nowraphr size noshadetd tdtd td colspan aligncenter nowraphr size noshadetd tr tr valignbottom bgcoloreeeeee td colspan alignleft valigntop div stylemarginleft px textindent px font sizedetermination earnings fontdiv td tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizenbspfonttd tdfont sizenbspfonttd tr tr tdfont sizenbspfonttd td colspan alignleft valigntop div stylemarginleft px textindent px font sizeearnings provision taxes income fontdiv td tdfont sizenbspfonttd td alignright valignbottomfont sizefonttd td alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttdtd alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tr tr valignbottom bgcoloreeeeee tdfont sizenbspfonttd td colspan alignleft valigntop div stylemarginleft px textindent px font sizefixed charges fontdiv td tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tr tr td colspanfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignlefthr size noshadetd tdfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignlefthr size noshadetd tdfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignlefthr size noshadetd tdfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignlefthr size noshadetd tdfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignlefthr size noshadetd tdfont sizenbspfonttd tr tr tdfont sizenbspfonttd tdfont sizenbspfonttd td alignleft valigntop div stylemarginleft px textindent px font sizetotal earnings defined fontdiv td tdfont sizenbspfonttd td alignright valignbottomfont sizefonttd td alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizefonttdtdfont sizenbspfonttd tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tr tr td colspanfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignlefthr size noshadetd tdfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignlefthr size noshadetd tdfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignlefthr size noshadetd tdfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignlefthr size noshadetd tdfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignlefthr size noshadetd tdfont sizenbspfonttd tr tr valignbottom bgcoloreeeeee td colspan alignleft valigntop div stylemarginleft px textindent px font sizefixed charges fontdiv td tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizenbspfonttd tdfont sizenbspfonttd tr tr tdfont sizenbspfonttd td colspan alignleft valigntop div stylemarginleft px textindent px font sizerents fontdiv td tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttdtd alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tr tr valignbottom bgcoloreeeeee tdfont sizenbspfonttd td colspan alignleft valigntop div stylemarginleft px textindent px font sizeinterest expense capitalization interest fontdiv td tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tr tr td colspanfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignlefthr size noshadetd tdfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignlefthr size noshadetd tdfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignlefthr size noshadetd tdfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignlefthr size noshadetd tdfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignlefthr size noshadetd tdfont sizenbspfonttd tr tr tdfont sizenbspfonttd tdfont sizenbspfonttd td alignleft valigntop div stylemarginleft px textindent px font sizetotal fixed charges fontdiv td tdfont sizenbspfonttd td alignright valignbottomfont sizefonttd td alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizefonttdtdfont sizenbspfonttd tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tr tr td colspanfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignlefthr size noshadetd tdfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignlefthr size noshadetd tdfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignlefthr size noshadetd tdfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignlefthr size noshadetd tdfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignlefthr size noshadetd tdfont sizenbspfonttd tr tr valignbottom bgcoloreeeeee td colspan alignleft valigntop div stylemarginleft px textindent px font sizeratio earnings fixed charges fontdiv td tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignright valignbottomfont sizenbspfonttd td alignright valignbottom nowrapfont sizefonttd tdfont sizenbspfonttd tr tr td colspanfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignlefthr size noshadetd tdfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignlefthr size noshadetd tdfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignlefthr size noshadetd tdfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignlefthr size noshadetdtdfont sizenbspfonttd tdfont sizenbspfonttd tdfont sizenbspfonttd td alignlefthr size noshadetd tdfont sizenbspfonttd tr table center div alignleft hr size width alignleft colorblack noshade div table width border cellpadding cellspacing tr td widthtd td widthtd tr tr valigntop tdsupfont sizefontsupfont sizenbspfonttd td alignleft font sizethe ratio earnings fixed charges computed dividing sum earnings provision taxes income fixed charges fixed charges fixed charges represent interest expense interest capitalized amortization debt discount appropriate interest factor operating leases fonttd tr table body html text document document typeex sequence filenameyexvtxt descriptionex pages annual report shareholders text exhibit management 's discussion analysis results operations financial condition organization business segments description company business segments company subsidiaries approximately employees worldwide engaged manufacture sale broad range products health care field company conducts business virtually countries world primary focus products related human health wellbeing company organized three business segments consumer pharmaceutical medical devices diagnostics consumer segment manufactures markets broad range products used baby child care skin care oral wound care women 's health care fields well nutritional overthecounter pharmaceutical products products marketed principally general public sold wholesalers directly independent chain retail outlets throughout world pharmaceutical segment includes products following therapeutic areas antifungal antiinfective cardiovascular contraceptive dermatology gastrointestinal hematology immunology neurology oncology pain management psychotropic central nervous system urology areas products distributed directly retailers wholesalers health care professionals prescription use general public medical devices diagnostics segment includes broad range products used principally professional fields physicians nurses therapists hospitals diagnostic laboratories clinics products include cordis ' circulatory disease management products depuy 's orthopaedic joint reconstruction spinal care products ethicon 's wound care women 's health products ethicon endosurgery 's minimally invasive surgical products lifescan 's blood glucose monitoring products orthoclinical diagnostics ' professional diagnostic products vision care 's disposable contact lenses company 's structure based upon principle decentralizedmanagement executive committee johnson johnson principal management group responsible operations allocation resources company committee oversees coordinates activities consumer pharmaceutical medical devices diagnostics business segments subsidiary within business segments exceptions managed citizens country located product lines company competes companies large small located throughout world competition strong product lines without regard number size competing companies involved competition research involving development improvement new existing products processes particularly significant development new improved products important company 's success areas business also includes protecting company 's portfolio intellectual property competitive environment requires substantial investments continuing research multiple sales forces addition development maintenance customer acceptance company 's consumer products involves significant expenditures advertising promotion management 's objectives company 's objective achieve superior levels capital efficient profitable growth accomplish company 's management operates business consistent certain strategic principles proven successful time end company participates growth areas human health care committed attaining leadership positions growth segments development innovative products services new products introduced within past five years accounted sales billion sales invested research development increase billion significant increase reflects management 's commitment importance ongoing development new differentiated products services sustain long term growth operating companies located countries company views principle decentralized management asset fundamental success broadly based business also fosters entrepreneurial spirit combining extensive resources large organization ability react quickly local market changes challenges company committed developing global business leaders drive growth objectives businesses managed long term order sustain leadership positions achieve growth provides enduring source value shareholders unifying management team company 's dedicated employees achieving objectives johnson johnson credo credo provides common set values serves constant reminder company 's responsibilities customers employees communities shareholders company believes basic principles along overall mission improving quality life people everywhere enable johnson johnson continue among leaders health care industry results operations analysis consolidated sales worldwide sales increased billion compared increases sales increases consisted following table caption sales increase due c c c volume price currency total table sales us companies billion billion billion represents increase sales international companies billion billion billion represents increase johnson johnson annual report fiveyear compound annual growth rates worldwide us international sales respectively tenyear compound annual growth rates worldwide us international sales respectively international geographic regions experienced sales growth consisting europe western hemisphere excluding us asiapacific africa regions sales gains include positive impact currency fluctuations us dollar foreign currencies europe western hemisphere excluding us asiapacific africa region company customer represented total revenues sales cardinal distribution mckesson hboc accounted total revenues sales mckesson hboc accounted total revenues results benefited inclusion rd week see note annual closing date details company estimated fiscal fourth quarter growth rate enhanced approximately year approximately net earnings impact additional week negligible analysis sales business segments consumer segment consumer segment sales billion increase operational growth accounting total growth due positive currency fluctuations us consumer segment sales billion increase international sales billion increase result operations due currency fluctuations consumer segment sales growth attributable strong sales performance major franchises including overthecounter otc pharmaceuticals nutritionals products skin care women 's health baby kids care otc franchise sales billion increase overall growth franchise primarily resulted rapid growth splendar calorie sweetener tabletop category adult pediatric analgesics sales growth partially offset negative impact retail restrictions implemented products containing pseudoephedrine continue negatively impact business products containing pseudoephedrine reformulated skin care franchise sales billion representing increase attributable sales growth rocr aveenor clean clearr neutrogenar brand products women 's health franchise grew billion strong contributions kyr stayfreer product lines baby kids care franchise grew billion growth franchise led success johnson'sr softwashr softlotiontm product lines babycentercomr table caption major consumer franchise sales change millions dollars ' vs ' ' vs ' c c c c c otc pharmaceuticals nutritionals skin care women 's health baby kids care total table management 's discussion analysis results operations financial condition consumer segment sales billion increase operational growth accounting total growth due positive currency impact us sales increased international sales increased due operational gains positive currency impact consumer segment sales billion increase increase due operational growth due positive currency impact us sales increased international sales gains due operational gains positive currency impact pharmaceutical segment pharmaceutical segment sales billion increase change due operational growth remaining increase related positive impact currency us pharmaceutical segment sales decreased international pharmaceutical segment sales increased included operational growth related positive impact currency pharmaceutical segment sales included benefit adjustments related previously estimated performance based rebate allowances managed care contracts adjustments less sales sales growth within segment led strong performances risperdalr risperidone remicader infliximab topamaxr topiramate levaquinr levofloxacin however growth offset generic competition related duragesicr fentanyl transdermal system ultracetr tramadol hydrochlorideacetaminophen sporanoxr itraconazole hormonal contraceptives key driver growth segment continued success risperdalr risperidone risperdalr constar risperidone long acting injection medication treats symptoms schizophrenia products achieved billion sales increase prior year ongoing country approvals use risperdalr additional indications key factor product growth procritr epoetin alfa eprexr epoetin alfa performance continued adversely affected competition combined two products sales billion decline compared volume associated share loss competitive products primary driver decline remicader infliximab biologic approved treatment crohn 's disease ankylosing spondylitis use treatment rheumatoid psoriatic arthritis experienced sales billion strong growth prior year us fda granted approval remicader used treatment psoriatic arthritis fiscal second quarter remicader received approval treatment ulcerative colitis fda fiscal third quarter european commission fiscal first quarter additionally european commission granted approval use treatment severe plaque psoriasis fiscal fourth quarter approvals contributed strong growth remicader sales topamaxr topiramate approved adjunctive use epilepsy well prophylactic treatment migraines accounted billion sales achieving strong growth prior year june topamaxr also approved fda use initial monotherapy treatment epilepsy duragesicr fentanyl transdermal system sales declined billion reduction primarily driven negative impact generic competition us beginning january additionally generic versions duragesicr launched europe authorized generic version duragesicr marketed company us launched fiscal first quarter levaquinr levofloxacin floxinr ofloxacin achieved combined sales billion representing growth prior year benefiting strong market growth fiscal third quarter levaquinr obtained fda approval short course treatment acute bacterial sinusitis hormonal contraceptive franchise accounted billion sales declining prior year reduced sales ortho tricyclenr norgestimateethinyl estradiol resulting generic competition partially offset strong growth ortho tricyclenr lo norgestimateethinyl estradiol low dose oral contraceptive overall sales increase compared ortho evrar norelgestrominethinyl estradiol first contraceptive patch approved fda labeling changes negative media coverage concerning product safety expected impact sales table caption major pharmaceutical product revenues change millions dollars ' vs ' ' vs ' c c c c c risperdalr risperidonerisperdalr constar risperidone procritreprexr epoetin alfa remicader infliximab topamaxr topiramate duragesicr fentanyl transdermal systemfentanyl transdermal levaquinrfloxinr levofloxacinofloxacin aciphexrparietr rabeprazole sodium hormonal contraceptives total table johnson johnson annual report concertar methylphenidate hcl product treatment attention deficit hyperactivity disorder achieved sales billion representing increase present fda approved generic version substitutable concertar abbreviated new drug applications andas generic versions concertar pending may approved time recent negative publicity fda activities concerning attention deficit hyperactivity products may impact concertar sales natrecorr nesiritide product treatment patients acutely decompensated congestive heart failure dyspnea rest minimal activity experienced significant decline demand due recent negative media coverage regarding meta analysis selected historical clinical trials company believes new data supporting conclusions medical consumer publications currently approved label natrecorr reflects available data date response company assembled expert panel review available data clinical development plans product engaged dialogue fda panel fda support continued appropriate use natrecorr natrecorr scios inc product purchased company resulted recording intangible asset amortized years remaining unamortized intangible value associated natrecorr billion end fiscal fourth quarter based current estimate projected future cash flows adjustment intangible asset required pharmaceutical segment sales included benefit adjustments related previously estimated performancebased rebate allowances managed care contracts adjustments made based review actual performance levels achieved customers compared expected performance levels favorable adjustments amounted less one percentage point pharmaceutical segment 's operational growth vast majority impact adjustment hormonal contraceptive franchise pharmaceutical segment sales billion increase change due operational growth remaining increase related positive impact currency us pharmaceutical segment sales increased international pharmaceutical segment sales increased included growth operationally related positive impact currency pharmaceutical segment sales billion increase due operational growth due positive currency fluctuations us sales increased international sales grew included operational growth positive impact currency medical devices diagnostics segment medical devices diagnostics segment achieved sales billion representing increase prior year operational growth positive impact currency us sales increased international sales increased operations currency strong sales growth medical devices diagnostics segment achieved multiple franchises cordis franchise key contributor segment results reported sales billion increase prior year primary growth driver cordis franchise cypherr sirolimuseluting stent us international markets excellent growth japan biosense webster also contributed success cordis franchise continued solid doubledigit growth fiscal fourth quarter biosense webster received approval use celsiustm rmt diagnostic ablation steerable tip catheterin april july cordis cardiology division cordis corporation received warning letters fda regarding good manufacturing practice regulations good clinical practice regulations observations followed postapproval site inspections completed early including sites involved production cypherr sirolimuseluting stent response warning letters cordis made improvements quality systems anticipates followup site inspections fiscal first second quarters table caption major medical devices diagnostics franchise sales change millions dollars ' vs ' ' vs ' c c c c c cordisr depuyr ethiconr ethicon endosurgeryr lifescanr vision care orthoclinical diagnosticsr total table management 's discussion analysis results operations financial condition depuy franchise reported billion sales represents growth prior year doubledigit growth depuy 's orthopaedic joint reconstruction unit led increase franchise strong sales growth also achieved depuy 's spine unit mitek sports medicine products ethicon worldwide franchise achieved billion sales representing growth prior year contributing strong results continued growth suture mesh products including vicrylr polyglactin plus antibacterial coated suture multipassr needles proceedr tissue separating mesh ethicon endosurgery franchise reported billion sales representing growth prior year growth mainly driven endocutter sales include products used performing bariatric procedures treatment obesity important focus area franchise doubledigit sales increases advanced sterilization products line also key contributor overall sales growth franchise lifescan franchise reported billion sales growth rate prior year onetouchr ultrar product line achieved strong growth vision care franchise achieved billion sales growth rate prior year led continued success acuvuer advancetm brand contact lenses hydracleartm day acuvuer additional contributor acuvuer oasystm hydracleartm tired dry eyes launched fiscal third quarter orthoclinical diagnostics franchise reported billion sales representing growth prior year growth mainly driven continued market penetration automated blood typing products ongoing growth eci product line success vitrosr fs clinical chemistry system medical devices diagnostics segment achieved sales billion representing increase prior year operational growth positive impact currency us sales increased international sales increased operations currency medical devices diagnostics segment achieved sales billion representing increase prior year operational growth positive impact currency us sales increased international sales increased operations currency analysis consolidated earnings provision taxes income consolidated earnings provision taxes income increased billion billion earned increase billion percent sales consolidated earnings provision taxes income representing decrease improvement decline sections thatfollow highlight significant components changes consolidated earnings provision taxes income cost products sold selling marketing administrative expenses cost products sold selling marketing administrative expenses percent sales follows table caption sales c c c cost products sold percent increasedecrease prior year selling marketing administrative expenses percent increasedecrease prior year table decrease percent sales cost products sold due lower manufacturing costs primarily related cypherr sirolimuseluting stent well ongoing cost containment activity across organization partially offset negative impact pharmaceutical product mix also decrease percent sales selling marketing administrative expenses due cost containment initiatives pharmaceutical segment partially offset increases investment spending medical devices diagnostics segment decrease percent sales cost products sold due favorable mix well cost improvement initiatives also decrease percent sales selling marketing administrative expenses due company 's focus managing expenses partially offset increase investment spending across number businesses focused driving future growth change percent sales selling marketing administrative expenses increase percent sales cost products sold due changes mix products varying cost structures well cost retirement enhancement program million expensed fiscal fourth quarter research development research activities represent significant part company 's business expenditures relate development new products improvement existing products technical support products compliance governmental regulations protection consumers patients worldwide costs research activities excluding process research development charges follows table caption millions dollars c c c research expense percent increase prior year percent sales table research development expense percent sales pharmaceutical segment combined consumer medical devices diagnostics segments averaged respectively johnson johnson annual report research activities accelerated pharmaceutical segment increasing billion compound annual growth rate approximately fiveyear period since increased investment research development segments demonstrates company 's focus knowledge based products reflects significant number projects late stage development inprocess research development company recorded inprocess research development iprd charges million tax related acquisitions transform pharmaceuticals inc closure medical corporation peninsula pharmaceuticals inc international commercial rights certain patents knowhow field sedation analgesiafrom scott lab inc transform pharmaceuticals inc company specializing discovery superior formulations novel crystalline forms drug molecules accounted million tax iprd charges included operating profit pharmaceutical segment closure medical corporation company expertise intellectual property biosurgicals market accounted million tax iprd charges included operating profit medical devices diagnostics segment peninsula pharmaceuticals inc biopharmaceutical company focused developing commercializing antibiotics treat lifethreatening infections accounted million tax iprd charges included operating profit pharmaceutical segment million tax iprd charge related scott lab inc referred included operating profit medical devices diagnostics segment company recorded iprd charges million tax result acquisition us commercial rights certain patents knowhow field sedation analgesia scott lab inc charge included operating profit medical devices diagnostics segment company recorded iprd charges million tax related acquisitions scios inc link spine group inc certain assets orquest inc dimensional pharmaceuticals inc scios inc biopharmaceutical company marketed product cardiovascular disease research projects focused autoimmune diseases acquisition scios inc accounted million tax iprd charges included operating profit pharmaceutical segment link spine group inc acquired provide company exclusive worldwide rights charitetm artificial disc treatment spine disorders acquisition link spine group inc accounted million tax iprd charges included operating profit medical devices diagnostics segment orquest inc biotechnology company focused developing biologicallybased implants orthopaedic spine surgery acquisition certain assets orquest inc accounted million tax iprd charges included operating profit medical devices diagnostics segment dimensional pharmaceuticals inc company technology platform focused discovery development potential new drugs early stage development inflammation acquisition dimensional pharmaceuticals inc accounted million tax iprd charges included operating profit pharmaceutical segment income expense net income expense includes gains losses related sale writedown certain investments equity securities held johnson johnson development corporation gains losses disposal property plant equipment currency gains losses minority interests litigation settlement income expense royalty income change net income expense increase income million income balance million included royalty income partially offset several expense items none individually significant expense balance million included several expense items none individually significant partially offset royalty income income million included favorable ruling stent patent settlement million amount received fourth quarter included medical devices diagnostics segment operating profit also included medical devices diagnostics segment operating profit gain sale various product lines longer compatible segment 's strategic goals income also included recovery million loan previously written included pharmaceutical segment operating profit operating profit segment operating profits segment business follows table caption percent segment sales millions dollars c c c c consumer pharmaceutical med devices diag segments total less expenses allocated segments earnings provision taxes income table amounts allocated segments include interest incomeexpense minority interest general corporate incomeexpense management 's discussion analysis results operations financial condition consumer segment consumer segment operating profit increased prior year percent sales increased slightly despite increases investment spending advertising research development consumer segment operating profit increased prior year percent sales experienced decrease primarily due additional investment consumer promotions advertising overthecounter pharmaceuticals nutritionals franchise pharmaceutical segment pharmaceutical segment operating profit decreased percent sales declined change primarily due increased investment research development spending well impact million iprd expenses pharmaceutical segment operating profit increased reflected operating profit percent sales improvement change primarily due impact million iprd expenses medical devices diagnostics segment medical devices diagnostics segment operating profit increased percent sales increased increase driven improved gross margins due cost reduction programs product mix primarily related cypherr sirolimuseluting stent partially offset increased investment research development spending medical devices diagnostics segment operating profit increased increase prior year achieved improved gross margins resulting cost reduction programs product mix impact million iprd expenses related acquisitions interest income expense interest income increased million due primarily higher rates interest well higher average cash balance cash balance including current marketable securities billion end averaged billion compared billion average cash balance interest expense decreased compared due part decrease average debt balance billion billion interest income increased million due primarily higher cash balance cash marketable securities combined balance end billion averaged billion significantly higher billion average cash balance interest expense decreased million compared primarily due decrease average debt balance billion billion provision taxes income worldwide effective income tax rate decrease tax rate attributable tax benefit million recorded related technical correction associated american jobs creation act also contributing decrease tax rate increase taxable income lower tax jurisdictions relative taxable income higher tax jurisdictions result increased expenditures higher tax jurisdictions shift sales mix benefits partially offset nondeductible iprd charges increase effective tax rate primarily due million tax cost intended repatriation undistributed international earnings associated american jobs creation act added effective income tax rate liquidity capital resources cash flows cash generated operations selected borrowings provide major sources funds growth business including working capital capital expenditures acquisitions uses cash include share repurchases dividends debt repayments cash flow operations billion increase billion increase cash generated operations result net income increase billion net noncash impact iprd charges billion decrease current noncurrent assets alsocontributed increase partially offset billion decrease accounts payable accrued liabilities additionally cash payments approximately billion made previously accrued taxes repatriation undistributed international earnings accordance american jobs creation act also increase approximately billion pension funding compared net cash used investing activities decreased billion due billion net increase sales investments partially offset billion increase capital expenditures billion increase acquisition activity detailed discussion mergers acquisitions see note net cash used financing activities decreased billion due net issuance debt partially offset increase dividends increased levels common stock repurchases cash current marketable securities billion end compared billion end cash generated operations amounted billion billion cash generated operations billion major factor contributing increase net income increase billion net noncash impact iprd charges johnson johnson annual report financing market risk company uses financial instruments manage impact foreign exchange rate changes cash flows accordingly company enters forward foreign exchange contracts protect value existing foreign currency assets liabilities hedge future foreign currency product costs gains losses contracts offset gains losses underlying transactions appreciation us dollar january market rates would increase unrealized value company 's forward contracts million conversely depreciation us dollar january market rates would decrease unrealized value company 's forward contracts million either scenario gain loss forward contract would offset change value forecasted transaction therefore would impact future earnings cash flows company hedges exposure fluctuations currency exchange rates effect certain assets liabilities foreign currency entering currency swap contracts change spread us foreign interest rates company 's interest rate sensitive financial instruments would either increase decrease unrealized value company 's swap contracts approximately million either scenario maturity gain loss swap contract would offset gain loss underlying transaction therefore would impact future earnings cash flows company use financial instruments trading speculative purposes company policy entering contracts parties least equivalent credit rating counterparties contracts major financial institutions significant concentration exposure one counterparty management believes risk loss remote total unused credit available company approximates billion including billion credit commitments billion expire september billion expire september also included billion uncommitted lines various banks worldwide expire total borrowings end billion billion respectively net cash cash current marketable securities net debt billion compared net cash billion total debt represented total capital shareholders ' equity total debt total capital shareholders ' equity per share end compared yearend increase august scios inc exercised right redeem outstanding million original principal amount convertible subordinated notes due redemption price principal amount per principal amount debentures accrued interest excluding date redemption period ended january material cash commitments johnson johnson continues one industrial companies triple credit rating summary borrowings found note longterm contractual obligations commitments company longterm contractual obligations primarily lease debt obligations unfunded retirement plans significant obligations satisfy obligations company use cash operations following table summarizes company 's contractual obligations aggregate maturities january see notes forfurther details table caption longterm unfunded operating debt retirement millions dollars leases obligations plans total c c c c total table amounts include interest expense dividends company increased dividend rd consecutive year cash dividends paid per share compared dividends per share per share dividends distributed follows table caption c c c first quarter second quarter third quarter fourth quarter total table january board directors declared regular cash dividend per share payable march shareholders record february company expects continue practice paying regular cash dividends management 's discussion analysis results operations financial condition information critical accounting policies estimates management 's discussion analysis results operations financial condition based company 's consolidated financial statements prepared accordance accounting principles generally accepted us preparation financial statements requires management make estimates assumptions affect amounts reported revenues expenses assets liabilities related disclosures actual results may may differ estimates company believes understanding certain key accounting policies estimates essential achieving insight company 's operating results financial condition key accounting policies include revenue recognition income taxes legal self insurance contingencies valuation longlived assets assumptions used determine amounts recorded pensions employee benefit plans accounting stock options revenue recognition company recognizes revenue product sales goods shipped delivered title risk loss pass customer provisions certain rebates sales incentives trade promotions coupons product returns discounts customers accounted reductions sales period related sales recorded product discounts granted based terms arrangements direct indirect market participants well market conditions including prices charged competitors rebates largest medicaid rebate provision estimated based sales terms historical experience trend analysis projected market conditions various markets served company evaluates market conditions products groups products primarily analysis wholesaler third party sellthrough market research data well internally generated information sales returns generally estimated recorded basedon historical sales returns information products exhibit unusual sales return patterns due dating competition marketing matters specifically investigated analyzed part accounting sales return accruals company also earns service revenue copromotion certain products years presented service revenues less total revenues included sales customers income taxes income taxes recorded based amounts refundable payable current year include results difference us gaap accounting us tax reporting recorded deferred tax assets liabilities company estimates deferred tax assets liabilities based current tax regulations rates changes tax laws rates may affect recorded deferred tax assets liabilities future management believes changes estimates would result material effect company 's results operations cash flows financial position company repatriated previously disclosed billion undistributed international earnings accordance american jobs creation act ajca recorded tax charge million fiscal fourth quarter fiscal second quarter company recorded tax benefit million due reversal tax liability previously recorded fiscal fourth quarter associated technical correction made ajca may january january cumulative amount undistributed international earnings approximately billion billion respectively company intends continue reinvest undistributed international earnings expand international operations therefore us tax expense recorded cover undistributed portion intended repatriation legal self insurance contingencies company records accruals various contingencies including legal proceedings product liability cases arise normal course business accruals based management 's judgment probability losses opinions legal counsel applicable actuarially determined estimates additionally company records insurance receivable amounts third party insurers recovery probable appropriate reserves receivables recorded estimated amounts may collected third party insurers longlived intangible assets company assesses changes economic conditions makes assumptions regarding estimated future cash flows evaluating value company 's property plant equipment goodwill intangible assets assumptions estimates may change time may may necessary company record impairment charges fiscal years certain tangible intangible assets written fair value resulting charge recorded cost products sold insignificant employee benefit plans company sponsors various retirement pension plans including defined benefit defined contribution termination indemnity plans cover employees worldwide plans based assumptions discount rate expected return plan assets expected salary increases health care cost trend rates see note detail rates effect rate change would company 's results operations johnson johnson annual report stock options company elected use accounting principles board opinion accounting stock issued employees apb require compensation costs related stock options charged net income options granted various stock options plans exercise price equal market value underlying common stock grant date statement financial accounting standard sfas accounting stockbased compensationtransition disclosurean amendment fasb statement requires pro forma disclosure net income earnings per share determined fair value method accounting stock options applied measuring compensation cost see notes information regarding stock options new accounting standards december fasb issued sfas r share based payment statement establishes standards accounting transactions entity exchanges equity instruments goods services focuses primarily accounting transactions entity obtains employee services sharebased payment transactions employee stock options restricted stock units statement requires measurement cost employee services received exchange award equity instruments employee stock options restricted stock units fair value grant date cost recognized period employee isrequired provide services exchange award requisite service period april sec approved new rule delayed effective date sfas r annual rather interim periods begin june result company adopt statement fiscal first quarter upon adoption standard company currently intends apply modified retrospective transition method previously reported financial statements restated reflect sfas disclosure amounts required sfas accounting stock based compensationtransition disclosurean amendment fasb statement company disclosed net income earnings per share effect company applied fair value recognition provision sfas disclosure impact compensation expense net tax million million earnings per share respectively company implement sfas inventory costs amendment arb fiscal first quarter company believes adoption statement material effect results operations cash flows financial position company implemented fin accounting conditional asset retirement obligationsan interpretation fasb statement fiscal fourth quarter implementation standard material effect company 's results operations cash flows financial position company implemented sfas exchanges nonmonetary assets amendment apb fiscal third quarter material effect results operations cash flows financial position following accounting pronouncements became effective material impact company 's results operations cash flows financial position eitf issue whether investor apply equity method accounting investments common stock eitf issue accounting preexisting relationships parties business combination following accounting pronouncements became effective material impact company 's results operations cash flows financial position fsp fas accounting disclosure requirements related medicare prescription drug improvement modernization act sfas amendment statement derivative instruments hedging activities fin fin r consolidation variable interest entities interpretation arb economic market factors johnson johnson aware products used environment decade policymakers consumers businesses expressed concerns rising cost health care response concerns johnson johnson long standing policy pricing products responsibly period us weighted average compound annual growth rate johnson johnson net price increases health care products prescription overthecounter drugs hospital professional products us consumer price index cpi inflation rates even though moderate many parts world continue effect worldwide economies consequently way companies operate face increasing costs company strives maintain profit margins cost reduction programs productivity improvements periodic price increases company faces various worldwide health care changes may result pricing pressures include health care cost containment government legislation relating sales promotions reimbursement management 's discussion analysis results operations financial condition company also operates environment become increasingly hostile intellectual property rights generic drug firms filed abbreviated new drug applications seeking market generic forms company 's key pharmaceutical products prior expiration applicable patents covering products event company successful defending patent claims challenged abbreviated new drug application filings generic firms introduce generic versions product issue resulting potential substantial market share revenue losses product information see discussion litigation filers abbreviated new drug applications note legal proceedings company involved numerous product liability cases us many concern adverse reactions drugs medical devices damagesclaimed substantial company confident adequacy warnings instructions use accompany products feasible predict ultimate outcome litigation however company believes liability results cases substantially covered existing amounts accrued company 's balance sheet available thirdparty product liability insurance company also involved number patent trademark lawsuits incidental business ultimate legal financial liability company respect claims lawsuits proceedings referred estimated certainty however company 's opinion based examination matters experience date discussions counsel ultimate outcome legal proceedings net liabilities already accrued company 's balance sheet expected material adverse effect company 's financial position although resolution reporting period one matters could significant impact company 's results operations cash flows period see note information regarding legal proceedings common stock market prices company 's common stock listed new york stock exchange symbol jnj composite market price ranges johnson johnson common stock table caption high low high low c c c c c c first quarter second quarter third quarter fourth quarter yearend close table cautionary factors may affect future results annual report contains forwardlooking statements forwardlooking statements relate strictly historical current facts anticipate results based management 's plans subject uncertainty forwardlooking statements may identified use words like plans expects anticipates estimates words similar meaning conjunction among things discussions future operations financial performance company 's strategy growth product development regulatory approval market position expenditures forwardlooking statements based current expectations future events company guarantee forwardlooking statement accurate although company believes reasonable expectations assumptions investors realize underlying assumptions prove inaccurate unknown risks uncertainties materialize actual results could vary materially company 's expectations projections investors therefore cautioned place undue reliance forwardlooking statements company assumes obligation update forwardlooking statements result new information future events developments risks uncertainties include general industry conditions competition economic conditions interest rate currency exchange rate fluctuations technological advances new products patents attained competitors challenges inherent new product development including obtaining regulatory approvals challenges patents us foreign health care reforms governmental laws regulations trends toward health care cost containment increased scrutiny health care industry government agencies product efficacy safety concerns resulting product recalls regulatory action company 's report year ended january includes exhibit b discussion additional factors could cause actual results differ expectations company notes factors permitted private securities litigation reform act johnson johnson annual report table caption consolidated balance sheets johnson johnson subsidiariesat january january dollars millions except share per share data note assets c c current assets cash cash equivalents notes marketable securities notes accounts receivable trade less allowances doubtful accounts inventories notes deferred taxes income note prepaid expenses receivables total current assets marketable securities noncurrent notes property plant equipment net notes intangible assets net notes goodwill net notes deferred taxes income note assets note total assets liabilities shareholders ' equity current liabilities loans notes payable note accounts payable accrued liabilities accrued rebates returns promotions accrued salaries wages commissions accrued taxes income total current liabilities longterm debt note deferred taxes income note employee related obligations notes liabilities total liabilities shareholders ' equity preferred stockwithout par value authorized unissued shares common stockpar value per share note authorized shares issued shares note receivable employee stock ownership plan note accumulated comprehensive income note retained earnings less common stock held treasury cost note shares shares total shareholders ' equity total liabilities shareholders ' equity table see notes consolidated financial statements consolidated financial statements table caption consolidated statements earnings johnson johnson subsidiaries dollars millions except per share figures note c c c sales customers cost products sold gross profit selling marketing administrative expenses research expense purchased inprocess research development note interest income interest expense net portion capitalized note income expense net earnings provision taxes income provision taxes income note net earnings basic net earnings per share notes diluted net earnings per share notes table see notes consolidated financial statements johnson johnson annual report table caption consolidated statements equity johnson johnson subsidiaries note receivable employee accumulated common stock stock treasury comprehensive retained ownership comprehensive issued stock dollars millions note total income earnings plan esop income amount amount c c c c c c c balance december net earnings cash dividends paid employee stock compensation stock option plans conversion subordinated debentures repurchase common stock business combinations comprehensive income net tax currency translation adjustment unrealized gains securities pension liability adjustment losses derivatives hedges reclassification adjustment total comprehensive income note receivable esop balance december net earnings cash dividends paid employee stock compensation stock option plans conversion subordinated debentures repurchase common stock comprehensive income net tax currency translation adjustment unrealized gains securities pension liability adjustment gains derivatives hedges reclassification adjustment total comprehensive income note receivable esop balance january net earnings cash dividends paid employee stock compensation stock option plans conversion subordinated debentures repurchase common stock comprehensive income net tax currency translation adjustment unrealized losses securities pension liability adjustment gains derivatives hedges reclassification adjustment total comprehensive income note receivable esop balance january table see notes consolidated financial statements consolidated financial statements table caption consolidated statements cash flows johnson johnson subsidiaries dollars millions note c c c cash flows operating activities net earnings adjustments reconcile net earnings cash flows depreciation amortization property intangibles purchased inprocess research development deferred tax provision accounts receivable allowances changes assets liabilities net effects acquisitions increase accounts receivable increasedecrease inventories decreaseincrease accounts payable accrued liabilities decreaseincrease current noncurrent assets increase current noncurrent liabilities net cash flows operating activities cash flows investing activities additions property plant equipment proceeds disposal assets acquisitions net cash acquired note purchases investments sales investments primarily intangibles net cash used investing activities cash flows financing activities dividends shareholders repurchase common stock proceeds shortterm debt retirement shortterm debt proceeds longterm debt retirement longterm debt proceeds exercise stock options net cash used financing activities effect exchange rate changes cash cash equivalents increase cash cash equivalents cash cash equivalents beginning year note cash cash equivalents end year note supplemental cash flow data cash paid year interest income taxes supplemental schedule noncash investing financing activities treasury stock issued employee compensation stock option plans net cash proceeds conversion debt acquisitions fair value assets acquired fair value liabilities assumed net cash paid acquisitions table see notes consolidated financial statements johnson johnson annual report notes consolidated financial statements summary significant accounting policies principles consolidation consolidated financial statements include accounts johnson johnson subsidiaries intercompany accounts transactions eliminated description company business segments company subsidiaries approximately employees worldwide engaged manufacture sale broad range products health care field company conducts business virtually countries world primary focus products related human health wellbeing company organized three business segments consumer pharmaceutical medical devices diagnostics consumer segment manufactures markets broad range products used baby child care skin care oral wound care women 's health care fields well nutritional overthecounter pharmaceutical products products marketed principally general public sold wholesalers directly independent chain retail outlets throughout world pharmaceutical segment includes products following therapeutic areas antifungal antiinfective cardiovascular contraceptive dermatology gastrointestinal hematology immunology neurology oncology pain management psychotropic central nervous system urology areas products distributed directly retailers wholesalers health care professionals prescription use general public medical devices diagnostics segment includes broad range products used principally professional fields physicians nurses therapists hospitals diagnostic laboratories clinics products include cordis ' circulatory disease management products depuy 's orthopaedic joint reconstruction spinal care products ethicon 's wound care women 's health products ethicon endosurgery 's minimally invasive surgical products lifescan 's blood glucose monitoring products orthoclinical diagnostics ' professional diagnostic products vision care 's disposable contact lenses new accounting pronouncements december fasb issued sfas r share based payment statement establishes standards accounting transactions entity exchanges equity instruments goods services focuses primarily accounting transactions entity obtains employee services sharebased payment transactions employee stock options restricted stock units statement requires measurement cost employee services received exchange award equity instruments employee stock options restricted stock units fair value grant date cost recognized period employee required provide services exchange award requisite service period april sec approved new rule delayed effective date sfas r annual rather interim periods begin june result company adopt statement fiscal first quarter upon adoption standard company currently intends apply modified retrospective transition method previously reported financial statements restated reflect sfas disclosure amounts required sfas accounting stock based compensationtransition disclosurean amendment fasb statement company disclosed net earnings earnings per share effect company applied fair value recognition provision sfas disclosure impact compensation expense net tax million million earnings per share respectively company implement sfas inventory costs amendment arb fiscal first quarter company believes adoption statement material effect results operations cash flows financial position company implemented fin accounting conditional asset retirement obligationsan interpretation fasb statement fiscal fourth quarter implementation standard material effect company 's results operations cash flows financial position company implemented sfas exchanges nonmonetary assets amendment apb fiscal third quarter material effect results operations cash flows financialposition following accounting pronouncements became effective material impact company 's results operations cash flows financial position eitf issue whether investor apply equity method accounting investments common stock eitf issue accounting preexisting relationships parties business combination following accounting pronouncements became effective material impact company 's results operations cash flows financial position fsp fas accounting disclosure requirements related medicare prescription drug improvement modernization act sfas amendment statement derivative instruments hedging activities fin fin r consolidation variable interest entitiesan interpretation arb cash equivalents company considers securities maturities three months less purchased cash equivalents investments shortterm marketable securities carried cost approximates fair value investments classified availableforsale carried estimated fair value unrealized gains losses recorded component accumulated comprehensive income longterm debt securities company ability intent hold maturity carried amortized cost also approximates fair value notes consolidated financial statements management determines appropriate classification investment debt equity securities time purchase reevaluates determination balance sheet date company periodically reviews investments equity securities impairment adjusts investments fair value decline market value deemed temporary property plant equipment depreciation property plant equipment stated cost company utilizes straightline method depreciation estimated useful lives assets table caption c building building equipment years land leasehold improvements years machinery equipment years table company capitalizes certain computer software development costs included machinery equipment incurred connection developing obtaining computer software internal use capitalized software costs amortized estimated useful lives software generally range years company reviews longlived assets assess recoverability using undiscounted cash flows necessary charges impairments longlived assets recorded amount present value future cash flows less carrying value assets revenue recognition company recognizes revenue product sales goods shipped delivered title risk loss pass customer provisions certain rebates sales incentives trade promotions coupons product returns discounts customers accounted reductions sales period related sales recorded product discounts granted based terms arrangements direct indirect market participants well market conditions including prices charged competitors rebates largest medicaid rebate provision estimated based sales terms historical experience trend analysis projected market conditions various markets served company evaluates market conditions products groups products primarily analysis wholesaler third party sellthrough market research data well internally generated information sales returns generally estimated recorded based historicalsales returns information products exhibit unusual sales return patterns due dating competition marketing matters specifically investigated analyzed part accounting sales return accruals company also earns service revenue copromotion certain products includes sales customers shipping handling shipping handling costs incurred million million million respectively included selling marketing administrative expense amount revenue received shipping handling less sales customers periods presented inventories inventories stated lower cost market determined firstin firstout method goodwill intangible assets effective beginning fiscal year accordance sfas company discontinued amortization relating existing goodwill indefinite lived intangible assets nonamortizable sfas requires goodwill nonamortizable intangible assets assessed annually impairment company completed annual impairment test fiscal fourth quarter impairment determined future impairment tests performed annually fiscal fourth quarter sooner triggering event occurs intangible assets finite useful lives continue amortized useful lives reviewed impairment warranted economic conditions see note details intangible assets financial instruments company follows provisions sfas accounting derivative instruments hedging activities amended sfas accounting certain derivative instruments certain hedging activities sfas amendment statement derivative instruments hedging activities collectively referred sfas sfas requires derivative instruments recorded balance sheet fair value changes fair value derivatives recorded period current earnings comprehensive income depending whether derivative designated part hedge transaction type hedge transaction company uses forward exchange contracts manage exposure variability cash flows primarily related foreign exchange rate changes future intercompany product third party purchases raw materials denominated foreign currency company also uses currency swaps manage currency risk primarily related borrowings types derivatives designated cash flow hedges additionally company uses forward exchange contracts offset exposure certain foreign currency assets liabilities forward exchange contracts designated hedges therefore changes fair values derivatives recognized earnings thereby offsetting current earnings effect related foreign currency assets liabilities designation cash flow hedge made entrance date derivative contract inception derivatives expected highly effective changes fair value derivative designated cash flow hedge highly effective recorded accumulated comprehensive income underlying transaction affects earnings reclassified earnings account hedged transaction fair value derivative instrument ie forward foreign exchange contract currency swap aggregation currency johnson johnson annual report future cash flows discounted present value prevailing market interest rates subsequently converted us dollar current spot foreign exchange rate ongoing basis company assesses whether derivative continues highly effective offsetting changes cash flows hedged items derivative longer expected highly effective hedge accounting discontinued hedge ineffectiveness included current period earnings insignificant company documents relationships hedged items derivatives overall risk management strategy includes reasons undertaking hedge transactions entering derivatives objectives strategy minimize foreign currency exposure 's impact company 's financial performance protect company 's cash flow adverse movements foreign exchange rates ensure appropriateness offinancial instruments manage enterprise risk associated financial institutions product liability accruals product liability claims recorded undiscounted basis probable liability incurred amount liability reasonably estimated based existing information accruals adjusted periodically additional information becomes available result cost availability factors effective november company ceased purchasing third party product liability insurance based availability prior coverage receivables insurance recoveries related product liability claims recorded undiscounted basis probable recovery realized research development research development expenses expensed incurred upfront milestone payments made third parties connection research development collaborations expensed incurred point regulatory approval payments made third parties subsequent regulatory approval capitalized amortized remaining useful life related product amounts capitalized payments included intangibles net accumulated amortization advertising costs associated advertising expensed year incurred included selling marketing administrative expenses advertising expenses worldwide comprised television radio print media internet advertising billion billion billion income taxes company intends continue reinvest undistributed international earnings expand international operations therefore us tax expense recorded cover undistributed portion intended repatriation january january cumulative amount undistributed international earnings approximately billion billion respectively deferred income taxes recognized tax consequences temporary differences applying enacted statutory tax rates applicable future years differences financial reporting tax basis existing assets liabilities net earnings per share basic net earnings per share computed dividing net earnings available common shareholders weighted average number common shares outstanding period diluted net earnings per share reflects potential dilution could occur securities exercised converted common stock using treasury stock method stock options january company stockbased employee compensation plans described note company accounts plans recognition measurement principles accounting principle board opinion accounting stock issued employees apb related interpretations compensation costs recorded net earnings stock options options granted plans exercise price equal market value underlying common stock date grant required sfas accounting stockbased compensationtransition disclosurean amendment fasb statement following table shows estimated effect net income earnings per share company applied fair value recognition provision sfas accounting stockbased compensation stockbased employee compensation table caption dollars millions except per share data c c c net earnings reported less compensation expense net earnings pro forma net earnings per share basic reported pro forma diluted reported pro forma table determined fair value based method awards net tax use estimates preparation consolidated financial statements conformity accounting principles generally accepted us requires management make estimates assumptions affect amounts reported estimates used accounting sales discounts rebates allowances incentives product liabilities income taxes depreciation amortization employee benefits contingencies asset liability valuations instance determining annual pension postemployment benefit costs company estimates rate return plan assets cost future health care benefits actual results may may differ estimates notes consolidated financial statements annual closing date company follows concept fiscal year ends sunday nearest end month december normally fiscal year consists weeks every five six years fiscal year consists weeks case reclassification certain prior year amounts reclassified conform current year presentation inventories end inventories comprised table caption dollars millions c c raw materials supplies goods process finished goods table property plant equipment end property plant equipment cost accumulated depreciation table caption dollars millions c c land land improvements buildings building equipment machinery equipment construction progress less accumulated depreciation table company capitalizes interest expense part cost construction offacilities equipment interest expense capitalized million million million respectively depreciation expense including amortization capitalized interest billion billion billion respectively upon retirement disposal property plant equipment cost related amount accumulated depreciation amortization eliminated asset accumulated depreciation accounts respectively difference net asset value proceeds recorded earnings rental expense lease commitments rentals space vehicles manufacturing equipment office data processing equipment operating leases approximately million million million approximate minimum rental payments required operating leases initial remaining noncancelable lease terms excess one year january table caption dollars millions total c c c c c c c table commitments capital leases significant employee related obligations end employee related obligations table caption dollars millions c c pension benefits postretirement benefits postemployment benefits deferred compensation less current benefits payable employee related obligations table prepaid employee related obligations million million respectively included assets consolidated balance sheet borrowings components longterm debt follows table caption effective effective dollars millions rate rate c c c c zero coupon convertible subordinated debentures due debentures due debentures due notes due debentures due notes due convertible subordinated notes due industrial revenue bonds less current portion table weighted average effective rate convertible subordinated notes redeemed scios inc august johnson johnson annual report company access substantial sources funds numerous banks worldwide total unused credit available company approximates billion including billion credit commitments billion expire september billion expire september also included billion uncommitted lines various banks worldwide expire interest charged borrowings credit line agreements based either bids provided banks prime rate london interbank offered rates libor plus applicable margins commitment fees agreements material periods presented company filed shelf registration securities exchange commission became effective january enables company issue billion debt securities warrants purchase debt securities debt issued shelf full amount remained available january august scios inc exercised right redeem outstanding million original principal amount convertible subordinated notes due redemption price principal amount per principal amount debentures accrued interest excluding date redemption july alza corporation completed private offering zero coupon convertible subordinated debentures issued price per principal amount maturity january outstanding debentures total principal amount maturity million yield maturity per annum computed semiannual bond equivalent basis periodic interest payments terms debentures holders entitled convert debentures approximately million shares johnson johnson stock price per share approximately million shares issued january due voluntary conversions note holders option holder debentures may repurchased company july purchase price equal issue price plus accreted original issue discount purchase date company option may elect deliver either johnson johnson common stock cash combination stock cash event repurchase debentures company option may also redeem debentures july issue price plus accreted original issue discount january january fair value based quoted market value debentures million million respectively shortterm borrowings current portion long term debt amounted million end million relates commercial paper program remainder represents principally local borrowing international subsidiaries november company exercised right redeem million aggregate principal amount debentures due redemption price principal amount per principal amount debentures accrued interest date redemption shortterm borrowings current portion longterm debt amounted million end principally local borrowing international subsidiaries aggregate maturities longterm obligations commencing table caption dollars millions c c c c c c table intangible assets goodwill end gross net amounts intangible assets table caption dollars millions c c trademarks nonamortizable gross less accumulated amortization trademarks nonamortizable net patents trademarksgross less accumulated amortization patents trademarksnet intangiblesgross less accumulated amortization intangibles net subtotal intangible assetsgross less accumulated amortization subtotal intangible assetsnet goodwill gross less accumulated amortization goodwill net total intangible assetsgross less accumulated amortization total intangible assetsnet table goodwill january january allocated segment business follows table caption med dev dollars millions consumer pharm diag total c c c c goodwill december acquisitions translationother goodwill january acquisitions translationother goodwill january table notes consolidated financial statements weighted average amortization periods patents trademarks intangible assets years years respectively amortization expense amortizable intangible assets fiscal years ended january january december million million million tax respectively certain patents intangibles written fair value fiscal years resulting charge included amortization expense estimated amortization expense five succeeding years approximates million tax per year substantially amortization expense included cost products sold income taxes provision taxes income consists tablecaption dollars millions c c c currently payable us taxes international taxes deferred us taxes international taxes table comparison income tax expense federal statutory rate company 's effective tax rate follows table caption dollars millions c c c us international earnings taxes income tax rates statutory puerto rico ireland operations research tax credits us state local international subsidiaries excluding ireland repatriation international earnings iprd effective tax rate table company subsidiaries operating puerto rico various tax incentive grants also us possessions tax credit expires applies certain operations puerto rico addition company subsidiaries manufacturing ireland incentive tax rate second quarter tax benefit million recorded due reversal tax liability related technical correction associated american jobs creation act decrease tax rate attributed increases taxable income lower tax jurisdictions relative taxable income higher tax jurisdictions result increased expenditures higher tax jurisdictions shift sales mix temporary differences carry forwards follows table caption deferred tax deferred tax dollars millions asset liability asset liability c c c c employee related obligations depreciation nondeductible intangibles international rd capitalized tax reserves liabilities income reported tax purposes miscellaneous international capitalized intangibles miscellaneous us total deferred income taxes table difference net deferred tax income per balance sheet net deferred tax included taxes income balance sheet johnson johnson annual report international currency translation translation subsidiaries operating nonus dollar currencies company determined local currencies international subsidiaries functional currencies except highly inflationary economies defined compound cumulative rates inflation past three years substantial portion cash flows local currency consolidating international subsidiaries balance sheet currency effects recorded component accumulated comprehensive income equity account includes results translating balance sheet assets liabilities current exchange rates except located highly inflationary economies reflected operating results analysis changes foreign currency translation adjustments included note net currency transaction translation gains losses included income expense losses million million million respectively common stock stock option plans stock compensation agreements january company stockbased compensation plans shares outstanding contracts company 's stock option plans long term incentive plan nonemployee director 's plan biosense centocor innovasive devices alza inverness scios stock option plans options granted plans except stock option plan long term incentive plan stock option plan expired april options granted subsequent date long term incentive plan stock options expire years date granted vest service periods range one five years options granted current market price date grant long term incentive plan company may issue million shares common stock shares available future grants long term incentive plan million end summary status company 's stock option plans january january december changes years ending dates presented table caption weighted options average shares thousands outstanding exercise price c c balance december options granted options exercised options canceledforfeited balance december options granted options exercised options canceledforfeited balance january options granted options exercised options canceledforfeited balance january tablethe average fair value options granted fair value estimated using blackscholes option pricing model based weighted average assumptions table caption c c c riskfree rate volatility expected life yrs yrs yrs dividend yield table following table summarizes stock options outstanding exercisable january table caption shares thousands outstanding exercisable average average exercise average exercise exercise price range options life price options price c c c c c table average contractual life remaining years stock options exercisable january december options average price options average price respectively notes consolidated financial statements table caption segments business geographic areas sales customers dollars millions c c c consumerunited states international total pharmaceutical united states international total medical devices diagnostics united states international total worldwide total table table caption operating profit identifiable assets dollars millions c c c c c c consumer pharmaceutical medical devices diagnostics segments total less expenses allocated segments general corporate worldwide total table table caption additions property depreciation plant equipment amortization dollars millions c c c c c c consumer pharmaceutical medical devices diagnostics segments total general corporate worldwide total table table caption sales customers longlived assets dollars millions c c c c c c united states europe western hemisphere excluding us asiapacific africa segments total general corporate non longlived assets worldwide total table see note description segments company operates export sales intersegment sales significant company customer represented total revenues sales top distributors accounted total revenues total revenues amounts allocated segments include interest incomeexpense minority interest general corporate incomeexpense general corporate includes cash marketable securities includes million million inprocess research development iprd pharmaceutical medical devices diagnostics segments respectively includes million iprd medical devices diagnostics segment includes million iprd pharmaceutical segment million iprd million arbitration ruling stent patents medical devices diagnostics segment longlived assets include property plant equipment net respectively intangible assets net respectively johnson johnson annual report table caption accumulated comprehensive income components comprehensive incomeloss consist following total unrealized gains accumulated foreign gains pension losses currency losses liability derivatives comprehensive dollars millions translation securities adjustments hedges incomeloss c c c c c dec changes net change due hedging transactions net amount reclassed net earnings net changes dec changes net change due hedging transactions net amount reclassed net earnings net changes jan changes net change due hedging transactions net amount reclassed net earnings net changes jan table total comprehensive income includes reclassification adjustment gains million realized sale equity securities associated tax expense million total comprehensive income includes reclassification adjustment gains million realized sale equity securities associated tax expense million total comprehensive income includes reclassification adjustment gains million realized sale equity securities associated tax expense million tax effect unrealized gainslosses equity securities balance expense million million million respectively tax effect related minimum pension liability million tax effect gainslosses derivatives hedges loss million benefits million million respectively see note additional information relating derivatives hedging currency translation adjustments currently adjusted income taxes relate permanent investments international subsidiaries pensions benefit plans company sponsors various retirement pension plans including defined benefit defined contribution termination indemnity plans cover employees worldwide company also provides postretirement benefits primarily health care us retired employees dependents many international employees covered governmentsponsored programs direct cost company significant retirement plan benefits primarily based employee 's compensation last three five years retirement number years service international subsidiaries plans funds deposited trustees annuities purchased group contracts reserves provided company fund retiree health care benefits advance right modify plans future company uses date consolidated financial statements january january respectively measurement date us international retirement benefit plans net periodic benefit cost company 's defined benefit retirement plans benefit plans included following componentstable caption retirement plans benefit plans dollars millions c c c c c c service cost interest cost expected return plan assets amortization prior service cost amortization net transition asset recognized actuarial losses curtailments settlements special termination benefits net periodic benefit cost table notes consolidated financial statements net periodic benefit cost attributable us retirement plans million million million company offered voluntary retirement program enhanced benefits called retirement enhancement program rep eligible us regular fulltime employees attained age least years pension credited service june program enhancements included elimination early retirement reduction pension benefit purposes normally per year prior age special termination benefit one week pay per year credited service program resulted onetime increase us pension expense million reflect value retirement enhancement weightedaverage assumptions following table represent rates used develop actuarial present value projected benefit obligation year listed also net periodic benefit cost following year table caption retirement plans benefit plans us benefit plans c c c c c c c c discount rate expected longterm rate return plan assets rate increase compensation levels international benefit plans discount rate expected longterm rate return plan assets rate increase compensation levels table company 's discount rates determined considering current yield curves representing high quality longterm fixed income instruments resulting discount rates consistent duration plan liabilities expected longterm rate return plan assets assumptions determined using building block approach considering historical averages real returns asset class certain countries historical returns meaningful consideration given local market expectations longterm returns following table displays assumed health care cost trend rates individuals table caption health care plans c c health care cost trend rate assumed next year rate cost trend rate assumed decline ultimate trend year rate reaches ultimate trend rate table onepercentagepoint change assumed health care cost trend rates would following effect table caption onepercentage onepercentage dollars millions point increase point decrease c c health care plans total interest service cost postretirement benefit obligation table johnson johnson annual report following table sets forth information related benefit obligation fair value plan assets yearend company 's defined benefit retirement plans postretirement plans table caption dollars millions retirement plans benefit plans change benefit obligation c c c c projected benefit obligation beginning year service cost interest cost plan participant contributions amendments actuarial losses divestitures acquisitions curtailments settlements benefits paid plan effect exchange rates projected benefit obligation end year change plan assets plan assets fair value beginning year actual return plan assets company contributions plan participant contributions divestitures benefits paid plan assets effect exchange rates plan assets fair valueend year table strategic asset allocations determined country based nature liabilities consideration demographic composition plan participants average age years service active versus retiree status company 's plans considered nonmature plans longterm strategic asset allocations consistent types plans emphasis placed diversifying equities broad basis combined currency matching fixed income assets following table displays projected future benefit payments company 's retirement benefit plans table caption dollars millions projected future benefit payments c c c c c c retirement plans benefit plans gross medicare rebates benefit plans net table company required fund us retirement plans order meet minimum statutory funding requirements international plans funded accordance local regulations additional discretionary contributions made deemed appropriate meet longterm obligations plans certain countries us funding pension plans common practice funding provides economic benefit consequently company several pension plans funded following table displays projected future minimum contributions company 's us international unfunded retirement plans amounts include discretionary contributions company may elect make future table caption dollars millions projected future contributions c c c c c c unfunded us retirement plans unfunded international retirement plans table notes consolidated financial statements table caption company 's retirement plan asset allocation january january target allocations follows percent target plan assets allocation us retirement plans c c c equity securities debt securities total plan assets international retirement plans equity securities debt securities real estate total plan assets table company 's benefit plans unfunded except us life insurance contract assets million million january january respectively fair value johnson johnson common stock directly held plan assets million total plan assets million total plan assets january january respectively amounts recognized company 's balance sheet consist following table caption retirement plans benefit plans dollars millions c c c cplan assets fair value projected benefit obligation funded status unrecognized actuarial losses unrecognized prior service cost unrecognized net transition asset total recognized consolidated balance sheet book accruals prepaid benefits intangible assets accumulated comprehensive income total recognized consolidated balance sheet table accumulated benefit obligation us international defined benefit retirement plans million million january january respectively minimum pension liability adjustment required actuarial present value accumulated benefits obligation abo exceeds fair value plan assets accrued pension liabilities minimum pension liabilities intangible assets accumulated comprehensive income million million respectively relate primarily plans outside us plans accumulated benefit obligations excess plan assets consist following table caption retirement plans dollars millions c c accumulated benefit obligation projected benefit obligation plan assets fair value table johnson johnson annual report december medicare prescription drug improvement modernization act enacted introduces prescription drug benefit medicare well subsidy sponsors retiree health care benefit plans company 's application centers medicare medicaid services attesting plan 's actuarial equivalence medicare accepted subsidy reimbursements expected beginning change estimated participation rates per capita claims costs result act company recognized effect subsidy prospective basis june recognition reduces beforetax aftertax expense million accumulated postretirement benefit obligation million cash equivalents marketable securities table caption january january amortized unrealized estimated amortized unrealized estimated dollars millions cost gainslosses fairvalue cost gainslosses fairvalue c c c c c c current investments government securities obligations corporate debt securities money market funds time deposits collateralized mortgage obligations asset backed securities bank notes total cash equivalents current marketable securities noncurrent investments marketable securities table current marketable securities include billion billion classified cash equivalents balance sheet january january respectively financial instruments company follows provisions sfas requiring derivative instruments recorded balance sheet fair value january balance deferred net gains derivatives included accumulated comprehensive income million aftertax additional information see note company expects substantially amount reclassified earnings next months result transactions expected occur period maximum length time company hedging transaction exposure months amount ultimately realized earnings differ foreign exchange rates change realized gains losses ultimately determined actual exchange rates maturity derivative derivative gainslosses initially reported component comprehensive income reclassified earnings period forecasted transaction affects earnings years ended january january december net impact hedge ineffectiveness transactions qualifying hedge accounting discontinuance hedges company 's financial statements insignificant refer note disclosures movements accumulated comprehensive income concentration credit risk company invests excess cash deposits major banks throughout world high quality money market instruments company policy making investments commercial institutions least equivalent credit rating average investments mature within six months company incurred related losses savings plan company voluntary k savings plans designed enhance existing retirement programs covering eligible employees company matches percentage employee 's contributions consistent provisions plan heshe eligible us salaried plan onethird company match paid company stock employee stock ownership plan esop unless employee chose notes consolidated financial statements redirect investment establish esop company loaned million esop trust purchase shares company stock open market exchange company received note balance recorded reduction shareholders ' equity remaining shares held esop trust allocated participant accounts end february march going forward company match made cash follow individual employee 's investment elections total company contributions plans million million million mergers acquisitions divestitures certain businesses acquired million cash million liabilities assumed acquisitions accounted purchase method accordingly results operations included financial statements respective dates acquisition acquisitions included transform pharmaceuticals inc company specializing discovery superior formulations novel crystalline forms drug molecules closure medical corporation company expertise intellectual property biosurgicals market peninsula pharmaceuticals inc biopharmaceutical company focused developing commercializing antibiotics treat lifethreatening infections rights consumer professionally dispensed rembrandtr brand oral care products whitening toothpastes strips systems mouth rinses excess purchase price estimated fair value tangible assets acquired amounted million assigned identifiable intangible assets residual recorded goodwill approximately million identified value inprocess research development iprd primarily associated acquisitions transform pharmaceuticals inc closure medical corporation peninsula pharmaceuticals inc iprd charge related acquisition transform pharmaceuticals inc million associated research related discovery application superior formulations value iprd calculated using cash flow projections discounted risk inherent projects discount rate applied iprd charge related acquisition closure medical corporation million associated omnextm surgical sealant vascular indications outside europe potential indications worldwide value iprd calculated using cash flow projections discounted risk inherent projects probability success factor vascular indications indications used reflect inherent clinical regulatory risk discount rate applied vascular indications iprd charge related acquisition peninsula pharmaceuticals inc million associated development doripenem phase iii clinical trials value iprd calculated using cash flow projections discounted risk inherent projects probability success factor used reflect inherent clinical regulatory risk discount rate applied remaining million iprd associated acquisition international commercial rights certain patents knowhow field sedation analgesia scott lab inc value iprd calculated using cash flow projections discounted risk inherent projects discount rate certain businesses acquired million cash million liabilities assumed acquisitions accounted purchase method accordingly results operations included financial statements respective dates acquisition addition per terms acquisition agreement link spine group inc million cash paid owners link spine group inc based date us food drug administration fda approved charite tm artificial disc thus total cash expenditures related acquisitions million acquisitions included merck 's interest johnson johnsonmerck consumer pharmaceuticals co european nonprescription pharmaceutical joint venture including infrastructure brand assets managed european joint venture egea biosciences inc exercise option acquire remaining outstanding stock owned johnson johnson developed proprietary technology platform called gene writer allows rapid highly accurate synthesis dna sequences gene assembly construction large synthetic gene libraries artemis medical inc privately held company ultrasound xray visible biopsy site breast markers well hybrid markers us commercial rights certain patents knowhow field sedation analgesia scott lab inc biapharm sas privately held french producer marketer skin care products centered around leading brand biafiner assets micomed privately owned manufacturer spinal implants primarily focused supplying german market acquisition ambir skin care brand women color excess purchase price estimated fair value tangible assets acquired amounted million assigned identifiable intangible assets residual recorded goodwill million related us fda approval charite tm artificial disc recorded additional goodwill associated link spine group inc acquisition thus total additions intangibles goodwill million approximately million identified value iprdassociated scott lab inc acquisition value iprd calculated using cash flow projections discounted risk inherent projects discount rate certain businesses acquired billion cash million liabilities assumed acquisitions accounted purchase method accordingly results operations included financial statements respective dates acquisition acquisitions included link spine group inc privately owned corporation exclusive worldwide rights johnson johnson annual report charitetm artificial disc scios inc biopharmaceutical company marketed product cardiovascular disease research projects focused autoimmune diseases dimensional pharmaceuticals inc company technology platform focused discovery development therapeutic small molecules orapharma inc specialty pharmaceutical company focused development commercialization unique oral therapeutics certain assets orquest inc privately held biotechnology company focused developing biologicallybased implants orthopaedics spine surgery excess purchase price estimated fair value tangible assets acquired amounted billion assigned identifiable intangible assets residual recorded goodwill approximately million identified value iprd primarily associated acquisition link spine group inc scios inc iprd charge related link spine group inc acquisition million associated charitetm artificial disc value iprd calculated using cash flow projections discounted risk inherent projects probability success factor used reflect inherent clinical regulatory risk discount rate purchase price link spine group inc acquisition allocated tangible identifiable intangible assets acquired liabilities assumed based estimated fair values acquisition date excess purchase price fair values assets liabilities acquired approximately million allocated goodwill substantially amount allocated goodwill deductible tax purposes iprd charge related scios inc million largely associated p kinase inhibitor program value iprd calculated using cash flow projections discounted risk inherent projects using probability success factor discount rate purchase price scios inc acquisition allocated tangible identifiable intangible assets acquired liabilities assumed based estimated fair values acquisition date identifiable intangible assets included patents trademarks valued approximately billion excess purchase price fair values assets liabilities acquired approximately million allocated goodwill substantially amount allocated goodwill deductible tax purposes remaining iprd associated orquest inc dimensional pharmaceuticals inc charges million million respectively supplemental pro forma information per sfas business combinations sfas goodwill intangible assets provided impact aforementioned acquisitions material effect company 's results operations cash flows financial position divestitures material effect company 's results operations cash flows financial position legal proceedings product liability company involved numerous product liability cases united states many concern adverse reactions drugs medical devices damages claimed substantial company confident adequacy warnings instructions use accompany products feasible predict ultimate outcome litigation however company believes liability results cases substantially covered existing amounts accrued company 's balance sheet available thirdparty product liability insurance one group cases company concerns product company 's subsidiary janssen pharmaceutica inc janssen propulsidr cisapride withdrawn general sale restricted limited use wake publicity events numerous lawsuits filed janssen company regarding propulsidr state federal courts across country actions seek substantial compensatory punitive damages accuse janssen company inadequately testing warning drug 's side effects promoting offlabel use promotion addition janssen company entered tolling agreements various plaintiffs ' counsel halting running statutes limitations respect potential claims significant number individuals whilethose attorneys evaluate whether sue janssen company behalf february janssen announced reached agreement principle plaintiffs steering committee psc propulsidr federal multidistrict litigation mdl resolve federal lawsuits related propulsidr agreement become effective death claimants remainder agreed terms settlement addition individuals filed lawsuits whose claims subject tolling agreements suspending running statutes limitations claims also agree participate settlement became effective march confirmed psc mdl enrolled enough plaintiffs claimants settlement program make agreement effective death plaintiffs subject program confirmed enrolled plaintiffs subject program confirmed enrolled addition tolled claimants confirmed enrolled participating settlement submit medical records independent panel physicians determine whether claimed injuries caused propulsidr otherwise meet standards compensation standards met courtappointed special master determine compensatory damages janssen paid compensation escrow account million established administrative fund million paid legal fees psc million amount approved court notes consolidated financial statements participating settlement program plaintiffs tolled claimants plaintiffs potentially subject mdl settlement enroll plaintiffs filed cases federal court subsequent february thus subject mdl settlement state court actions thus subject settlement participating subject mdl settlement plaintiffs alleged died use drug assert personal injury claims nature claims tolled claimants unknown remaining federal state plaintiffs cases venued mississippi december janssen reached agreement mdl psc plaintiffs ' state liaison committee slc create second settlement program resolving remaining state federal lawsuits filed november well remaining unfiled claims subject tolling agreements new program becomes effective plaintiffs representing decedents plaintiffs agree terms settlement new program allows enrollment claimant eligible prior settlement program chose enroll plus state court plaintiffs federal court plaintiffs filing february thus eligible janssen pay compensation minimum million maximum million new settlement program depending upon percentage enrollment thresholds janssen also establish administrative fund exceed million pay legal fees exceed million subject court approval janssen company believe adequate selfinsurance accruals thirdparty product liability insurance respect cases communications company excess insurance carriers raised certain defenses liability policies date declined voluntarily reimburse janssen company propulsidrrelated costs despite demand payment may hearings held london arbitration proceeding commenced janssen company allianz underwriters insurance company issued first layer applicable excess insurance coverage obtain reimbursement propulsidrrelated costs proceeding resolved fashion satisfactory janssen company november may company commenced arbitration lexington insurance company issued second layer excess insurance coverage opinion company excess carriers remain legally obligated provide coverage propulsidrrelated losses issue affirmative stent patent litigation patent infringement actions tried delaware federal district court late cordis corporation cordis subsidiary johnson johnson obtained verdicts infringement patent validity damage awards boston scientific corporation boston scientific medtronic ave inc medtronic based number cordis vascular stent patents december jury damage action boston scientific returned verdict million december jury medtronic action returned verdict million sums represent lost profit reasonable royalty damages compensate cordis infringement include pre post judgment interest march may district judge granted boston scientific new trial liability damages vacated verdict medtronic onlegal grounds august court appeals federal circuit found trial judge erred vacating verdict medtronic remanded case trial judge proceedings march remaining issues tried remanded case medtronic retrial proceeded boston scientific juries returned verdicts infringement patent validity favor cordis retrials cordis requested trial court reinstate interest verdicts obtained entities defendants cases filed posttrial motions seeking vacate jury verdicts alternatively grant new trial damages cordis also pending delaware federal district court second action medtronic ave accusing medtronic infringement sale stent products introduced medtronic subsequent gfxr microstentr products subject earlier action referenced second action stayed april pending outcome arbitration held late concerning medtronic 's claim products issue case licensed pursuant license january cordis filed patent infringement action boston scientific delaware federal district court accusing expresstmtaxusr liberte stents infringing palmaz patent expired november liberte stent also accused infringing cordis ' gray patent expires june jury found expresstm taxusr liberte stents infringed palmaz patent liberte stent also infringed gray patent boston scientific filed posttrial motions seeking vacate verdict obtain new trial motions denied trial damages willfulness future johnson johnson annual report patent litigation various johnson johnson subsidiaries products various johnson johnson subsidiaries subject various patent lawsuits outcomes could potentially adversely affect ability subsidiaries sell products require payment past damages future royalties respect matters johnson johnson subsidiary involved vigorously defending claims infringement disputing appropriate validity enforceability patent claims asserted july jury federal district court delaware found cordis cypherr stent infringed boston scientific 's ding patent cordis cypherr bx velocityr stents also infringed boston scientific corporation 's jang patent jury also found patents valid cordis asked judge overturn jury verdicts grant new trial judge overturn jury verdicts damage willfulness trial boston scientific seek injunction cypherr upheld trial court cordis appeal jury verdicts court appeals federal circuit march boston scientific 's case asserting infringement cypherr stent another boston scientific patent scheduled trial delaware federal district court case well boston scientific seeks injunction substantial damages january federal district court southern district florida granted cordis summary judgment dismissing breach contract patent infringement suit filed cordis arlaine gina rockey seeking royalties sales cordis balloon expandable stents plaintiffs filed appeal court appeals federal circuit action filed belgium boston scientific kastenhofer patent boston scientific seeking paneuropean injunction sale infringing catheters ie injunction would effective belgium countries served european patent office trial scheduled could occur following chart summarizes various patent lawsuits concerning products johnson johnson subsidiaries table caption jj plaintiff product company patents patent holder court trial date date filed c c c c c c drug eluting stents cordis grainger boston scientific corp del stents cordis boneau medtronic inc del twolayer catheters cordis kastenhofer boston scientific corp nd cal forman belgium stents cordis israel medinol multiple eu jurisdictions contact lenses vision care nicolson ciba vision md fla table trial date established litigation filers abbreviated new drug applications andas following chart indicates lawsuits pending generic firms filed abbreviated new drug applications seeking market generic forms products sold various subsidiaries company prior expiration applicable patents covering products andas typically include allegations noninfringement invalidity unenforceability patents event subsidiary company involved successful actions month stay expires ruling district court obtained firms involved ability introduce generic versions product issue resulting substantial market share revenue losses product company 's subsidiary previously communicated noted following chart month stays scheduled expire respect anda challenges regarding ortho tricyclenr lo risperdalr topamaxr trial occur expiration stays respect ortho tricyclenr lo unlikely occur respect risperdalr could occur case topamaxr unless month stays extended preliminary injunctions granted outcomes uncertain final fda approval market occur shortly expiration month stays firm launches anda product trial would liable potentially lost profits found trial infringe valid patent typically anda products launched circumstances nonetheless risk launches occurred cases involving drugs johnson johnson subsidiaries risk launch ruled notes consolidated financial statements table caption brand name patentnda generic trial date month product holder challenger court date filed stay expires c c c c c c aciphexr mg delay eisai teva sdny release tablet janssen dr reddy 's sdny mylan sdny concertar mcneilppc impax ddel none mg alza andrx controlled release tablet ditropan xlr mg orthomcneil mylan dwv controlled release tablet alza impax n dcal levaquinr tablets daiichi mylan dwv mg tablets jjprd orthomcneil teva dnj levaquinr injectable daiichi jjprd sicor teva dnj single use vials orthomcneil mgml premix levaquinr injectable daiichi jjprd american dnj single use vials orthomcneil pharmaceutical partners quixinr ophthalmic daiichi hitech dnj solution levofloxacin orthomcneil pharmacal ophthalmic solution ortho tri cyclenr lo orthomcneil barr dnj mg mg mg mg mg mg pepcidr complete mcneilppc perrigo sdny razadynetm janssen teva del mylan del dr reddy 's del purepac del barr del par del alphapharm del risperdalr tablets janssen mylan dnj dr reddy 's dnj mg tablets risperdalr mtab janssen dr reddy 's dnj mg barr dnj topamaxr orthomcneil mylan dnj mg tablet cobalt dnj topamaxr sprinkle orthomcneil cobalt dnj mg capsule ultracetr tram orthomcneil kali par dnj apap tablet teva dnj caraco ed mich table trial date established action mylan pharmaceuticals usa mylan involving company 's subsidiary orthomcneil pharmaceutical inc 's orthomcneil product ditropan xlr oxybutynin chloride court september found ditropan xlr patent invalid infringed mylan 's anda product orthomcneil alza corporation alza subsidiary company appealed action impax impax also received judgment invalidity based decision mylan suit orthomcneil alza appealed decision appeals consolidated neither mylan impax received final fda approval launch anda product approval could come point johnson johnson annual report december mylan announced entered two agreements orthomcneil pharmaceutical inc regarding oxybutynin chloride extended release tablets one agreement relates orthomcneil 's supply certain dosages oxybutynin chloride extended release tablets second relates patent license alza intellectual property regarding ditropan xlr terms agreements confidential depend outcome appeal west virginia court 's decision subject review federal trade commission weeks following adverse ruling ditropan xlr anda litigation mylan september orthomcneil alza received five antitrust class action complaints filed indirect purchasers product complaints filed various federal courts claim damages based laws states allege orthomcneil alza violated antitrust laws various states knowingly pursuing baseless patent litigation thereby delaying entry market mylan impax action mylan involving orthomcneil levaquinr levofloxacin trial judge december found patent issue valid enforceable infringed mylan 's anda product issued injunction precluding sale product patent expiration late december court appeals federal circuit affirmed judgment validity enforceability infringement mylan filed motion rehearing court appeals consolidated actions teva sicor hitech pharmacal american pharmaceutical partners involving andas various levofloxacin preparations trial tentatively scheduled begin april claim levaquin patent obtained inequitable conduct therefore unenforceable action kali involving orthomcneil 's ultracetr tramadol hydrochlorideacetaminophen kali moved summary judgment issues infringement invalidity briefing motion completed october decision expected anytime respect claims issue litigation kali orthomcneil filed reissue application us patent trademark office seeking narrow scope claims notice allowance patent received october kali obtained final approval anda expiration month stay april launched generic product day orthomcneil ultimately prevails patent infringement action kali kali subject injunction damages action teva pharmaceuticals usa teva involvingorthomcneil 's ultracetr tramadol hydrocholorideacetaminophen teva moved summary judgment issues infringement validity briefing motion completed march ruling could issue point action caraco involving orthomcneil 's ultracetr tramadol hydrocholorideacetaminophen caraco 's motion summary judgment noninfringement granted october orthomcneil appealed decision caraco launched generic ultracetr risk december respect matters johnson johnson subsidiary involved vigorously defending validity enforceability asserting infringement licensor 's patents average wholesale price awp litigation johnson johnson pharmaceutical subsidiaries along numerous pharmaceutical companies defendants series lawsuits state federal courts involving allegations pricing marketing certain pharmaceutical products amounted fraudulent otherwise actionable conduct among things companies allegedly reported inflated average wholesale price awp drugs issue cases federal actions state actions removed federal court consolidated pretrial purposes multidistrict litigation mdl federal district court boston massachusetts plaintiffs cases include classes private persons entities paid portion purchase drugs issue based awp state government entities made medicaid payments drugs issue based awp mdl proceeding boston plaintiffs moved class certification portion claims august trial judge certified massachusetts classes private insurers providing medigap insurance coverage private payers physicianadministered drugs payments based awp judge also allowed plaintiffs file new complaint seeking name proper parties represent national class individuals made copayments physicianadministered drugs covered medicare court appeals declined allow appeal issues january hearing class certification issues court indicated intent certify national class noted new york state attorney general 's office ny ag federal trade commission issued subpoenas january february seeking documents relating marketing sutures endoscopic instruments company 's ethicon ethicon endosurgery subsidiaries february ny ag advised closed investigation connecticut state attorney general 's office also issued subpoena documents subpoenas focus bundling sutures endoscopic instruments contracts offered group purchasing organizations individual hospitals discounts predicated hospital achieving specified market share targets categories products operating companies involved responded subpoenas june company received request records information us house representatives ' committee energy commerce connection investigation pharmaceutical reimbursements rebates medicaid committee 's request focuses drug remicader infliximab marketed company 's centocor inc centocor subsidiary july centocor received notes consolidated financial statements request voluntarily provide documents information criminal division us attorney 's office district new jersey connection investigation various centocor marketing practices subsequent requests documents received us attorney 's office company centocor responded process responding requests documents information august securities exchange commission sec advised company informal investigation foreign corrupt practices act allegations payments polish governmental officials us pharmaceutical companies november sec advised company investigation become formal issued subpoena information previously requested informal fashion addition background documents company operating units poland responded requests december orthomcneil received subpoena united states attorney 's office boston massachusetts seeking documents relating marketing including alleged offlabel marketing drug topamaxr topiramate orthomcneil cooperating responding subpoena october us attorney 's office boston asked attorneys orthomcneil cooperate facilitating subpoenaed testimony several present former orthomcneil employees grand jury boston cooperation securing testimony additional witnesses grandjury requested provided january janssen received subpoena office inspector general united states office personnel management seeking documents concerning sales marketing payments physicians connection sales marketing clinical trials risperdalr risperidone documents subsequent also requested additional subpoena seeking information marketing adverse reactions risperdalr received united states attorney 's office eastern district pennsylvania november janssen cooperating responding subpoenas april company 's pharmaceutical companies requested submit information us senate finance committee use nominal pricing exception calculating best price medicaid rebate program request sent manufacturers top twenty drugs reimbursed medicaid program company 's pharmaceutical companies responded request february request supplemental information received senate finance committee responded company 's pharmaceutical companies july company received letter request new york state attorney general 's office documents pertaining marketing offlabel sales clinical trials topamaxr topiramate risperdalr risperidone procritr epoetin alfa razadynetm galantamine hbr remicader infliximab aciphexr rabeprazole sodium company responded request august johnson johnson health care systems inc hcs johnson johnson subsidiary received subpoena dallas texas u attorney 's office seeking documents relating relationships group purchasing organization novation hcs johnson johnson subsidiaries company 's subsidiaries involved responded subpoena september ortho biotech inc ortho biotech johnson johnson subsidiary received subpoena us office inspector general 's denver colorado field office seeking documents directed sales marketing procritr epoetin alfa present well dealings us oncology inc healthcare services network oncologists ortho biotech responded subpoena march depuy orthopaedics inc depuy johnson johnson subsidiary received subpoena us attorney 's office district new jersey seeking records concerning contractual relationships depuy surgeons surgeons training involved hip knee replacement reconstructive surgery leading orthopaedic companies known received subpoena depuy responding subpoena june united states senate committee finance requested company produce information regarding use educational grants similar request sent major pharmaceutical companies july committee specifically requested information educational grants connection drug propulsidr follow request received committee additional information january company process responding recent request july scios inc scios johnson johnson subsidiary received subpoena united states attorney 's office district massachusetts seeking documents related sales marketing natrecorr scios responding subpoena early august scios advised investigation handled united states attorney 's office northern district california san francisco september johnson johnson received subpoena united states attorney 's office district massachusetts seeking documents related sales marketing eight drugs omnicare inc manager pharmaceutical benefits longterm care facilities johnson johnson subsidiaries involved process responding subpoena january janssen received civil investigative demand texas attorney general seeking broad categories documents related sales marketing risperdalr janssen process responding request september plaintiffs employment discrimination litigation initiated company federal district court new jersey moved certify class african american hispanic salaried employees company affiliates us employed time november present plaintiffs seek monetary damages period present including punitive damages equitable relief company filed response plaintiffs ' class certification motion johnson johnson annual report may company disputes allegations lawsuit vigorously defending company along wholly owned ethicon ethicon endosurgery subsidiaries defendants three federal antitrust actions challenging suture endomechanical contracts group purchasing organizations andhospitals discounts predicated hospital achieving specified market share targets categories products case plaintiffs seek substantial monetary damages injunctive relief actions applied medical v ethicon inc et al cdca filed september conmed v johnson johnson et al sdny filed november genico v ethicon inc et al ed tx filed october december two purported class actions filed behalf purchasers endomechanical instruments actions captioned delaware valley surgical supply co inc v johnson johnson et al niagara falls memorial medical center v johnson johnson et al filed federal district court central district california remand federal circuit court appeals january partial retrial commenced october concluded november federal district court boston massachusetts action amgen inc amgen v transkaryotic therapies inc tkt aventis pharmaceutical inc aventis matter patent infringement action brought amgen tkt developer geneactivated epo product aventis held marketing rights tkt product asserting tkt 's product infringes various amgen patent claims tkt aventis dispute infringement seeking invalidate amgen patents asserted october district court issued rulings upheld initial findings amgen 's patent claims valid infringed appeal court appeals federal circuit argued december amgen patents issue case exclusively licensed ortho biotech us nondialysis indications ortho biotech party action november amgen filed suit hoffmannlaroche inc united states district court district massachusetts seeking declaration roche product cera roche indicated seek introduce united states infringes number amgen patents concerning epo suit preliminary stages company also involved number patent trademark lawsuits incidental business ultimate legal financial liability company respect claims lawsuits proceedings referred estimated certainty however company 's opinion based examination matters experience date discussions counsel ultimate outcome legal proceedings net liabilities already accrued company 's balance sheet expected material adverse effect company 's financial position although resolution reporting period one matters could significant impact company 's results operations cash flows period earnings per share following reconciliation basic net earnings per share diluted net earnings per share years ended january january december table caption shares millions c c c basic net earnings per share average shares outstandingbasic potential shares exercisable stock option plans less shares repurchased treasury stock method convertible debt shares adjusted average shares outstandingdiluted diluted net earnings per share table diluted net earnings per share calculation includes dilutive effect convertible debt decrease interest expense million million million tax years respectively diluted net earnings per share excludes million million million shares underlying stock options respectively exercise price options greater average market value would result antidilutive effect diluted earnings per share capital treasury stock changes treasury stock weretable caption treasury stock amounts millions except treasury stock number shares thousands shares amount c c balance december employee compensation stock option plans conversion subordinated debentures repurchase common stock balance december employee compensation stock option plans conversion subordinated debentures repurchase common stock balance january employee compensation stock option plans conversion subordinated debentures repurchase common stock balance january table shares common stock issued shares end cash dividends paid per share compared dividends per share per share notes consolidated financial statements table caption selected quarterly financial data unaudited selected unaudited quarterly financial data years summarized first second third fourth first second third fourth dollars millions except per share data quarter quarter quarter quarter quarter quarter quarter quarter c c c c c c c c segment sales customers consumer pharmaceutical med devices diagnostics total sales gross profit earnings provision taxes income net earnings basic net earnings per share diluted net earnings per share table second quarter includes aftertax charge million inprocess research development iprd million tax benefit due reversal tax liability related technical correction associated american jobs creation act fourth quarter includes aftertax charge million iprd shifts sales lower tax jurisdictions expenditures higher tax jurisdictions significant impact fiscal fourth quarter 's tax rate third quarter includes aftertax charge million iprd fourth quarter includes million taxes repatriation unremitted foreign earnings associated american jobs creation act subsequent events january definitive agreement acquire guidant corporation guidant terminated guidant accordance terms pursuant terms agreement guidant paid company fee million january fiscal fourth quarter company announced acquisition animas corporation leading maker insulin infusion pumps related products purchase price net cash acquired transaction approximately million closed fiscal first quarter fiscal first quarter company completed acquisition hand innovations llc privately held manufacturer widely used fracture fixation products upper extremities management 's report internal control financial reporting section sarbanesoxley act management required assess effectiveness company 's internal control financial reporting end fiscal year report based assessment whether company 's internal control financial reporting effective management company responsible establishing maintaining adequate internal control financial reporting company 's internal control financial reporting designed provide reasonable assurance reliability company 's financial reporting preparation financial statements accordance generally accepted accounting principles internal controls financial reporting matter well designed inherent limitations therefore internal control financial reporting determined effective provide reasonable assurance respect financial statement preparation may prevent detect misstatements moreover projections evaluation effectiveness future periods subject risk controls may become inadequate changes conditions degree compliance policies procedures may deteriorate company 's management assessed effectiveness company 's internal control financial reporting january making assessment company used criteria established committee sponsoring organizations treadway commission coso internal controlintegrated framework criteria areas control environment risk assessment control activities information communication monitoring company 's assessment included extensive documenting evaluating testing design operating effectiveness internal controls financial reporting based company 's processes assessment described management concluded january company 's internal control financial reporting effective management 's assessment effectiveness company 's internal control financial reporting january audited pricewaterhousecoopers llp independent registered public accounting firm stated report appears herein johnson johnson annual report report independent registered public accounting firm shareholders board directors johnson johnson completed integrated audits johnson johnson 's consolidated financial statements years ended january january internal control financial reporting january audit consolidated financial statements year ended december accordance standards public company accounting oversight board united states opinions based audits presented consolidated financial statements opinion accompanying consolidated balance sheets related consolidated statements earnings statements equity statements cash flows present fairly material respects financial position johnson johnson subsidiaries company january january results operations cash flows three years period ended january conformity accounting principles generally accepted united states america financial statements responsibility company 's management responsibility express opinion financial statements based audits conducted audits statements accordance standards public company accounting oversight board united states standards require plan perform audit obtain reasonable assurance whether financial statements free material misstatement audit financial statements includes examining test basis evidence supporting amounts disclosures financial statements assessing accounting principles used significant estimates made management evaluating overall financial statement presentation believe audits provide reasonable basis opinion internal control financial reporting also opinion management 's assessment included accompanying management 's report internal control financial reporting company maintained effective internal control financial reporting january based criteria established internal controlintegrated framework issued committee sponsoring organizations treadway commission coso fairly stated material respects based criteria furthermore opinion company maintained material respects effective internal control financial reporting january based criteria established internal controlintegrated framework issued coso company 's management responsible maintaining effective internal control financial reporting assessment effectiveness internal control financial reporting responsibility express opinions management 's assessment effectiveness company 's internal control financial reporting based audit conducted audit internal control financial reporting accordance standards public company accounting oversight board united states standards require plan perform audit obtain reasonable assurance whether effective internal control financial reporting maintained material respects audit internal control financial reporting includes obtaining understanding internal control financial reporting evaluating management 's assessment testing evaluating design operating effectiveness internal control performing procedures consider necessary circumstances believe audit provides reasonable basis opinions company 's internal control financial reporting process designed provide reasonable assurance regarding reliability financial reporting preparation financial statements external purposes accordance generally accepted accounting principles company 's internal control financial reporting includes policies procedures pertain maintenance records reasonable detail accurately fairly reflect transactions dispositions assets company ii provide reasonable assurance transactions recorded necessary permit preparation financial statements accordance generally accepted accounting principles receipts expenditures company made accordance authorizations management directors company iii provide reasonable assurance regarding prevention timely detection unauthorized acquisition use disposition company 's assets could material effect financial statements inherent limitations internal control financial reporting may prevent detect misstatements also projections evaluation effectiveness future periods subject risk controls may become inadequate changes conditions degree compliance policies procedures may deteriorate pricewaterhousecoopers llp new york new york february report independent registered public accounting firm table caption summary operations statistical data johnson johnson subsidiaries dollars millions except per share figures c c c c c c c c sales customersus sales customersinternational total sales cost products sold selling marketing administrative expenses research expense purchased inprocess research development interest income interest expense net portion capitalized income expense net earnings provision taxes income provision taxes income net earnings percent sales customers diluted net earnings per share common stock percent return average shareholders ' equity percent increase previous year sales customers diluted net earnings per share supplementary expense data cost materials services total employment costs depreciation amortization maintenance repairs total tax expense supplementary balance sheet data property plant equipment net additions property plant equipment total assets longterm debt operating cash flow common stock information dividends paid per share shareholders ' equity per share market price per share yearend close average shares outstanding millions basic diluted employees thousands dollars millions except per share figures c c c sales customersus sales customersinternational total sales cost products sold selling marketing administrative expenses research expense purchased inprocess research development interest income interest expense net portion capitalized income expense net earnings provision taxes income provision taxes income net earnings percent sales customers diluted net earnings per share common stock percent return average shareholders ' equity percent increase previous year sales customers diluted net earnings per share supplementary expense data cost materials services total employment costs depreciation amortization maintenance repairs total tax expense supplementary balance sheet data property plant equipment net additions property plant equipment total assets longterm debt operating cash flow common stock information dividends paid per share shareholders ' equity per share market price per share yearend close average shares outstanding millions basic diluted employees thousands table net interest income also included cost materials services category includes taxes income payroll property business taxes johnson johnson annual report text document document typeex sequence filenameyexvhtm descriptionex subsidiaries text html head titleextitle head body bgcolorffffff pagebreak h alignleft stylebreakbeforealwaysnbsphp p alignright bfont sizeexhibit fontb p aligncenter bfont sizesubsidiariesfontb p alignleftnbspnbspnbspnbspnbsp font sizejohnson johnson new jersey corporation domestic international subsidiaries shown januarynbsp certain us subsidiaries international subsidiaries named significant aggregate johnson johnson parent font center table width aligncenter cellspacing cellpadding border tr td widthfont sizenbspfonttd td widthfont sizenbspfonttd td widthfont sizenbspfonttd td widthfont sizenbspfonttd tr tr td colspantd tdtd td aligncenter nowrapbfont sizejurisdiction offontbtd tr tr td colspan aligncenter nowrapbfont sizename subsidiaryfontbtd tdtd td aligncenter nowrapbfont sizeorganizationfontbtd tr tr td colspan aligncenter nowraphr size noshadetd tdtd td aligncenter nowraphr size noshadetd tr tr valignbottom bgcoloreeeeee td colspan alignleft valigntopdiv stylemarginleft px textindent px font sizeus subsidiaries fontdiv td tdfont sizenbspfonttd tdfont sizenbspfonttd tr tr tdfont sizenbspfonttd td alignleft valigntop div stylemarginleft px textindent px font sizeadvanced sterilization products services incnbspfontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizenew jersey fonttd tr tr valignbottom bgcoloreeeeee tdfont sizenbspfonttd td alignleft valigntop div stylemarginleft px textindent px font sizealza corporation fontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizedelaware fonttd tr tr tdfont sizenbspfonttd td alignleft valigntop div stylemarginleft px textindent px font sizealza land management incnbspfontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizedelaware fonttd tr tr valignbottom bgcoloreeeeee tdfont sizenbspfonttd td alignleft valigntop div stylemarginleft px textindent px font sizebiosense webster incnbspfontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizecalifornia fonttd tr tr tdfont sizenbspfonttd td alignleft valigntop div stylemarginleft px textindent px font sizecentocor biologicsnbspllc fontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizepennsylvania fonttd tr tr valignbottom bgcoloreeeeee tdfont sizenbspfonttd td alignleft valigntop div stylemarginleft px textindent px font sizecentocor incnbspfontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizepennsylvania fonttdtr tr tdfont sizenbspfonttd td alignleft valigntop div stylemarginleft px textindent px font sizecentocor researchnbspnbspdevelopment incnbspfontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizepennsylvania fonttd tr tr valignbottom bgcoloreeeeee tdfont sizenbspfonttd td alignleft valigntop div stylemarginleft px textindent px font sizeclosure medical corporation fontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizedelaware fonttd tr tr tdfont sizenbspfonttd td alignleft valigntop div stylemarginleft px textindent px font sizecna development llc fontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizedelaware fonttd tr tr valignbottom bgcoloreeeeee tdfont sizenbspfonttd td alignleft valigntop div stylemarginleft px textindent px font sizecodman shurtleff incnbspfontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizenew jersey fonttd tr tr tdfont sizenbspfonttd td alignleft valigntop div stylemarginleft px textindent px font sizecordis corporation fontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizeflorida fonttd tr tr valignbottom bgcoloreeeeee tdfont sizenbspfonttd td alignleft valigntop div stylemarginleft px textindent px font sizecordis development corporation fontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizeflorida fonttd tr tr tdfont sizenbspfonttdtd alignleft valigntop div stylemarginleft px textindent px font sizecordis international corporation fontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizedelaware fonttd tr tr valignbottom bgcoloreeeeee tdfont sizenbspfonttd td alignleft valigntop div stylemarginleft px textindent px font sizecordis llc fontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizedelaware fonttd tr tr tdfont sizenbspfonttd td alignleft valigntop div stylemarginleft px textindent px font sizecordis neurovascularnbspincnbspfontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizeflorida fonttd tr tr valignbottom bgcoloreeeeee tdfont sizenbspfonttd td alignleft valigntop div stylemarginleft px textindent px font sizedepuy disc incnbspfontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizedelaware fonttd tr tr tdfont sizenbspfonttd td alignleft valigntop div stylemarginleft px textindent px font sizedepuy incnbspfontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizedelaware fonttd tr tr valignbottom bgcoloreeeeee tdfont sizenbspfonttd td alignleft valigntop div stylemarginleft px textindent px font sizedepuy mitek incnbspfontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizemassachusetts fonttd tr tr tdfont sizenbspfonttd td alignleft valigntop div stylemarginleft px textindent px font sizedepuy orthopaedics incnbspfontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizeindianafonttd tr tr valignbottom bgcoloreeeeee tdfont sizenbspfonttd td alignleft valigntop div stylemarginleft px textindent px font sizedepuy products incnbspfontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizeindiana fonttd tr tr tdfont sizenbspfonttd td alignleft valigntop div stylemarginleft px textindent px font sizedepuy spine incnbspfontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizeohio fonttd tr tr valignbottom bgcoloreeeeee tdfont sizenbspfonttd td alignleft valigntop div stylemarginleft px textindent px font sizedepuy spine sales limited partnership fontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizemassachusetts fonttd tr tr tdfont sizenbspfonttd td alignleft valigntop div stylemarginleft px textindent px font sizediabetes diagnostics incnbspfontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizedelaware fonttd tr tr valignbottom bgcoloreeeeee tdfont sizenbspfonttd td alignleft valigntop div stylemarginleft px textindent px font sizeethicon endosurgery incnbspfontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizeohio fonttd tr tr tdfont sizenbspfonttd td alignleft valigntop div stylemarginleft px textindent px font sizeethicon endosurgery llcnbspfontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizedelaware fonttd tr tr valignbottom bgcoloreeeeee tdfont sizenbspfonttd td alignleft valigntop div stylemarginleft px textindent px font sizeethicon endosurgeryservicesnbsplpnbspfontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizetexas fonttd tr tr tdfont sizenbspfonttd td alignleft valigntop div stylemarginleft px textindent px font sizeethicon incnbspfontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizenew jersey fonttd tr tr valignbottom bgcoloreeeeee tdfont sizenbspfonttd td alignleft valigntop div stylemarginleft px textindent px font sizeethicon llc fontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizedelaware fonttd tr tr tdfont sizenbspfonttd td alignleft valigntop div stylemarginleft px textindent px font sizeglobal biologics supply chainnbspllc fontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizepennsylvania fonttd tr tr valignbottom bgcoloreeeeee tdfont sizenbspfonttd td alignleft valigntop div stylemarginleft px textindent px font sizegynopharma incnbspfontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizedelaware fonttd tr tr tdfont sizenbspfonttd td alignleft valigntop div stylemarginleft px textindent px font sizeiso holding corpnbspfontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizedelaware fonttd tr tr valignbottom bgcoloreeeeee tdfont sizenbspfonttd td alignleft valigntop div stylemarginleft px textindent px font sizejj holdings nevada incnbspfontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizenevada fonttd trtr tdfont sizenbspfonttd td alignleft valigntop div stylemarginleft px textindent px font sizejanssen finance company fontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizeflorida fonttd tr tr valignbottom bgcoloreeeeee tdfont sizenbspfonttd td alignleft valigntop div stylemarginleft px textindent px font sizejanssen incnbspfontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizedelaware fonttd tr tr tdfont sizenbspfonttd td alignleft valigntop div stylemarginleft px textindent px font sizejanssen ortho llc fontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizedelaware fonttd tr tr valignbottom bgcoloreeeeee tdfont sizenbspfonttd td alignleft valigntop div stylemarginleft px textindent px font sizejanssen lpnbspfontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizenew jersey fonttd tr tr tdfont sizenbspfonttd td alignleft valigntop div stylemarginleft px textindent px font sizejjhcnbspllc fontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizedelaware fonttd tr tr valignbottom bgcoloreeeeee tdfont sizenbspfonttd td alignleft valigntop div stylemarginleft px textindent px font sizejohnson johnson baby products incnbspfontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizedelaware fonttd tr table center pagebreak phr noshadep h alignleft stylebreakbeforealwaysnbsphp center table width aligncenter cellspacing cellpadding border tr td widthfont sizenbspfonttd td widthfont sizenbspfonttd td widthfont sizenbspfonttd tr tr tdtd tdtd td aligncenter nowrapbfont sizejurisdiction offontbtd tr tr td aligncenter nowrapbfont sizename subsidiaryfontbtd tdtd td aligncenter nowrapbfont sizeorganizationfontbtd tr tr td aligncenter nowraphr size noshadetd tdtd td aligncenter nowraphr size noshadetd tr tr valignbottom bgcoloreeeeee td alignleft valigntop div stylemarginleft px textindent px font sizejohnson johnson consumer companies incnbspfontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizenew jersey fonttd tr tr td alignleft valigntop div stylemarginleft px textindent px font sizejohnson johnson development corporation fontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizenew jersey fonttd tr tr valignbottom bgcoloreeeeee td alignleft valigntop div stylemarginleft px textindent px font sizejohnson johnson finance corporation fontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizenew jersey fonttd tr tr td alignleft valigntop div stylemarginleft px textindent px font sizejohnson johnson health care systems incnbspfontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizenew jersey fonttd tr tr valignbottom bgcoloreeeeee td alignleft valigntop div stylemarginleft px textindent pxfont sizejohnson johnson international fontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizenew jersey fonttd tr tr td alignleft valigntop div stylemarginleft px textindent px font sizejohnson johnson japan incnbspfontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizenew jersey fonttd tr tr valignbottom bgcoloreeeeee td alignleft valigntop div stylemarginleft px textindent px font sizejohnson johnsonnbspnbspmerck consumer pharmaceuticals conbspfontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizenew jersey fonttd tr tr td alignleft valigntop div stylemarginleft px textindent px font sizejohnson johnson middle east incnbspfontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizenew jersey fonttd tr tr valignbottom bgcoloreeeeee td alignleft valigntop div stylemarginleft px textindent px font sizejohnson johnson pharmaceutical research development llcnbspfontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizenew jersey fonttd tr tr td alignleft valigntop div stylemarginleft px textindent px font sizejohnson johnson pharmaceutical services llc fontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizenew jersey fonttd tr tr valignbottom bgcoloreeeeee td alignleft valigntop div stylemarginleft px textindent px font sizejohnson johnson pharmaceutical trading co incnbspfontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizedelaware fonttd tr trtd alignleft valigntop div stylemarginleft px textindent px font sizejohnsonnbsp johnson professional co pr incnbspfontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizedelaware fonttd tr tr valignbottom bgcoloreeeeee td alignleft valigntop div stylemarginleft px textindent px font sizejohnson johnson sales logistics company llc fontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizenew jersey fonttd tr tr td alignleft valigntop div stylemarginleft px textindent px font sizejohnson johnson services incnbspfontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizenew jersey fonttd tr tr valignbottom bgcoloreeeeee td alignleft valigntop div stylemarginleft px textindent px font sizejohnson johnson urban renewal associates fontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizenew jersey fonttd tr tr td alignleft valigntop div stylemarginleft px textindent px font sizejohnson johnson vision care incnbspfontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizeflorida fonttd tr tr valignbottom bgcoloreeeeee td alignleft valigntop div stylemarginleft px textindent px font sizejoint medical products corporation fontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizedelaware fonttd tr tr td alignleft valigntop div stylemarginleft px textindent px font sizelifescan incnbspfontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizecalifornia fonttd trtr valignbottom bgcoloreeeeee td alignleft valigntop div stylemarginleft px textindent px font sizelifescan llc fontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizedelaware fonttd tr tr td alignleft valigntop div stylemarginleft px textindent px font sizemcneil healthcare llcnbspfontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizedelaware fonttd tr tr valignbottom bgcoloreeeeee td alignleft valigntop div stylemarginleft px textindent px font sizemcneil nutritionalsnbspllc fontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizedelaware fonttd tr tr td alignleft valigntop div stylemarginleft px textindent px font sizemcneilppc incnbspfontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizenew jersey fonttd tr tr valignbottom bgcoloreeeeee td alignleft valigntop div stylemarginleft px textindent px font sizemiddlesex assurance company limited fontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizevermont fonttd tr tr td alignleft valigntop div stylemarginleft px textindent px font sizeneutrogena corporation fontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizedelaware fonttd tr tr valignbottom bgcoloreeeeee td alignleft valigntop div stylemarginleft px textindent px font sizenitinol development corporation fontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizecalifornia fonttdtr tr td alignleft valigntop div stylemarginleft px textindent px font sizenoramco incnbspfontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizegeorgia fonttd tr tr valignbottom bgcoloreeeeee td alignleft valigntop div stylemarginleft px textindent px font sizeomj pharmaceuticals incnbspfontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizedelaware fonttd tr tr td alignleft valigntop div stylemarginleft px textindent px font sizeorapharma incnbspfontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizedelaware fonttd tr tr valignbottom bgcoloreeeeee td alignleft valigntop div stylemarginleft px textindent px font sizeortho biologics llc fontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizedelaware fonttd tr tr td alignleft valigntop div stylemarginleft px textindent px font sizeortho biotech clinical affairs llc fontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizenew jersey fonttd tr tr valignbottom bgcoloreeeeee td alignleft valigntop div stylemarginleft px textindent px font sizeortho biotech holding corpnbspfontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizedelaware fonttd tr tr td alignleft valigntop div stylemarginleft px textindent px font sizeortho biotech incnbspfontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizenew jersey fonttd trtr valignbottom bgcoloreeeeee td alignleft valigntop div stylemarginleft px textindent px font sizeortho biotech products lpnbspfontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizenew jersey fonttd tr tr td alignleft valigntop div stylemarginleft px textindent px font sizeorthoclinical diagnostics incnbspfontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizenew york fonttd tr tr valignbottom bgcoloreeeeee td alignleft valigntop div stylemarginleft px textindent px font sizeorthomcneil finance conbspfontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizeflorida fonttd tr tr td alignleft valigntop div stylemarginleft px textindent px font sizeorthomcneil incnbspfontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizenew jersey fonttd tr tr valignbottom bgcoloreeeeee td alignleft valigntop div stylemarginleft px textindent px font sizeorthomcneil neurologics incnbspfontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizenew jersey fonttd tr tr td alignleft valigntop div stylemarginleft px textindent px font sizeorthomcneil pharmaceutical incnbspfontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizedelaware fonttd tr tr valignbottom bgcoloreeeeee td alignleft valigntop div stylemarginleft px textindent px font sizerutan realty llc fontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizenew jersey fonttd tr tr td alignleft valigntop div stylemarginleft px textindent pxfont sizescios incnbspfontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizedelaware fonttd tr tr valignbottom bgcoloreeeeee td alignleft valigntop div stylemarginleft px textindent px font sizeteramed corporation fontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizedelaware fonttd tr tr td alignleft valigntop div stylemarginleft px textindent px font sizetherapeutic discovery corporation fontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizedelaware fonttd tr tr valignbottom bgcoloreeeeee td alignleft valigntop div stylemarginleft px textindent px font sizethe tylenol company fontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizenew jersey fonttd tr tr td alignleft valigntop div stylemarginleft px textindent px font sizetransform pharmaceuticals incnbspfontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizedelaware fonttd tr tr valignbottom bgcoloreeeeee td alignleft valigntop div stylemarginleft px textindent px font sizewinthorpe valentine incnbspfontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizedelaware fonttd tr table center pagebreak phr noshadep h alignleft stylebreakbeforealwaysnbsphp center table width aligncenter cellspacing cellpadding border tr td widthfont sizenbspfonttd td widthfont sizenbspfonttd td widthfont sizenbspfonttd td widthfont sizenbspfonttdtr tr td colspantd tdtd td aligncenter nowrapbfont sizejurisdiction offontbtd tr tr td colspan aligncenter nowrapbfont sizename subsidiaryfontbtd tdtd td aligncenter nowrapbfont sizeorganizationfontbtd tr tr td colspan aligncenter nowraphr size noshadetd tdtd td aligncenter nowraphr size noshadetd tr tr valignbottom bgcoloreeeeee td colspan alignleft valigntop div stylemarginleft px textindent px font sizeinternational subsidiaries fontdiv td tdfont sizenbspfonttd tdfont sizenbspfonttd tr tr tdfont sizenbspfonttd td alignleft valigntop div stylemarginleft px textindent px font sizealza ireland limited fontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizeireland fonttd tr tr valignbottom bgcoloreeeeee tdfont sizenbspfonttd td alignleft valigntop div stylemarginleft px textindent px font sizeapsis sasnbspfontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizefrance fonttd tr tr tdfont sizenbspfonttd td alignleft valigntop div stylemarginleft px textindent px font sizecentocor biologics ireland limited fontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizeireland fonttd tr tr valignbottom bgcoloreeeeee tdfont sizenbspfonttd td alignleft valigntop div stylemarginleft px textindent px font sizecentocornbspbvnbspfontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizenetherlands fonttd tr trtdfont sizenbspfonttd td alignleft valigntop div stylemarginleft px textindent px font sizecilag advanced technologiesnbspgmbh fontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizeswitzerland fonttd tr tr valignbottom bgcoloreeeeee tdfont sizenbspfonttd td alignleft valigntop div stylemarginleft px textindent px font sizecilag ag fontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizeswitzerland fonttd tr tr tdfont sizenbspfonttd td alignleft valigntop div stylemarginleft px textindent px font sizecilag de mexico de rl de cv fontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizemexico fonttd tr tr valignbottom bgcoloreeeeee tdfont sizenbspfonttd td alignleft valigntop div stylemarginleft px textindent px font sizecilag gmbh international fontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizeswitzerland fonttd tr tr tdfont sizenbspfonttd td alignleft valigntop div stylemarginleft px textindent px font sizecilag holding ag fontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizeswitzerland fonttd tr tr valignbottom bgcoloreeeeee tdfont sizenbspfonttd td alignleft valigntop div stylemarginleft px textindent px font sizecodman sarl fontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizeswitzerland fonttd tr tr tdfont sizenbspfonttd td alignleft valigntop div stylemarginleft px textindent pxfont sizecordis europa nvnbspfontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizenetherlands fonttd tr tr valignbottom bgcoloreeeeee tdfont sizenbspfonttd td alignleft valigntop div stylemarginleft px textindent px font sizecordis medizinische apparate gmbhnbspfontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizegermany fonttd tr tr tdfont sizenbspfonttd td alignleft valigntop div stylemarginleft px textindent px font sizecordis sasnbspfontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizefrance fonttd tr tr valignbottom bgcoloreeeeee tdfont sizenbspfonttd td alignleft valigntop div stylemarginleft px textindent px font sizedepuy ace sarlnbspfontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizeswitzerland fonttd tr tr tdfont sizenbspfonttd td alignleft valigntop div stylemarginleft px textindent px font sizedepuy france sasnbspfontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizefrance fonttd tr tr valignbottom bgcoloreeeeee tdfont sizenbspfonttd td alignleft valigntop div stylemarginleft px textindent px font sizedepuy international limited fontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizeunited kingdom fonttd tr tr tdfont sizenbspfonttd td alignleft valigntop div stylemarginleft px textindent px font sizedepuy international holdings limited fontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizeunited kingdom fonttd trtr valignbottom bgcoloreeeeee tdfont sizenbspfonttd td alignleft valigntop div stylemarginleft px textindent px font sizedepuy ireland limited fontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizeireland fonttd tr tr tdfont sizenbspfonttd td alignleft valigntop div stylemarginleft px textindent px font sizedepuy mitek sarl fontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizeswitzerland fonttd tr tr valignbottom bgcoloreeeeee tdfont sizenbspfonttd td alignleft valigntop div stylemarginleft px textindent px font sizedepuy orthopadie gmbh fontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizegermany fonttd tr tr tdfont sizenbspfonttd td alignleft valigntop div stylemarginleft px textindent px font sizedepuy orthopedie sas fontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizefrance fonttd tr tr valignbottom bgcoloreeeeee tdfont sizenbspfonttd td alignleft valigntop div stylemarginleft px textindent px font sizedepuy spine sarlnbspfontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizeswitzerland fonttd tr tr tdfont sizenbspfonttd td alignleft valigntop div stylemarginleft px textindent px font sizedepuy uk holdings limited fontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizeunited kingdom fonttd tr tr valignbottom bgcoloreeeeee tdfont sizenbspfonttd td alignleft valigntopdiv stylemarginleft px textindent px font sizedrumbeat limited fontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizeireland fonttd tr tr tdfont sizenbspfonttd td alignleft valigntop div stylemarginleft px textindent px font sizeethicon gmbh fontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizegermany fonttd tr tr valignbottom bgcoloreeeeee tdfont sizenbspfonttd td alignleft valigntop div stylemarginleft px textindent px font sizeethicon ireland limited fontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizeireland fonttd tr tr tdfont sizenbspfonttd td alignleft valigntop div stylemarginleft px textindent px font sizeethicon sarl fontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizescotland fonttd tr tr valignbottom bgcoloreeeeee tdfont sizenbspfonttd td alignleft valigntop div stylemarginleft px textindent px font sizeethicon sas fontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizefrance fonttd tr tr tdfont sizenbspfonttd td alignleft valigntop div stylemarginleft px textindent px font sizeethnor proprietary limited fontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizesouth africa fonttd tr tr valignbottom bgcoloreeeeee tdfont sizenbspfonttd td alignleft valigntop div stylemarginleft px textindent px font sizegreiter ag fontdivtd tdfont sizenbspfonttd td alignleft valignbottom font sizeswitzerland fonttd tr tr tdfont sizenbspfonttd td alignleft valigntop div stylemarginleft px textindent px font sizegreiter international ag fontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizeswitzerland fonttd tr tr valignbottom bgcoloreeeeee tdfont sizenbspfonttd td alignleft valigntop div stylemarginleft px textindent px font sizehigh wycombe property management limited fontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizeunited kingdom fonttd tr tr tdfont sizenbspfonttd td alignleft valigntop div stylemarginleft px textindent px font sizejanssen animal health bvba fontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizebelgium fonttd tr tr valignbottom bgcoloreeeeee tdfont sizenbspfonttd td alignleft valigntop div stylemarginleft px textindent px font sizejanssencilag fontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizenorway fonttd tr tr tdfont sizenbspfonttd td alignleft valigntop div stylemarginleft px textindent px font sizejanssencilag ab fontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizesweden fonttd tr tr valignbottom bgcoloreeeeee tdfont sizenbspfonttd td alignleft valigntop div stylemarginleft px textindent px font sizejanssencilag ag fontdiv td tdfont sizenbspfonttd td alignleft valignbottomfont sizeswitzerland fonttd tr tr tdfont sizenbspfonttd td alignleft valigntop div stylemarginleft px textindent px font sizejanssencilag bvnbspfontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizenetherlands fonttd tr tr valignbottom bgcoloreeeeee tdfont sizenbspfonttd td alignleft valigntop div stylemarginleft px textindent px font sizejanssencilag farmaceutica ldanbspfontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizeportugal fonttd tr tr tdfont sizenbspfonttd td alignleft valigntop div stylemarginleft px textindent px font sizejanssencilag farmaceutica ltdanbspfontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizebrazil fonttd tr tr valignbottom bgcoloreeeeee tdfont sizenbspfonttd td alignleft valigntop div stylemarginleft px textindent px font sizejanssencilag gmbh fontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizegermany fonttd tr tr tdfont sizenbspfonttd td alignleft valigntop div stylemarginleft px textindent px font sizejanssencilag ltdnbspfontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizeunited kingdom fonttd tr tr valignbottom bgcoloreeeeee tdfont sizenbspfonttd td alignleft valigntop div stylemarginleft px textindent px font sizejanssencilag nvnbspfontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizebelgium fonttd tr tr tdfont sizenbspfonttd td alignleft valigntop div stylemarginleft px textindent pxfont sizejanssencilag pharmaceutical sacinbspfontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizegreece fonttd tr tr valignbottom bgcoloreeeeee tdfont sizenbspfonttd td alignleft valigntop div stylemarginleft px textindent px font sizejanssencilag pharma gmbh fontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizeaustria fonttd tr table center pagebreak phr noshadep h alignleft stylebreakbeforealwaysnbsphp center table width aligncenter cellspacing cellpadding border tr td widthfont sizenbspfonttd td widthfont sizenbspfonttd td widthfont sizenbspfonttd tr tr tdtd tdtd td aligncenter nowrapbfont sizejurisdiction offontbtd tr tr td aligncenter nowrapbfont sizename subsidiaryfontbtd tdtd td aligncenter nowrapbfont sizeorganizationfontbtd tr tr td aligncenter nowraphr size noshadetd tdtd td aligncenter nowraphr size noshadetd tr tr valignbottom bgcoloreeeeee td alignleft valigntop div stylemarginleft px textindent px font sizejanssencilag polskanbspspnbspznbspoo fontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizepoland fonttd tr tr td alignleft valigntop div stylemarginleft px textindent px font sizejanssencilag pty ltdnbspfontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizeaustralia fonttd tr tr valignbottom bgcoloreeeeee td alignleft valigntop div stylemarginleft px textindent pxfont sizejanssencilag sanbspfontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizespain fonttd tr tr td alignleft valigntop div stylemarginleft px textindent px font sizejanssencilag sa de cvnbspfontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizemexico fonttd tr tr valignbottom bgcoloreeeeee td alignleft valigntop div stylemarginleft px textindent px font sizejanssencilag sasnbspfontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizefrance fonttd tr tr td alignleft valigntop div stylemarginleft px textindent px font sizejanssencilag spanbspfontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizeitaly fonttd tr tr valignbottom bgcoloreeeeee td alignleft valigntop div stylemarginleft px textindent px font sizejanssen korea ltdnbspfontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizekorea fonttd tr tr td alignleft valigntop div stylemarginleft px textindent px font sizejanssenortho incnbspfontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizecanada fonttd tr tr valignbottom bgcoloreeeeee td alignleft valigntop div stylemarginleft px textindent px font sizejanssen pharmaceutica nvnbspfontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizebelgium fonttd tr tr td alignleft valigntop div stylemarginleft px textindent px font sizejanssen pharmaceutica pty limited fontdiv td tdfont sizenbspfonttdtd alignleft valignbottom font sizesouth africa fonttd tr tr valignbottom bgcoloreeeeee td alignleft valigntop div stylemarginleft px textindent px font sizejanssen pharmaceutical kknbspfontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizejapan fonttd tr tr td alignleft valigntop div stylemarginleft px textindent px font sizejanssen pharmaceutical limited fontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizeireland fonttd tr tr valignbottom bgcoloreeeeee td alignleft valigntop div stylemarginleft px textindent px font sizejcnbspgeneral servicesnbspcvba fontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizebelgium fonttd tr tr td alignleft valigntop div stylemarginleft px textindent px font sizejc healthcare ltdnbspfontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizeisrael fonttd tr tr valignbottom bgcoloreeeeee td alignleft valigntop div stylemarginleft px textindent px font sizejhc nederland bvnbspfontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizenetherlands fonttd tr tr td alignleft valigntop div stylemarginleft px textindent px font sizejohnson johnson ab fontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizesweden fonttd tr tr valignbottom bgcoloreeeeee td alignleft valigntop div stylemarginleft px textindent px font sizejohnson johnson ag fontdiv td tdfont sizenbspfonttdtd alignleft valignbottom font sizeswitzerland fonttd tr tr td alignleft valigntop div stylemarginleft px textindent px font sizejohnsonnbsp johnson china investmentnbspco ltdnbspfontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizechina fonttd tr tr valignbottom bgcoloreeeeee td alignleft valigntop div stylemarginleft px textindent px font sizejohnson johnson china ltdnbspfontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizechina fonttd tr tr td alignleft valigntop div stylemarginleft px textindent px font sizejohnson johnson comercio e distribuicao ltdanbspfontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizebrazil fonttd tr tr valignbottom bgcoloreeeeee td alignleft valigntop div stylemarginleft px textindent px font sizejohnson johnson consumer france sasnbspfontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizefrance fonttd tr tr td alignleft valigntop div stylemarginleft px textindent px font sizejohnson johnson consumer hongnbspkong limited fontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizehong kong fonttd tr tr valignbottom bgcoloreeeeee td alignleft valigntop div stylemarginleft px textindent px font sizejohnson johnson de argentina sace inbspfontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizeargentina fonttd tr tr td alignleft valigntop div stylemarginleft px textindent px font sizejohnson johnson de colombiasanbspfontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizecolombia fonttd tr tr valignbottom bgcoloreeeeee td alignleft valigntop div stylemarginleft px textindent px font sizejohnson johnson de venezuela sanbspfontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizevenezuela fonttd tr tr td alignleft valigntop div stylemarginleft px textindent px font sizejohnson johnson european treasury company fontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizeireland fonttd tr tr valignbottom bgcoloreeeeee td alignleft valigntop div stylemarginleft px textindent px font sizejohnson johnson egypt saenbspfontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizeegypt fonttd tr tr td alignleft valigntop div stylemarginleft px textindent px font sizejohnson johnson finance limited fontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizeengland fonttd tr tr valignbottom bgcoloreeeeee td alignleft valigntop div stylemarginleft px textindent px font sizejohnson johnson gesellschaft mbh fontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizeaustria fonttd tr tr td alignleft valigntop div stylemarginleft px textindent px font sizejohnson johnson gmbh fontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizegermany fonttd tr tr valignbottom bgcoloreeeeee td alignleft valigntopdiv stylemarginleft px textindent px font sizejohnson johnson group holdings gmbhnbspfontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizegermany fonttd tr tr td alignleft valigntop div stylemarginleft px textindent px font sizejohnson johnson hellas sanbspfontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizegreece fonttd tr tr valignbottom bgcoloreeeeee td alignleft valigntop div stylemarginleft px textindent px font sizejohnson johnson holding ab fontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizesweden fonttd tr tr td alignleft valigntop div stylemarginleft px textindent px font sizejohnson johnson holding gmbh fontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizegermany fonttd tr tr valignbottom bgcoloreeeeee td alignleft valigntop div stylemarginleft px textindent px font sizejohnson johnson hong kong limited fontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizehong kong fonttd tr tr td alignleft valigntop div stylemarginleft px textindent px font sizejohnson johnson incnbspfontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizecanada fonttd tr tr valignbottom bgcoloreeeeee td alignleft valigntop div stylemarginleft px textindent px font sizejohnson johnson industrial ltdanbspfontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizebrazil fonttd tr trtd alignleft valigntop div stylemarginleft px textindent px font sizejohnson johnson international financial services company fontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizeireland fonttd tr tr valignbottom bgcoloreeeeee td alignleft valigntop div stylemarginleft px textindent px font sizejohnson johnson ireland limited fontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizeireland fonttd tr tr td alignleft valigntop div stylemarginleft px textindent px font sizejohnson johnson kftnbspfontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizehungary fonttd tr tr valignbottom bgcoloreeeeee td alignleft valigntop div stylemarginleft px textindent px font sizejohnson johnson kknbspfontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizejapan fonttd tr tr td alignleft valigntop div stylemarginleft px textindent px font sizejohnsonnbsp johnson koreanbspltdnbspfontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizekorea fonttd tr tr valignbottom bgcoloreeeeee td alignleft valigntop div stylemarginleft px textindent px font sizejohnson johnson limitada fontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizeportugal fonttd tr tr td alignleft valigntop div stylemarginleft px textindent px font sizejohnson johnson limited fontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizeindia fonttd trtr valignbottom bgcoloreeeeee td alignleft valigntop div stylemarginleft px textindent px font sizejohnson johnson management limited fontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizeengland fonttd tr table center pagebreak phr noshadep h alignleft stylebreakbeforealwaysnbsphp center table width aligncenter cellspacing cellpadding border tr td widthfont sizenbspfonttd td widthfont sizenbspfonttd td widthfont sizenbspfonttd tr tr tdtd tdtd td aligncenter nowrapbfont sizejurisdiction offontbtd tr tr td aligncenter nowrapbfont sizename subsidiaryfontbtd tdtd td aligncenter nowrapbfont sizeorganizationfontbtd tr tr td aligncenter nowraphr size noshadetd tdtd td aligncenter nowraphr size noshadetd tr tr valignbottom bgcoloreeeeee td alignleft valigntop div stylemarginleft px textindent px font sizejohnson johnson medical bvnbspfontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizenetherlands fonttd tr tr td alignleft valigntop div stylemarginleft px textindent px font sizejohnson johnson medical china ltdnbspfontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizechina fonttd tr tr valignbottom bgcoloreeeeee td alignleft valigntop div stylemarginleft px textindent px font sizejohnsonnbspnbspjohnson medical holdingnbspspanbspfontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizeitaly fonttd trtr td alignleft valigntop div stylemarginleft px textindent px font sizejohnson johnson medical korea limited fontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizekorea fonttd tr tr valignbottom bgcoloreeeeee td alignleft valigntop div stylemarginleft px textindent px font sizejohnson johnson medical limited fontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizeunited kingdom fonttd tr tr td alignleft valigntop div stylemarginleft px textindent px font sizejohnson johnson medical mexico sa de cvnbspfontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizemexico fonttd tr tr valignbottom bgcoloreeeeee td alignleft valigntop div stylemarginleft px textindent px font sizejohnsonnbspnbspjohnson medical productsnbspgmbh fontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizeaustria fonttd tr tr td alignleft valigntop div stylemarginleft px textindent px font sizejohnson johnson medical pty limitednbspfontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizesouth africa fonttd tr tr valignbottom bgcoloreeeeee td alignleft valigntop div stylemarginleft px textindent px font sizejohnson johnson medical pty limitednbspfontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizeaustralia fonttd tr tr td alignleft valigntop div stylemarginleft px textindent px font sizejohnson johnson medical sanbspfontdiv td tdfont sizenbspfonttd td alignleft valignbottomfont sizeargentina fonttd tr tr valignbottom bgcoloreeeeee td alignleft valigntop div stylemarginleft px textindent px font sizejohnson johnson medical shanghai ltdnbspfontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizechina fonttd tr tr td alignleft valigntop div stylemarginleft px textindent px font sizejohnsonnbspnbspjohnson medicalnbspspanbspfontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizeitaly fonttd tr tr valignbottom bgcoloreeeeee td alignleft valigntop div stylemarginleft px textindent px font sizejohnsonnbspnbspjohnsonnbspnbspmerck consumer pharmaceuticals canada fontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizecanada fonttd tr tr td alignleft valigntop div stylemarginleft px textindent px font sizejohnson johnson pacific pty limitednbspfontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizeaustralia fonttd tr tr valignbottom bgcoloreeeeee td alignleft valigntop div stylemarginleft px textindent px font sizejohnson johnson pakistan private limited fontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizepakistan fonttd tr tr td alignleft valigntop div stylemarginleft px textindent px font sizejohnson johnson philippines incnbspfontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizephilippines fonttd tr tr valignbottom bgcoloreeeeee td alignleft valigntop div stylemarginleft px textindent px font sizejohnson johnson poland sp zoonbspfontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizepoland fonttd tr tr td alignleft valigntop div stylemarginleft px textindent px font sizejohnson johnson produtos profissionais ltdanbspfontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizebrazil fonttd tr tr valignbottom bgcoloreeeeee td alignleft valigntop div stylemarginleft px textindent px font sizejohnson johnson proprietary limited fontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizesouth africa fonttd tr tr td alignleft valigntop div stylemarginleft px textindent px font sizejohnson johnson pte ltdnbspfontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizesingapore fonttd tr tr valignbottom bgcoloreeeeee td alignleft valigntop div stylemarginleft px textindent px font sizejohnson johnson pty limited fontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizeaustralia fonttd tr tr td alignleft valigntop div stylemarginleft px textindent px font sizejohnson johnson research pty ltdnbspfontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizeaustralia fonttd tr tr valignbottom bgcoloreeeeee td alignleft valigntop div stylemarginleft px textindent px font sizejohnson johnson sanbspfontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizespain fonttd tr tr td alignleft valigntop div stylemarginleft px textindent pxfont sizejohnson johnson sa de cvnbspfontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizemexico fonttd tr tr valignbottom bgcoloreeeeee td alignleft valigntop div stylemarginleft px textindent px font sizejohnson johnson sdn bhdnbspfontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizemalaysia fonttd tr tr td alignleft valigntop div stylemarginleft px textindent px font sizejohnson johnson spanbspfontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizeitaly fonttd tr tr valignbottom bgcoloreeeeee td alignleft valigntop div stylemarginleft px textindent px font sizejohnson johnsonnbspsronbspfontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizeczech republic fonttd tr tr td alignleft valigntop div stylemarginleft px textindent px font sizejohnson johnson swiss finance company limitednbspfontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizeunited kingdom fonttd tr tr valignbottom bgcoloreeeeee td alignleft valigntop div stylemarginleft px textindent px font sizejohnson johnson taiwan ltdnbspfontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizetaiwan fonttd tr tr td alignleft valigntop div stylemarginleft px textindent px font sizejohnson johnson thailand ltd fontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizethailand fonttd tr tr valignbottom bgcoloreeeeee td alignleft valigntop div stylemarginleft px textindent px font sizejohnson johnson vision care ireland limitednbspfontdivtd tdfont sizenbspfonttd td alignleft valignbottom font sizeireland fonttd tr tr td alignleft valigntop div stylemarginleft px textindent px font sizelaboratoires polivenbspsncnbspfontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizefrance fonttd tr tr valignbottom bgcoloreeeeee td alignleft valigntop div stylemarginleft px textindent px font sizelatam properties holdings fontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizeireland fonttd tr tr td alignleft valigntop div stylemarginleft px textindent px font sizelifescan canada ltdnbspfontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizecanada fonttd tr tr valignbottom bgcoloreeeeee td alignleft valigntop div stylemarginleft px textindent px font sizelifescan scotlandnbspltdnbspfontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizescotland fonttd tr tr td alignleft valigntop div stylemarginleft px textindent px font sizemcneil gmbhnbspnbspconbspohg fontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizegermany fonttd tr tr valignbottom bgcoloreeeeee td alignleft valigntop div stylemarginleft px textindent px font sizemcneil ibericanbspslunbspfontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizespain fonttd tr tr td alignleft valigntop div stylemarginleft px textindent px font sizemcneilnbsppdinbspincnbspfontdiv td tdfont sizenbspfonttdtd alignleft valignbottom font sizecanada fonttd tr tr valignbottom bgcoloreeeeee td alignleft valigntop div stylemarginleft px textindent px font sizemcneilnbspsas fontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizefrance fonttd tr tr td alignleft valigntop div stylemarginleft px textindent px font sizemedos international sarl fontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizeswitzerland fonttd tr tr valignbottom bgcoloreeeeee td alignleft valigntop div stylemarginleft px textindent px font sizemedos sarl fontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizeswitzerland fonttd tr tr td alignleft valigntop div stylemarginleft px textindent px font sizeomj ireland limited fontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizeireland fonttd tr tr valignbottom bgcoloreeeeee td alignleft valigntop div stylemarginleft px textindent px font sizeomj manufacturing limited fontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizeireland fonttd tr tr td alignleft valigntop div stylemarginleft px textindent px font sizeorthoclinical diagnostics fontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizeunited kingdom fonttd tr tr valignbottom bgcoloreeeeee td alignleft valigntop div stylemarginleft px textindent px font sizeorthoclinical diagnostics gmbhfontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizegermany fonttd tr table center pagebreak phr noshadep h alignleft stylebreakbeforealwaysnbsphp center table width aligncenter cellspacing cellpadding border tr td widthfont sizenbspfonttd td widthfont sizenbspfonttd td widthfont sizenbspfonttd tr tr tdtd tdtd td aligncenter nowrapbfont sizejurisdiction offontbtd tr tr td aligncenter nowrapbfont sizename subsidiaryfontbtd tdtd td aligncenter nowrapbfont sizeorganizationfontbtd tr tr td aligncenter nowraphr size noshadetd tdtd td aligncenter nowraphr size noshadetd tr tr valignbottom bgcoloreeeeee td alignleft valigntop div stylemarginleft px textindent px font sizeorthoclinical diagnostics kknbspfontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizejapan fonttd tr tr td alignleft valigntop div stylemarginleft px textindent px font sizeorthoclinical diagnostics nv fontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizebelgium fonttd tr tr valignbottom bgcoloreeeeee td alignleft valigntop div stylemarginleft px textindent px font sizeorthoclinical diagnostics sasnbspfontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizefrance fonttd tr tr td alignleft valigntop div stylemarginleft px textindent px font sizept johnson johnson indonesia fontdivtd tdfont sizenbspfonttd td alignleft valignbottom font sizeindonesia fonttd tr tr valignbottom bgcoloreeeeee td alignleft valigntop div stylemarginleft px textindent px font sizeshanghai johnson johnson pharmaceuticals ltd fontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizechina fonttd tr tr td alignleft valigntop div stylemarginleft px textindent px font sizetasmanian alkaloids pty ltdnbspfontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizeaustralia fonttd tr tr valignbottom bgcoloreeeeee td alignleft valigntop div stylemarginleft px textindent px font sizetibotec bvba fontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizebelgium fonttd tr tr td alignleft valigntop div stylemarginleft px textindent px font sizetibotec pharmaceuticals ltdnbspfontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizeireland fonttd tr tr valignbottom bgcoloreeeeee td alignleft valigntop div stylemarginleft px textindent px font sizetibotecvirco comm va fontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizebelgium fonttd tr tr td alignleft valigntop div stylemarginleft px textindent px font sizeturnbuckle investment company fontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizeireland fonttd tr tr valignbottom bgcoloreeeeee td alignleft valigntop div stylemarginleft px textindent pxfont sizevania expansion snc fontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizefrance fonttd tr tr td alignleft valigntop div stylemarginleft px textindent px font sizexianjanssen pharmaceutical ltdnbspfontdiv td tdfont sizenbspfonttd td alignleft valignbottom font sizechina fonttd tr table center body html text document document typeex sequence filenameyexvhtm descriptionex consent independent registered public accounting firm text html head titleextitle head body bgcolorffffff pagebreak h alignleft stylebreakbeforealwaysnbsphp p alignright bfont sizeexhibit fontb p aligncenter bfont sizeconsent independent registered public accounting firmfontb p alignleftnbspnbspnbspnbspnbsp font sizewe hereby consent incorporation reference registration statements form nonbsp formnbsps nonbsp johnson johnson report dated februarynbsp relating financial statements managements assessment effectiveness internal control financial reporting effectiveness internal control financial reporting appears annual report shareholders incorporated annual report formnbspk also consent incorporation reference report dated februarynbsp relating financial statement schedule appears formnbspk font p alignleft font sizes pricewaterhousecoopers llp font div alignleft hr size width alignleft colorblack noshade div div alignleft font sizepricewaterhousecoopers llp font divp alignleft font sizenew york new york font div alignleft font sizemarchnbsp font div body html text document document typeexa sequence filenameyexvwahtm descriptionexa certification text html head titleexatitle head body bgcolorffffff pagebreak h alignleft stylebreakbeforealwaysnbsphp p alignright bfont sizeexhibit afontb p aligncenter bfont sizecertification chief executive officerfontb div aligncenter bfont sizepursuant sectionnbsp sarbanesoxley actfontb div p alignleftnbspnbspnbspnbspnbsp font sizei william c weldon certify font p table width border cellpadding cellspacing tr td widthtd td widthtd tr tr valigntop tdnbsptd td alignleftnbspnbspnbspnbspnbsp font sizenbspnbspnbspnbspnbspi reviewed annual report formnbspk fiscal year ended januarynbsp report johnson johnson company fonttd tr tr tdnbsptd tr tr valigntop tdnbsptd td alignleftnbspnbspnbspnbspnbsp font sizenbspnbspnbspnbspnbspbased knowledge report contain untrue statement material fact omit state material fact necessary make statements made light circumstances statements made misleading respect period covered report fonttd tr tr tdnbsptd trtr valigntop tdnbsptd td alignleftnbspnbspnbspnbspnbsp font sizenbspnbspnbspnbspnbspbased knowledge financial statements financial information included report fairly present material respects financial condition results operations cash flows company periods presented report fonttd tr tr tdnbsptd tr tr valigntop tdnbsptd td alignleftnbspnbspnbspnbspnbsp font sizenbspnbspnbspnbspnbspthe companys certifying officer responsible establishing maintaining disclosure controls procedures defined exchange act rulenbspae internal control financial reporting defined exchange act rule af company fonttd tr table p table width border cellpadding cellspacing tr td widthtd td widthtd tr tr valigntop tdnbsptd td alignleftnbspnbspnbspnbspnbsp font sizeanbspdesigned disclosure controls procedures caused disclosure controls procedures designed supervision ensure material information relating company including consolidated subsidiaries made known us others within entities particularly period report prepared fonttd tr tr tdnbsptd tr tr valigntop tdnbsptd td alignleftnbspnbspnbspnbspnbsp font sizebnbspdesigned internal control financial reporting caused internal control financial reporting designed supervision provide reasonable assurance regarding reliability financial reporting preparation financial statements external purposes accordance generally accepted accounting principles fonttd tr tr tdnbsptd tr tr valigntop tdnbsptd td alignleftnbspnbspnbspnbspnbsp font sizecnbspevaluated effectiveness companys disclosure controls procedures presented report conclusions effectiveness disclosure controls procedures end period covered report based evaluation fonttdtr tr tdnbsptd tr tr valigntop tdnbsptd td alignleftnbspnbspnbspnbspnbsp font sizednbspdisclosed report change companys internal control financial reporting occurred companys fourth fiscal quarter materially affected reasonably likely materially affect companys internal control financial reporting fonttd tr table p table width border cellpadding cellspacing tr td widthtd td widthtd tr tr valigntop tdnbsptd td alignleftnbspnbspnbspnbspnbsp font sizenbspnbspnbspnbspnbspthe companys certifying officer disclosed based recent evaluation internal control financial reporting companys auditors audit committee companys board directors persons performing equivalent functions fonttd tr table p table width border cellpadding cellspacing tr td widthtd td widthtd tr tr valigntop tdnbsptd td alignleftnbspnbspnbspnbspnbsp font sizeanbspall significant deficiencies material weaknesses design operation internal control financial reporting reasonably likely adversely affect companys ability record process summarize report financial information fonttd tr tr tdnbsptd tr tr valigntop tdnbsptd td alignleftnbspnbspnbspnbspnbsp font sizebnbspany fraud whether material involves management employees significant role companys internal control financial reporting fonttd tr table p table width border cellpadding cellspacing trtd widthtd td widthtd tr tr valigntop tdnbsptd td alignleft font sizes william c weldon fonttd tr tr valigntop tdnbsptd td alignleft hr size alignleft colorblack noshadetd tr tr valigntop tdnbsptd td aligncenter font sizewilliam c weldon fonttd tr tr valigntop tdnbsptd td aligncenter ifont sizechief executive officerfontitd tr table p alignleft font sizedatenbspmarchnbsp font body html text document document typeexb sequence filenameyexvwbhtm descriptionexb certification text html head titleexbtitle head body bgcolorffffff pagebreak h alignleft stylebreakbeforealwaysnbsphp p alignright bfont sizeexhibit bfontb p aligncenter bfont sizecertification chief financial officerfontb div aligncenter bfont sizepursuant sectionnbsp sarbanesoxley actfontb div p alignleftnbspnbspnbspnbspnbsp font sizei robertnbspj darretta certify font p table width border cellpadding cellspacing tr td widthtd td widthtd tr tr valigntop tdnbsptd td alignleftnbspnbspnbspnbspnbsp font sizenbspnbspnbspnbspnbspi reviewedthis annual report formnbspk fiscal year ended januarynbsp report johnson johnson company fonttd tr tr tdnbsptd tr tr valigntop tdnbsptd td alignleftnbspnbspnbspnbspnbsp font sizenbspnbspnbspnbspnbspbased knowledge report contain untrue statement material fact omit state material fact necessary make statements made light circumstances statements made misleading respect period covered report fonttd tr tr tdnbsptd tr tr valigntop tdnbsptd td alignleftnbspnbspnbspnbspnbsp font sizenbspnbspnbspnbspnbspbased knowledge financial statements financial information included report fairly present material respects financial condition results operations cash flows company periods presented report fonttd tr tr tdnbsptd tr tr valigntop tdnbsptd td alignleftnbspnbspnbspnbspnbsp font sizenbspnbspnbspnbspnbspthe companys certifying officer responsible establishing maintaining disclosure controls procedures defined exchange act rulenbspae internal control financial reporting defined exchange act rule af company fonttd tr table p table width border cellpadding cellspacing tr td widthtd td widthtd tr tr valigntop tdnbsptd td alignleftnbspnbspnbspnbspnbsp font sizeanbspdesigned disclosure controls procedures caused disclosure controls procedures designed supervision ensure material information relating company including consolidated subsidiaries made known us others within entities particularly period report prepared fonttd tr tr tdnbsptd trtr valigntop tdnbsptd td alignleftnbspnbspnbspnbspnbsp font sizebnbspdesigned internal control financial reporting caused internal control financial reporting designed supervision provide reasonable assurance regarding reliability financial reporting preparation financial statements external purposes accordance generally accepted accounting principles fonttd tr tr tdnbsptd tr tr valigntop tdnbsptd td alignleftnbspnbspnbspnbspnbsp font sizecnbspevaluated effectiveness companys disclosure controls procedures presented report conclusions effectiveness disclosure controls procedures end period covered report based evaluation fonttd tr tr tdnbsptd tr tr valigntop tdnbsptd td alignleftnbspnbspnbspnbspnbsp font sizednbspdisclosed report change companys internal control financial reporting occurred companys fourth fiscal quarter materially affected reasonably likely materially affect companys internal control financial reporting fonttd tr table p table width border cellpadding cellspacing tr td widthtd td widthtd tr tr valigntop tdnbsptd td alignleftnbspnbspnbspnbspnbsp font sizenbspnbspnbspnbspnbspthe companys certifying officer disclosed based recent evaluation internal control financial reporting companys auditors audit committee companys board directors persons performing equivalent functions fonttd tr table p table width border cellpadding cellspacing tr td widthtd td widthtd tr tr valigntop tdnbsptd td alignleftnbspnbspnbspnbspnbsp font sizeanbspall significant deficiencies material weaknesses design operation internal control overfinancial reporting reasonably likely adversely affect companys ability record process summarize report financial information fonttd tr tr tdnbsptd tr tr valigntop tdnbsptd td alignleftnbspnbspnbspnbspnbsp font sizebnbspany fraud whether material involves management employees significant role companys internal control financial reporting fonttd tr table p table width border cellpadding cellspacing tr td widthtd td widthtd tr tr valigntop tdnbsptd td alignleft font sizes robert j darretta fonttd tr tr valigntop tdnbsptd td alignleft hr size alignleft colorblack noshadetd tr tr valigntop tdnbsptd td aligncenter font sizerobert j darretta fonttd tr tr valigntop tdnbsptd td aligncenter ifont sizechief financial officerfontitd tr table p alignleft font sizedatenbspmarchnbsp font body html text document document typeexa sequence filenameyexvwahtm descriptionexa certification text html head titleexatitle head body bgcolorffffff pagebreak h alignleft stylebreakbeforealwaysnbsphp p alignrightbfont sizeexhibit afontb p aligncenter bfont sizecertification chief executive officerfontb div aligncenter bfont sizepursuant sectionnbsp sarbanesoxley actfontb div p alignleftnbspnbspnbspnbspnbsp font sizethe undersigned william c weldon chief executive officer johnson johnson new jersey corporation company pursuant nbspuscnbsp adopted pursuant sectionnbsp sarbanesoxley act hereby certifies best knowledge font p table width border cellpadding cellspacing tr td widthtd td widthtd tr tr valigntop tdnbsptd td alignleftnbspnbspnbspnbspnbsp font sizenbspthe companys annual report formnbspk fiscal year ended januarynbsp report fully complies requirements sectionnbspa securities exchange act fonttd tr tr tdnbsptd tr tr valigntop tdnbsptd td alignleftnbspnbspnbspnbspnbsp font sizenbspthe information contained report fairly presents material respects financial condition results operations company fonttd tr table p table width border cellpadding cellspacing tr td widthtd td widthtd tr tr valigntop tdnbsptd td alignleft font sizes william c weldon fonttd tr tr valigntop tdnbsptd td alignleft hr size alignleft colorblack noshadetd tr tr valigntop tdnbsptd td aligncenter font sizewilliam c weldon fonttd trtr valigntop tdnbsptd td aligncenter ifont sizechief executive officerfontitd tr table p alignleft font sizedatednbspmarchnbsp font p alignleftnbspnbspnbspnbspnbsp font sizethis certification furnished sec report formnbspk pursuant sectionnbsp sarbanesoxley act shall except extent required act deemed filed company purposes sectionnbsp securities exchange act font body html text document document typeexb sequence filenameyexvwbhtm descriptionexb certification text html head titleexbtitle head body bgcolorffffff pagebreak h alignleft stylebreakbeforealwaysnbsphp p alignright bfont sizeexhibit bfontb p aligncenter bfont sizecertification chief financial officerfontb div aligncenter bfont sizepursuant sectionnbsp sarbanesoxley actfontb div p alignleftnbspnbspnbspnbspnbsp font sizethe undersigned robertnbspj darretta chief financial officer johnson johnson new jersey corporation company pursuant nbspuscnbsp adopted pursuant sectionnbsp sarbanesoxley act hereby certifies best knowledge font p table width border cellpadding cellspacing tr td widthtd td widthtd tr tr valigntop tdnbsptd td alignleftnbspnbspnbspnbspnbsp font sizenbspthe companys annual report formnbspk fiscal year ended januarynbsp report fully complies requirements sectionnbspa securities exchange act fonttd tr tr tdnbsptd trtr valigntop tdnbsptd td alignleftnbspnbspnbspnbspnbsp font sizenbspthe information contained report fairly presents material respects financial condition results operations company fonttd tr table p table width border cellpadding cellspacing tr td widthtd td widthtd tr tr valigntop tdnbsptd td alignleft font sizes robert j darretta fonttd tr tr valigntop tdnbsptd td alignleft hr size alignleft colorblack noshadetd tr tr valigntop tdnbsptd td aligncenter font sizerobert j darretta fonttd tr tr valigntop tdnbsptd td aligncenter ifont sizechief financial officerfontitd tr table p alignleft font sizedatednbspmarchnbsp font p alignleftnbspnbspnbspnbspnbsp font sizethis certification furnished sec report formnbspk pursuant sectionnbsp sarbanesoxley act shall except extent required act deemed filed company purposes sectionnbsp securities exchange act font body html text document document typeex sequence filenameyexvhtm descriptionex cautionary statement text html head titleextitle head body bgcolorffffff pagebreak h alignleft stylebreakbeforealwaysnbsphp p alignright bfont sizeexhibit fontbp aligncenter bfont sizecautionary statement pursuant private securities litigation reformfontb div aligncenter bfont sizeact nbsp safe harbor forwardlooking statementsfontb div p alignleftnbspnbspnbspnbspnbsp font sizethe company may time time make certain forwardlooking statements publiclyreleased materials written oral forwardlooking statements relate strictly historical current facts anticipate results based managements plans subject uncertainty forwardlooking statements may identified use words like plans expects anticipates estimates words similar meaning conjunction among things discussions future operations financial performance companys strategy growth product development regulatory approvals market position expenditures font p alignleftnbspnbspnbspnbspnbsp font sizeforwardlooking statements based current expectations future events company guarantee forwardlooking statement accurate although company believes reasonable expectations assumptions investors realize underlying assumptions prove inaccurate unknown risks uncertainties materialize actual results could vary materially companys expectations projections investors therefore cautioned place undue reliance forwardlooking statements furthermore company assumes obligation update forwardlooking statements result new information future events developments font p alignleftnbspnbspnbspnbspnbsp font sizesome important factors could cause companys actual results differ companys expectations forwardlooking statements follows font p table width border cellpadding cellspacing tr td widthtd td widthtd tr tr valigntop tdnbsptd td alignleftnbspnbspnbspnbspnbsp font sizeeconomic factors including inflation fluctuations interest rates currency exchange rates potential effect fluctuations revenues expenses resulting margins fonttd tr tr tdnbsptd tr tr valigntop tdnbsptd td alignleftnbspnbspnbspnbspnbsp font sizecompetitive factors including technological advances achieved patents attained competitors well new products introduced competitors fonttd tr tr tdnbsptd trtr valigntop tdnbsptd td alignleftnbspnbspnbspnbspnbsp font sizechallenges companys patents competitors allegations companys products infringe patents third parties could potentially affect companys competitive position ability sell products question require payment past damages future royalties particular generic drug firms filed abbreviated new drug applications seeking market generic forms companys key pharmaceutical products prior expiration applicable patents covering products event company successful defending resulting lawsuits generic versions product issue introduced resulting substantial market share revenue losses fonttd tr tr tdnbsptd tr tr valigntop tdnbsptd td alignleftnbspnbspnbspnbspnbsp font sizefinancial distress bankruptcies experienced significant customers suppliers could impair ability case may purchase companys products pay products previously purchased meet obligations company supply arrangements fonttd tr tr tdnbsptd tr tr valigntop tdnbsptd td alignleftnbspnbspnbspnbspnbsp font sizethe impact political economic conditions due terrorist attacks us parts world us military action overseas well instability financial markets could result terrorism military actions fonttd tr tr tdnbsptd tr tr valigntop tdnbsptd td alignleftnbspnbspnbspnbspnbsp font sizeinterruptions computer communication systems including computer viruses could impair companys ability conduct business communicate internally customers fonttd tr tr tdnbsptd tr tr valigntop tdnbsptd td alignleftnbspnbspnbspnbspnbsp font sizehealth care changes us countries resulting pricing pressures including continued consolidation among health care providers trends toward managed care health care cost containment shift towards governments becoming primary payers health care expenses government laws regulations relating sales promotion reimbursement pricing generally fonttd trtable pagebreak phr noshadep h alignleft stylebreakbeforealwaysnbsphp p table width border cellpadding cellspacing tr td widthtd td widthtd tr tr valigntop tdnbsptd td alignleftnbspnbspnbspnbspnbsp font sizegovernment laws regulations affecting us foreign operations including relating securities laws compliance trade monetary fiscal policies taxes price controls regulatory approval new products licensing patent rights including particular proposed amendments hatchwaxman act implementation medicare prescription drug improvement modernization act possible drug reimportation legislation fonttd tr tr tdnbsptd tr tr valigntop tdnbsptd td alignleftnbspnbspnbspnbspnbsp font sizecompetition research involving development improvement new existing products processes particularly significant results time time product process obsolescence development new improved products important companys success areas business fonttd tr tr tdnbsptd tr tr valigntop tdnbsptd td alignleftnbspnbspnbspnbspnbsp font sizechallenges difficulties inherent product development including potential inability successfully continue technological innovation complete clinical trials obtain regulatory approvals united states abroad gain maintain market approval products possibility encountering infringement claims competitors respect patent intellectual property rights preclude delay commercialization product fonttd tr tr tdnbsptd tr tr valigntop tdnbsptd td alignleftnbspnbspnbspnbspnbsp font sizesignificant litigation adverse company including product liability claims patent infringement claims antitrust claims fonttd tr tr tdnbsptd tr tr valigntop tdnbsptdtd alignleftnbspnbspnbspnbspnbsp font sizethe health care industry come increased scrutiny government agencies state attorneys general resulting investigations prosecutions carry risk significant civil criminal penalties including debarment government business fonttd tr tr tdnbsptd tr tr valigntop tdnbsptd td alignleftnbspnbspnbspnbspnbsp font sizeproduct efficacy safety concerns whether based scientific evidence resulting product withdrawals recalls regulatory action part fda foreign counterparts declining sales fonttd tr tr tdnbsptd tr tr valigntop tdnbsptd td alignleftnbspnbspnbspnbspnbsp font sizethe impact business combinations including acquisitions divestitures internally company externally pharmaceutical medical device health care industries fonttd tr tr tdnbsptd tr tr valigntop tdnbsptd td alignleftnbspnbspnbspnbspnbsp font sizeissuance new revised accounting standards american institute certified public accountants financial accounting standards board securities exchange commission public company accounting oversight board fonttd tr table p alignleftnbspnbspnbspnbspnbsp font sizethe foregoing list sets forth many factors could impact upon companys ability achieve results described forwardlooking statements investors understand possible predict identify factors consider list complete statement potential risks uncertainties company identified factors list permitted private securities litigation reform act font body html text document secdocument end privacyenhanced message